WO2016209732A1 - Polymer-cyclodextrin-lipid conjugates - Google Patents
Polymer-cyclodextrin-lipid conjugates Download PDFInfo
- Publication number
- WO2016209732A1 WO2016209732A1 PCT/US2016/038134 US2016038134W WO2016209732A1 WO 2016209732 A1 WO2016209732 A1 WO 2016209732A1 US 2016038134 W US2016038134 W US 2016038134W WO 2016209732 A1 WO2016209732 A1 WO 2016209732A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- mpeg
- acid
- group
- peg
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 171
- 150000001875 compounds Chemical class 0.000 claims abstract description 81
- 239000003814 drug Substances 0.000 claims abstract description 48
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229930182558 Sterol Natural products 0.000 claims abstract description 35
- 150000003432 sterols Chemical class 0.000 claims abstract description 35
- 235000003702 sterols Nutrition 0.000 claims abstract description 35
- 229940088594 vitamin Drugs 0.000 claims abstract description 31
- 239000011782 vitamin Substances 0.000 claims abstract description 31
- 229930003231 vitamin Natural products 0.000 claims abstract description 27
- 235000013343 vitamin Nutrition 0.000 claims abstract description 27
- 239000000194 fatty acid Substances 0.000 claims abstract description 25
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 24
- 229930195729 fatty acid Natural products 0.000 claims abstract description 24
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 24
- -1 stanols Chemical class 0.000 claims description 130
- 229920001223 polyethylene glycol Polymers 0.000 claims description 82
- 229920001427 mPEG Polymers 0.000 claims description 61
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 58
- 230000027455 binding Effects 0.000 claims description 51
- 150000002632 lipids Chemical class 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 41
- 229920000642 polymer Polymers 0.000 claims description 35
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 230000002209 hydrophobic effect Effects 0.000 claims description 29
- 229940024606 amino acid Drugs 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 150000004985 diamines Chemical class 0.000 claims description 22
- 230000021615 conjugation Effects 0.000 claims description 18
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 17
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 17
- 150000001414 amino alcohols Chemical class 0.000 claims description 17
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 14
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims description 14
- 229920000768 polyamine Polymers 0.000 claims description 14
- 150000004072 triols Chemical class 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 13
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 12
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 12
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 12
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 claims description 12
- 239000011975 tartaric acid Substances 0.000 claims description 12
- 235000002906 tartaric acid Nutrition 0.000 claims description 12
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims description 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 10
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 10
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 10
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 10
- 235000005282 vitamin D3 Nutrition 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 9
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 9
- 229960004853 betadex Drugs 0.000 claims description 9
- OTBHHUPVCYLGQO-UHFFFAOYSA-N bis(3-aminopropyl)amine Chemical compound NCCCNCCCN OTBHHUPVCYLGQO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 229930003799 tocopherol Natural products 0.000 claims description 9
- 239000011732 tocopherol Substances 0.000 claims description 9
- 239000011731 tocotrienol Substances 0.000 claims description 9
- 229930003802 tocotrienol Natural products 0.000 claims description 9
- 235000019148 tocotrienols Nutrition 0.000 claims description 9
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims description 8
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 8
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 8
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims description 8
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 8
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 8
- 229940068778 tocotrienols Drugs 0.000 claims description 8
- 239000011647 vitamin D3 Substances 0.000 claims description 8
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 8
- 229940021056 vitamin d3 Drugs 0.000 claims description 8
- 239000001116 FEMA 4028 Substances 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 7
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 7
- 235000021466 carotenoid Nutrition 0.000 claims description 7
- 150000001747 carotenoids Chemical class 0.000 claims description 7
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 7
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 7
- 235000018977 lysine Nutrition 0.000 claims description 7
- 235000019149 tocopherols Nutrition 0.000 claims description 7
- 229960001727 tretinoin Drugs 0.000 claims description 7
- 239000011800 void material Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 claims description 6
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims description 6
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004386 Erythritol Substances 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 229940009714 erythritol Drugs 0.000 claims description 6
- 235000019414 erythritol Nutrition 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims description 5
- CIAMOALLBVRDDK-UHFFFAOYSA-N 1,1-diaminopropan-2-ol Chemical compound CC(O)C(N)N CIAMOALLBVRDDK-UHFFFAOYSA-N 0.000 claims description 5
- BTWNEJOURYOHME-UHFFFAOYSA-N 1,3-thiazol-2-ylhydrazine Chemical compound NNC1=NC=CS1 BTWNEJOURYOHME-UHFFFAOYSA-N 0.000 claims description 5
- JVYDLYGCSIHCMR-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)butanoic acid Chemical compound CCC(CO)(CO)C(O)=O JVYDLYGCSIHCMR-UHFFFAOYSA-N 0.000 claims description 5
- GHKSKVKCKMGRDU-UHFFFAOYSA-N 2-(3-aminopropylamino)ethanol Chemical compound NCCCNCCO GHKSKVKCKMGRDU-UHFFFAOYSA-N 0.000 claims description 5
- LJSUIIHXGIFTAO-UHFFFAOYSA-N 3-(3-aminopropylamino)propan-1-ol Chemical compound NCCCNCCCO LJSUIIHXGIFTAO-UHFFFAOYSA-N 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 235000009582 asparagine Nutrition 0.000 claims description 5
- 229960001230 asparagine Drugs 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- MRNZSTMRDWRNNR-UHFFFAOYSA-N bis(hexamethylene)triamine Chemical compound NCCCCCCNCCCCCCN MRNZSTMRDWRNNR-UHFFFAOYSA-N 0.000 claims description 5
- 150000002009 diols Chemical class 0.000 claims description 5
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims description 5
- 229960002061 ergocalciferol Drugs 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- 235000004554 glutamine Nutrition 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- 229930002330 retinoic acid Natural products 0.000 claims description 5
- 229940063673 spermidine Drugs 0.000 claims description 5
- 229940063675 spermine Drugs 0.000 claims description 5
- 125000002640 tocopherol group Chemical class 0.000 claims description 5
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 5
- 235000001892 vitamin D2 Nutrition 0.000 claims description 5
- 239000011653 vitamin D2 Substances 0.000 claims description 5
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims description 4
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 claims description 4
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims description 4
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 4
- MCWVPSBQQXUCTB-UHFFFAOYSA-N (24Z)-5alpha-Stigmasta-7,24(28)-dien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(=CC)C(C)C)CCC33)C)C3=CCC21 MCWVPSBQQXUCTB-UHFFFAOYSA-N 0.000 claims description 4
- QJHZPCLORSPENH-YVJYXHLXSA-N (3s,6r,8s,9s,13r,14s,17r)-6-(iodomethyl)-13-methyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol Chemical compound C1([C@H](CI)C[C@H]2[C@@H]3CC[C@@H]([C@]3(CC[C@@H]22)C)[C@H](C)CCCC(C)C)=C2CC[C@H](O)C1 QJHZPCLORSPENH-YVJYXHLXSA-N 0.000 claims description 4
- NPEIGRBGMUJNFE-UHFFFAOYSA-N 1-aminohexan-1-ol Chemical compound CCCCCC(N)O NPEIGRBGMUJNFE-UHFFFAOYSA-N 0.000 claims description 4
- WGAOZGUUHIBABN-UHFFFAOYSA-N 1-aminopentan-1-ol Chemical compound CCCCC(N)O WGAOZGUUHIBABN-UHFFFAOYSA-N 0.000 claims description 4
- MXZROAOUCUVNHX-UHFFFAOYSA-N 2-Aminopropanol Chemical compound CCC(N)O MXZROAOUCUVNHX-UHFFFAOYSA-N 0.000 claims description 4
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 claims description 4
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims description 4
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 claims description 4
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 4
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims description 4
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims description 4
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 4
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 4
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 claims description 4
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 4
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- MCWVPSBQQXUCTB-OQTIOYDCSA-N avenasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC/C(=C/C)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 MCWVPSBQQXUCTB-OQTIOYDCSA-N 0.000 claims description 4
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims description 4
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 claims description 4
- 235000004420 brassicasterol Nutrition 0.000 claims description 4
- QVYARBLCAHCSFJ-UHFFFAOYSA-N butane-1,1-diamine Chemical compound CCCC(N)N QVYARBLCAHCSFJ-UHFFFAOYSA-N 0.000 claims description 4
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 4
- 235000000431 campesterol Nutrition 0.000 claims description 4
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 4
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 claims description 4
- 150000002423 hopanoids Chemical class 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- KJOMYNHMBRNCNY-UHFFFAOYSA-N pentane-1,1-diamine Chemical compound CCCCC(N)N KJOMYNHMBRNCNY-UHFFFAOYSA-N 0.000 claims description 4
- GGHDAUPFEBTORZ-UHFFFAOYSA-N propane-1,1-diamine Chemical compound CCC(N)N GGHDAUPFEBTORZ-UHFFFAOYSA-N 0.000 claims description 4
- ZNZJJSYHZBXQSM-UHFFFAOYSA-N propane-2,2-diamine Chemical compound CC(C)(N)N ZNZJJSYHZBXQSM-UHFFFAOYSA-N 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 4
- 235000015500 sitosterol Nutrition 0.000 claims description 4
- 229950005143 sitosterol Drugs 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 229940032091 stigmasterol Drugs 0.000 claims description 4
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 4
- 235000016831 stigmasterol Nutrition 0.000 claims description 4
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 4
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 claims description 4
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 claims description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 3
- 235000020944 retinol Nutrition 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- QTRJLNBPPRTNEC-UHFFFAOYSA-N 4,4-bis(aminomethyl)heptane-1,7-diamine Chemical compound NCCCC(CN)(CN)CCCN QTRJLNBPPRTNEC-UHFFFAOYSA-N 0.000 claims description 2
- YJLYANLCNIKXMG-UHFFFAOYSA-N N-Methyldioctylamine Chemical compound CCCCCCCCN(C)CCCCCCCC YJLYANLCNIKXMG-UHFFFAOYSA-N 0.000 claims description 2
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 claims description 2
- 235000021322 Vaccenic acid Nutrition 0.000 claims description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
- 229940113720 aminosalicylate Drugs 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
- 229960002747 betacarotene Drugs 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 claims description 2
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 150000003704 vitamin D3 derivatives Chemical class 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- SKWCZPYWFRTSDD-UHFFFAOYSA-N 2,3-bis(azaniumyl)propanoate;chloride Chemical compound Cl.NCC(N)C(O)=O SKWCZPYWFRTSDD-UHFFFAOYSA-N 0.000 claims 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 35
- 238000005804 alkylation reaction Methods 0.000 abstract description 19
- 230000029936 alkylation Effects 0.000 abstract description 17
- 230000032050 esterification Effects 0.000 abstract description 17
- 238000005886 esterification reaction Methods 0.000 abstract description 17
- 239000000969 carrier Substances 0.000 abstract description 16
- 238000006266 etherification reaction Methods 0.000 abstract description 16
- 230000009435 amidation Effects 0.000 abstract description 14
- 238000007112 amidation reaction Methods 0.000 abstract description 14
- 125000000524 functional group Chemical group 0.000 abstract description 12
- 238000005859 coupling reaction Methods 0.000 abstract description 10
- 238000007126 N-alkylation reaction Methods 0.000 abstract description 8
- 229920001477 hydrophilic polymer Polymers 0.000 abstract description 7
- 238000010934 O-alkylation reaction Methods 0.000 abstract description 6
- 238000001311 chemical methods and process Methods 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 6
- 150000002634 lipophilic molecules Chemical class 0.000 abstract description 6
- 239000002417 nutraceutical Substances 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 60
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 50
- 239000000126 substance Substances 0.000 description 49
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- 239000000203 mixture Substances 0.000 description 48
- 229940097362 cyclodextrins Drugs 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 37
- 239000000243 solution Substances 0.000 description 37
- 125000005647 linker group Chemical group 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 31
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 21
- 239000012043 crude product Substances 0.000 description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 20
- 230000008569 process Effects 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 14
- 229940068917 polyethylene glycols Drugs 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000012384 transportation and delivery Methods 0.000 description 13
- 230000003993 interaction Effects 0.000 description 12
- 229920001542 oligosaccharide Polymers 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 150000003722 vitamin derivatives Chemical class 0.000 description 10
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000003381 solubilizing effect Effects 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 229960004740 voriconazole Drugs 0.000 description 9
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 8
- 239000004530 micro-emulsion Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 238000005063 solubilization Methods 0.000 description 8
- 230000007928 solubilization Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- IQGMRVWUTCYCST-UHFFFAOYSA-N 3-Aminosalicylic acid Chemical class NC1=CC=CC(C(O)=O)=C1O IQGMRVWUTCYCST-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 230000002949 hemolytic effect Effects 0.000 description 7
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 7
- 229960004134 propofol Drugs 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- ARXKVVRQIIOZGF-UHFFFAOYSA-N 1,2,4-butanetriol Chemical compound OCCC(O)CO ARXKVVRQIIOZGF-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 125000004103 aminoalkyl group Chemical group 0.000 description 6
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229960002898 threonine Drugs 0.000 description 6
- 229960001124 trientine Drugs 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000010668 complexation reaction Methods 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 5
- ZQXIMYREBUZLPM-UHFFFAOYSA-N 1-aminoethanethiol Chemical compound CC(N)S ZQXIMYREBUZLPM-UHFFFAOYSA-N 0.000 description 4
- AEUVIXACNOXTBX-UHFFFAOYSA-N 1-sulfanylpropan-1-ol Chemical compound CCC(O)S AEUVIXACNOXTBX-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 4
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 4
- IVUOMFWNDGNLBJ-UHFFFAOYSA-N 4-azaniumyl-2-hydroxybutanoate Chemical compound NCCC(O)C(O)=O IVUOMFWNDGNLBJ-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 239000005700 Putrescine Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- WJXSWCUQABXPFS-UHFFFAOYSA-N aminohydroxybenzoic acid Natural products NC1=C(O)C=CC=C1C(O)=O WJXSWCUQABXPFS-UHFFFAOYSA-N 0.000 description 4
- 229960005261 aspartic acid Drugs 0.000 description 4
- GCAIEATUVJFSMC-UHFFFAOYSA-N benzene-1,2,3,4-tetracarboxylic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1C(O)=O GCAIEATUVJFSMC-UHFFFAOYSA-N 0.000 description 4
- VERMEZLHWFHDLK-UHFFFAOYSA-N benzene-1,2,3,4-tetrol Chemical compound OC1=CC=C(O)C(O)=C1O VERMEZLHWFHDLK-UHFFFAOYSA-N 0.000 description 4
- UJMDYLWCYJJYMO-UHFFFAOYSA-N benzene-1,2,3-tricarboxylic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1C(O)=O UJMDYLWCYJJYMO-UHFFFAOYSA-N 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 229960002743 glutamine Drugs 0.000 description 4
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical group OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 description 4
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 235000012658 paprika extract Nutrition 0.000 description 4
- 239000001688 paprika extract Substances 0.000 description 4
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 4
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- KKTUQAYCCLMNOA-UHFFFAOYSA-N 2,3-diaminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-N 0.000 description 3
- PCAXITAPTVOLGL-UHFFFAOYSA-N 2,3-diaminophenol Chemical compound NC1=CC=CC(O)=C1N PCAXITAPTVOLGL-UHFFFAOYSA-N 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 3
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229960003305 alfaxalone Drugs 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229960004909 aminosalicylic acid Drugs 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 235000019244 cryptoxanthin Nutrition 0.000 description 3
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- PONXTPCRRASWKW-KBPBESRZSA-N diphenylethylenediamine Chemical compound C1([C@H](N)[C@@H](N)C=2C=CC=CC=2)=CC=CC=C1 PONXTPCRRASWKW-KBPBESRZSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 229960004130 itraconazole Drugs 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 239000007908 nanoemulsion Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000012454 non-polar solvent Substances 0.000 description 3
- 235000021313 oleic acid Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 229960002957 praziquantel Drugs 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- DGYNEKPTRLXGTP-UHFFFAOYSA-N propane-1,3-diamine Chemical compound NCCCN.NCCCN DGYNEKPTRLXGTP-UHFFFAOYSA-N 0.000 description 3
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 3
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 3
- 235000020945 retinal Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 239000008137 solubility enhancer Substances 0.000 description 3
- 150000003429 steroid acids Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- CYFJIBWZIQDUSZ-UHFFFAOYSA-N thioglycine Chemical compound NCC(S)=O CYFJIBWZIQDUSZ-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 3
- XIRPBQNRBONGQR-UHFFFAOYSA-N (1-hydroxypiperidin-2-yl)methanol Chemical compound OCC1CCCCN1O XIRPBQNRBONGQR-UHFFFAOYSA-N 0.000 description 2
- WKIKHHMUNOVQLD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-prop-2-ynoxypropanoate Chemical compound C#CCOCCC(=O)ON1C(=O)CCC1=O WKIKHHMUNOVQLD-UHFFFAOYSA-N 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 2
- JRHJXXLCNATYLS-SOOLLQOPSA-N (2s,6s,7ar)-2-[(2e,4e,6e,8e,10e,12e,14e,16e)-17-[(1r,4r)-4-hydroxy-2,6,6-trimethylcyclohex-2-en-1-yl]-6,11,15-trimethylheptadeca-2,4,6,8,10,12,14,16-octaen-2-yl]-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-6-ol Chemical compound C/C([C@@H]1C=C2C(C)(C)C[C@H](O)C[C@@]2(C)O1)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C JRHJXXLCNATYLS-SOOLLQOPSA-N 0.000 description 2
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 2
- ABTRFGSPYXCGMR-KXQOOQHDSA-N (3R)-beta,psi-caroten-3-ol Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C ABTRFGSPYXCGMR-KXQOOQHDSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 2
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 2
- GVOIABOMXKDDGU-XRODXAHISA-N (3S,3'S,5R,5'R)-3,3'-dihydroxy-kappa,kappa-carotene-6,6'-dione Chemical compound O=C([C@@]1(C)C(C[C@H](O)C1)(C)C)/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C GVOIABOMXKDDGU-XRODXAHISA-N 0.000 description 2
- GVOIABOMXKDDGU-LOFNIBRQSA-N (3S,3'S,5R,5'R)-3,3'-dihydroxy-kappa,kappa-carotene-6,6'-dione Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C(=O)C1(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C GVOIABOMXKDDGU-LOFNIBRQSA-N 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 2
- OTVRYZXVVMZHHW-FNOPAARDSA-N (8s,9s,10r,13r,14s,17r)-3-chloro-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1C=C2CC(Cl)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OTVRYZXVVMZHHW-FNOPAARDSA-N 0.000 description 2
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 description 2
- CUXYLFPMQMFGPL-BGDVVUGTSA-N (9Z,11E,13Z)-octadecatrienoic acid Chemical compound CCCC\C=C/C=C/C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-BGDVVUGTSA-N 0.000 description 2
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 2
- QYEURSSKQCQMHG-UHFFFAOYSA-N 1-(hydroxymethylamino)cyclopentane-1,2-diol Chemical compound OC1C(CCC1)(NCO)O QYEURSSKQCQMHG-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- YANNINVHYCGRMI-UHFFFAOYSA-N 2-(dihydroxyamino)phenol Chemical compound ON(O)C1=CC=CC=C1O YANNINVHYCGRMI-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
- LDOMKUVUXZRECL-UHFFFAOYSA-N 2-aminobenzene-1,3-dicarboxylic acid Chemical compound NC1=C(C(O)=O)C=CC=C1C(O)=O LDOMKUVUXZRECL-UHFFFAOYSA-N 0.000 description 2
- WVDGHGISNBRCAO-UHFFFAOYSA-N 2-hydroxyisophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1O WVDGHGISNBRCAO-UHFFFAOYSA-N 0.000 description 2
- JKRIWPXSEMPTNP-UHFFFAOYSA-N 2-hydroxylaminobenzoic acid Chemical compound ONC1=CC=CC=C1C(O)=O JKRIWPXSEMPTNP-UHFFFAOYSA-N 0.000 description 2
- QHKDQJHPIRRPBA-UHFFFAOYSA-N 3,4-dimethoxybenzene-1,2-diamine Chemical compound COC1=CC=C(N)C(N)=C1OC QHKDQJHPIRRPBA-UHFFFAOYSA-N 0.000 description 2
- HWZGZWSHHNWSBP-UHFFFAOYSA-N 3-(2,3-diaminophenoxy)benzene-1,2-diamine Chemical compound NC1=CC=CC(OC=2C(=C(N)C=CC=2)N)=C1N HWZGZWSHHNWSBP-UHFFFAOYSA-N 0.000 description 2
- ZSNIVQDQECTJAJ-UHFFFAOYSA-N 3-amino-2-bromophenol Chemical compound NC1=CC=CC(O)=C1Br ZSNIVQDQECTJAJ-UHFFFAOYSA-N 0.000 description 2
- MGBKJKDRMRAZKC-UHFFFAOYSA-N 3-aminobenzene-1,2-diol Chemical compound NC1=CC=CC(O)=C1O MGBKJKDRMRAZKC-UHFFFAOYSA-N 0.000 description 2
- DOMSGNHHKOFONC-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-2,3-dihydroxy-4-oxobutanoic acid Chemical compound OC(=O)C(O)C(O)C(=O)ON1C(=O)CCC1=O DOMSGNHHKOFONC-UHFFFAOYSA-N 0.000 description 2
- QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 2
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- AFPLNGZPBSKHHQ-UHFFFAOYSA-N Betulaprenol 9 Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCO AFPLNGZPBSKHHQ-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- BDMCAOBQLHJGBE-UHFFFAOYSA-N C60-polyprenol Natural products CC(=CCCC(=CCCC(=CCCC(=CCCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CO)C)C)C)C)C)C)C)C)C)C)C)C BDMCAOBQLHJGBE-UHFFFAOYSA-N 0.000 description 2
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 2
- GVOIABOMXKDDGU-SUKXYCKUSA-N Capsorubin Natural products O=C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C(=O)[C@@]1(C)C(C)(C)C[C@H](O)C1)\C)/C)\C)/C)[C@@]1(C)C(C)(C)C[C@H](O)C1 GVOIABOMXKDDGU-SUKXYCKUSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- IFYMEZNJCAQUME-APKWKYNESA-N Chrysanthemaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C=CC3=C(C)CC(O)CC3(C)C IFYMEZNJCAQUME-APKWKYNESA-N 0.000 description 2
- 239000004212 Cryptoxanthin Substances 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
- PVNVIBOWBAPFOE-UHFFFAOYSA-N Dinoxanthin Natural products CC1(O)CC(OC(=O)C)CC(C)(C)C1=C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1(C(CC(O)C2)(C)C)C2(C)O1 PVNVIBOWBAPFOE-UHFFFAOYSA-N 0.000 description 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000004213 Violaxanthin Substances 0.000 description 2
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 2
- QNEPTKZEXBPDLF-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 2
- PGYAYSRVSAJXTE-CLONMANBSA-N all-trans-neoxanthin Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C=C=C1C(C)(C)C[C@H](O)C[C@@]1(C)O PGYAYSRVSAJXTE-CLONMANBSA-N 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 238000011938 amidation process Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- LHIJANUOQQMGNT-UHFFFAOYSA-N aminoethylethanolamine Chemical compound NCCNCCO LHIJANUOQQMGNT-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- YLUSVJDFTAATNS-RVORTWRGSA-N auroxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(C)/C3OC4(C)CC(O)CC(C)(C)C4=C3 YLUSVJDFTAATNS-RVORTWRGSA-N 0.000 description 2
- YLUSVJDFTAATNS-BXOKDNRRSA-N auroxanthin Chemical compound O1C2(C)CC(O)CC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C1C=C2C(C)(C)CC(O)CC2(C)O1 YLUSVJDFTAATNS-BXOKDNRRSA-N 0.000 description 2
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 2
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000001615 biotins Chemical class 0.000 description 2
- 235000018889 capsanthin Nutrition 0.000 description 2
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 2
- 235000009132 capsorubin Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000015861 cell surface binding Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- VYOCYWDJTQRZLC-KCDKBNATSA-N deoxyfuconojirimycin Chemical compound C[C@@H]1NC[C@@H](O)[C@H](O)[C@@H]1O VYOCYWDJTQRZLC-KCDKBNATSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000019256 formaldehyde Nutrition 0.000 description 2
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 2
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 2
- YQGDEPYYFWUPGO-UHFFFAOYSA-N gamma-amino-beta-hydroxybutyric acid Chemical compound [NH3+]CC(O)CC([O-])=O YQGDEPYYFWUPGO-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
- 229960002867 griseofulvin Drugs 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- AXEYWFGSQDLHDX-UHFFFAOYSA-N hexane-1,3,6-triamine Chemical compound NCCCC(N)CCN AXEYWFGSQDLHDX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012051 hydrophobic carrier Substances 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000010189 intracellular transport Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- OWAAYLVMANNJOG-OAKWGMHJSA-N neoxanthin Natural products CC(=C/C=C(C)/C=C/C=C(C)/C=C=C1C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC23OC2(C)CC(O)CC3(C)C OWAAYLVMANNJOG-OAKWGMHJSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 2
- 229960001589 posaconazole Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 2
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 235000009514 rubixanthin Nutrition 0.000 description 2
- 239000000455 rubixanthin Substances 0.000 description 2
- ABTRFGSPYXCGMR-SDPRXREBSA-N rubixanthin Natural products O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=C(\CC/C=C(\C)/C)/C)\C)/C)\C)/C)=C(C)C1 ABTRFGSPYXCGMR-SDPRXREBSA-N 0.000 description 2
- JBYXPOFIGCOSSB-UQGDGPGGSA-N rumenic acid Chemical compound CCCCCC\C=C/C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-UQGDGPGGSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 2
- AFPLNGZPBSKHHQ-MEGGAXOGSA-N solanesol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO AFPLNGZPBSKHHQ-MEGGAXOGSA-N 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical class C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 235000019245 violaxanthin Nutrition 0.000 description 2
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- 235000010930 zeaxanthin Nutrition 0.000 description 2
- 239000001775 zeaxanthin Substances 0.000 description 2
- 229940043269 zeaxanthin Drugs 0.000 description 2
- MAKGRQMFNNEEKW-KTKRTIGZSA-N (2,5-dioxopyrrolidin-1-yl) (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)ON1C(=O)CCC1=O MAKGRQMFNNEEKW-KTKRTIGZSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- DTBVNEAXNUOQSR-LURJTMIESA-N (2S)-3-hydroxy-2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCC(=O)N[C@@H](CO)C(O)=O DTBVNEAXNUOQSR-LURJTMIESA-N 0.000 description 1
- SZQQHKQCCBDXCG-BAHYSTIISA-N (2e,4e,6e)-hexadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C(O)=O SZQQHKQCCBDXCG-BAHYSTIISA-N 0.000 description 1
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 description 1
- HPSWUFMMLKGKDS-DNKOKRCQSA-N (2e,4e,6e,8e,10e,12e)-tetracosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O HPSWUFMMLKGKDS-DNKOKRCQSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 description 1
- DWAWDSVKAUWFHC-QHCPKHFHSA-N (2s)-5-[methyl(2-phenylethyl)amino]-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound C([C@@](C(C)C)(C#N)C=1C=CC=CC=1)CCN(C)CCC1=CC=CC=C1 DWAWDSVKAUWFHC-QHCPKHFHSA-N 0.000 description 1
- KXVFBCSUGDNXQF-DZDBOGACSA-N (2z,4z,6z,8z,10z)-tetracosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C=C/C(O)=O KXVFBCSUGDNXQF-DZDBOGACSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 description 1
- DQGMPXYVZZCNDQ-KBPWROHVSA-N (8E,10E,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C=C/C=C/CCCCCCC(O)=O DQGMPXYVZZCNDQ-KBPWROHVSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8r,9s,10r,13s,14s,16r)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- WTMLOMJSCCOUNI-QQFSJYTNSA-N (9Z,11E,15Z)-octadeca-9,11,15-trienoic acid Chemical compound CC\C=C/CC\C=C\C=C/CCCCCCCC(O)=O WTMLOMJSCCOUNI-QQFSJYTNSA-N 0.000 description 1
- HVGRZDASOHMCSK-UHFFFAOYSA-N (Z,Z)-13,16-docosadienoic acid Natural products CCCCCC=CCC=CCCCCCCCCCCCC(O)=O HVGRZDASOHMCSK-UHFFFAOYSA-N 0.000 description 1
- DWHJJLTXBKSHJG-HWKANZROSA-N (e)-5-hydroxy-2-methylpent-2-enoic acid Chemical compound OC(=O)C(/C)=C/CCO DWHJJLTXBKSHJG-HWKANZROSA-N 0.000 description 1
- AZWHPGZNOIYGFB-UHFFFAOYSA-N 1,3,5-trimethylcyclohexane-1,3,5-tricarboxylic acid Chemical compound OC(=O)C1(C)CC(C)(C(O)=O)CC(C)(C(O)=O)C1 AZWHPGZNOIYGFB-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- ZUTNVKDMDDLIEF-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-methylperoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound [H]C([H])([H])OOC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])O ZUTNVKDMDDLIEF-UHFFFAOYSA-N 0.000 description 1
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- RXFCIXRFAJRBSG-UHFFFAOYSA-N 3,2,3-tetramine Chemical compound NCCCNCCNCCCN RXFCIXRFAJRBSG-UHFFFAOYSA-N 0.000 description 1
- SSZWWUDQMAHNAQ-UHFFFAOYSA-N 3-chloropropane-1,2-diol Chemical compound OCC(O)CCl SSZWWUDQMAHNAQ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- OQOCQFSPEWCSDO-JLNKQSITSA-N 6Z,9Z,12Z,15Z,18Z-Heneicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O OQOCQFSPEWCSDO-JLNKQSITSA-N 0.000 description 1
- DQGMPXYVZZCNDQ-KDQYYBQISA-N 8Z,10E,12Z-octadecatrienoic acid Chemical compound CCCCC\C=C/C=C/C=C\CCCCCCC(O)=O DQGMPXYVZZCNDQ-KDQYYBQISA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- QQXWWCIEPUFZQL-YAJBEHDUSA-N Bosseopentaenoic acid Natural products CCCCCC=C/C=C/C=C/C=CCC=C/CCCC(=O)O QQXWWCIEPUFZQL-YAJBEHDUSA-N 0.000 description 1
- BQMUFHCSMOQBQZ-JXGYXAOLSA-N C(CCCCCCC\C=C/CCCC)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)O Chemical compound C(CCCCCCC\C=C/CCCC)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)O BQMUFHCSMOQBQZ-JXGYXAOLSA-N 0.000 description 1
- 0 C*C(CC*)N Chemical compound C*C(CC*)N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- CUXYLFPMQMFGPL-WJTNUVGISA-N Catalpic acid Chemical compound CCCC\C=C/C=C/C=C/CCCCCCCC(O)=O CUXYLFPMQMFGPL-WJTNUVGISA-N 0.000 description 1
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DQGMPXYVZZCNDQ-XUAYTHHASA-N Jacaric acid Natural products CCCCCC=C/C=C/C=CCCCCCCC(=O)O DQGMPXYVZZCNDQ-XUAYTHHASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- DUQGREMIROGTTD-UHFFFAOYSA-N Monuron-TCA Chemical compound OC(=O)C(Cl)(Cl)Cl.CN(C)C(=O)NC1=CC=C(Cl)C=C1 DUQGREMIROGTTD-UHFFFAOYSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- BIGZKRLPEMVRLD-UHFFFAOYSA-N N,N-dimethylmethanamine hexadecan-1-ol Chemical compound CN(C)C.CCCCCCCCCCCCCCCCO BIGZKRLPEMVRLD-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241000939411 Salpa thompsoni Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000251555 Tunicata Species 0.000 description 1
- RNZDACWUXZHQMI-PCHCLZCRSA-N [(8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 4-methylbenzenesulfonate Chemical compound C([C@H]1[C@@H]2CC[C@@H]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)[C@H](C)CCCC(C)C)C=C1CC2OS(=O)(=O)C1=CC=C(C)C=C1 RNZDACWUXZHQMI-PCHCLZCRSA-N 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical group ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229920006187 aquazol Polymers 0.000 description 1
- 239000012861 aquazol Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DQGMPXYVZZCNDQ-OBWVEWQSSA-N beta-calendic acid Chemical compound CCCCC\C=C\C=C\C=C\CCCCCCC(O)=O DQGMPXYVZZCNDQ-OBWVEWQSSA-N 0.000 description 1
- DMASLKHVQRHNES-FKKUPVFPSA-N beta-cryptoxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C DMASLKHVQRHNES-FKKUPVFPSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- QQXWWCIEPUFZQL-JMFSJNRSSA-N bosseopentaenoic acid Chemical compound CCCCC\C=C/C=C/C=C/C=C\C\C=C/CCCC(O)=O QQXWWCIEPUFZQL-JMFSJNRSSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- YAGCIXJCAUGCGI-UHFFFAOYSA-N butoxycarbonyl butyl carbonate Chemical compound CCCCOC(=O)OC(=O)OCCCC YAGCIXJCAUGCGI-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000005493 condensed matter Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- CVCXSNONTRFSEH-UHFFFAOYSA-N docosa-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCCCCCC=CC=CC(O)=O CVCXSNONTRFSEH-UHFFFAOYSA-N 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940080812 glyceryl caprate Drugs 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- OQOCQFSPEWCSDO-UHFFFAOYSA-N heneicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCC(O)=O OQOCQFSPEWCSDO-UHFFFAOYSA-N 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- IPVSQRLZENDNRL-KVVVOXFISA-N hexadecanoic acid;(z)-octadec-9-enoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O IPVSQRLZENDNRL-KVVVOXFISA-N 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- SWFMWXHHVGHUFO-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN.NCCCCCCN SWFMWXHHVGHUFO-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229950000483 levemopamil Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000885 poly(2-vinylpyridine) Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000767 polyaniline Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920001444 polymaleic acid Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 150000003726 retinal derivatives Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-M serinate Chemical compound OCC(N)C([O-])=O MTCFGRXMJLQNBG-UHFFFAOYSA-M 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- 229960005240 telavancin Drugs 0.000 description 1
- 108010089019 telavancin Proteins 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical class CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- UIYOVVYZPVVUMJ-UHFFFAOYSA-N tert-butyl carbamoyl carbonate Chemical compound CC(C)(C)OC(=O)OC(N)=O UIYOVVYZPVVUMJ-UHFFFAOYSA-N 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- IJTNSXPMYKJZPR-BYFNFPHLSA-N trans-parinaric acid Chemical compound CC\C=C\C=C\C=C\C=C\CCCCCCCC(O)=O IJTNSXPMYKJZPR-BYFNFPHLSA-N 0.000 description 1
- IJTNSXPMYKJZPR-UHFFFAOYSA-N trans-parinaric acid Natural products CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- CUXYLFPMQMFGPL-UYWAGRGNSA-N trichosanic acid Natural products CCCCC=C/C=C/C=CCCCCCCCC(=O)O CUXYLFPMQMFGPL-UYWAGRGNSA-N 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Definitions
- the present invention relates to polymer-cyclodextrin-lipid Conjugates, detailed and specific disclosures are given for synthetic polyethylene glycol (PEG)-cyclodextrin-lipid conjugates with fatty or sterols or so called “fat soluble” vitamins ("lipo-vitamin”) as the lipophilic carriers in the conjugates and preferably having substantially monodisperse PEG chains if used for intravenous drug administration. More particularly, the present invention relates to novel polymer-cyclodextrin-lipid conjugates having cyclic oligosaccharides to replace linear oligosaccharides as for the carbohydrate component in our previous inventions.
- Such combination of the core characters of lipophilic solubilization wherein polymer-lipids and inclusion comlexation wherein cyclodextrins may maximize the ability of the conjugates for delivering poor water soluble therapeutic agents and reduction of toxicity in pharmaceutical products as well use for cosmetics or foods and other purposes.
- Systemic drug delivery may be achieved by intravenous or intraperiplieral injection and therefore is non-invasive.
- the drugs may be administered repeatedly as needed.
- systemic administration requires large dosages with relatively high vehicle contents which may cause side effects such as allergic reactions ["Cremophor-based paclitaxel 'chemo' drug triggers fatal allergic reactions," The Medical News. 9 June 2009],
- Cyclodextrins are cyclic oligosaccharides (Chemical Structure 1) that have been studied for several decades and as one of the leading pharmaceutical excipients approved by the US FDA (Food and Drug administration) for dozens of marketed pharmaceutical products, they are continued being utilized as an important vehicle for poor water soluble agents. Unlike polymer excipients, CDs are biological active and their solubilizing ability achieved through forming water- soluble complexes with many hydrophobic agents.
- Lipids are a group of naturally occurring molecules including fatty acids, sterols and fat- soluble vitamins (vitamin A, D and E), monoglycerides, diglycerides, triglycerides, phospholipids, and others.
- the main biological functions of lipids include storing energy, signaling, and acting as structural components of cell membranes [Fahy E, Subramaniam S, Brown HA, et al. (2005). "A comprehensive classification system for lipids”. J Lipid Res. 46 (5): 839-61].
- the lipid classification scheme is chemically based and driven by the distinct hydrophobic and hydrophilic elements that compose the lipid.
- Lipids such as sterols and related compounds play essential roles in the physiology of eukaryotic organisms are a subgroup of the steroids. They occur naturally in plants, animals, and fungi, the most familiar type of animal sterol is cholesterol. Cholesterol is vital to animal cell membrane structure and function and forms part of the cellular membrane in animals, where it affects the cell membrane's fluidity and serves as secondary messenger in developmental signaling [Alberts B, Johnson A, Lewis J, Raff M, Roberts K, and Walter P (2002). Molecular biology of the cell. 4 th Edition, New York: Garland Science, p. 1874].
- the present invention compromises one of the three carrier groups consisting of a lipid including but not limited to fatty acids, sterols including but not limited to cholesterol, stigmasterol, ergosterol, hopanoids, phytosterol, sitosterol, campesterol, brassicasterol, avenasterol adosterol, and stanols (saturated steroid alcohols or hydrogenated sterols).
- Sterols are biological importance as a highly compatible vehicle for drug delivery, for instance cholesterol makes up about 10-50 percent of the total lipid in natural cell membranes, the conjugates containing sterols or fat soluble vitamins may increase the drug permeation for cell targeted delivering.
- the human body has a natural tendency to maintain homeostasis, and may be elaborated from substances present in the diet, sometimes exclusively, for vitamins, minerals, essential amino-acids and essential fatty acids including polyunsaturated fatty acids which play a significant role in the prevention of cardiovascular disease in human.
- Vitamin E is the general term for all tocopherols and tocotrienols, of which alpha-tocopherol is the natural and biologically most active form.
- the antioxidant function of vitamin E is considered to be critical for the prevention of oxidation of tissue. While these molecules are essential for the human body, they may be utilized as safer ingredients to design for an ideal carbohydrate-lipid conjugate.
- the present invention compromises one of the three carrier groups consisting of a sterol or fat soluble vitamin.
- Another carrier group is a cyclodextrins containing a number of glucose monomers ranging from six to eight units in a ring.
- the third carrier is a water soluble polymer such as polyethylene glycol.
- the three carrier groups are attached covalently to a center backbone where at least three bonding positions or sites available. The conjugation may be achieved via one or more types of reactions or combination of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation.
- Vitamins are either water-soluble or fat-soluble (soluble in lipids and nonpolar compounds), depending on their molecular structures.
- Water-soluble vitamins have many polar groups and are hence soluble in polar solvents such as water.
- fat-soluble vitamins are predominantly nonpolar and hence are soluble in nonpolar solvents such as the fatty (nonpolar) tissue of the body.
- Solubility is a complex phenomenon that depends on the change in free energy (AG) of the process.
- AG free energy
- the change in free energy may be negative (i.e., AG ⁇ 0)
- AG free energy
- Narrow molecular weight distribution of drug delivery polymers is crucially important for biomedical applications, especially if used for intravenous injections.
- PEG-8 Caprylic/Capric Glycerides are mixtures of monoesters, diesters, and triesters of glycerol and monoesters and diesters of polyethylene glycols with a mean relative molecular weight between 200 and 400.
- PEG-8 CCG Paranteral administration of many water-insoluble drugs is restricted and hence is limited usable for human drug formulations.
- the present invention comprises compounds having a polymer-lipid conjugate comprising a backbone and three or four appended functional groups as showed in Figure 1 : one or two lipophilic vitamins or sterols or alike, one or two hydrophilic polymers, the polymer-lipid conjugates are then further attached to a cyclodextrin, the number of polymer-lipid conjugates attached to the cyclodextrin may be dependent on the available primary hydroxyl groups.
- the primary hydroxyl groups on the C-6 (denoted by an open arrow) have the highest reactivity, especially when bulky substitution reagents are used, and the secondary hydroxyl groups on C-2 and C-3 (denoted by a solid arrow) have least reactivity.
- the monotosylated cyclodextrin derivatives are synthesized by reacting molar equivalent of benzene or p-toluene- sulfonyl chloride with cyclodextrin in pyridine or DMF containing a base [R. C. Petter, J. S. Salek, C. T. Sikorsky, G. Kumaravel and F. T. Lin, J. Am. Chem. Soc, 1990, 1 12, 3860; X. M. Gao, L. H. Tong, Y. Inoue, and A. Tai, Synth. Commun., 1995, 25, 703; K. A. Martin and A. W.
- the monosubstituted 6-tosylcyclodextrins and mono-6- mesosylcyclodextrins are important precursors for a variety of modified cyclodextrins.
- a nucleophilic displacement of the tosyl or mesoyl group by suitable nuleophiles such as iodide, azide, thioacetate, alkyl, hydroxylamine or polyalkylamines yields monoiodo-, azido-, thio-, hydroxylamino-, or alkylamino-cyclodextrins [L. E. Fikes, D. T. Winn, R. W.
- n is a number of the glucopyranose rings of cyclodextrins ranging from 6 to 8 and "i” is the averaged number of substituents (molar degree of substitution) of PEG-lipid per glucopyranose repeat unit ranging from 0.5 to 3.
- Specific polymer or liphophilic groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutraceuticals, and the like.
- a variety of linkers between the backbone and functional groups may also be selected to optimize performance.
- the coupling reaction is one or combination or series of alkylation, esterification, etherification and amidation chemical process.
- Figure 1 shows a representation of PEG-p-cyclodextrin-cholesteryl- diaminopropane in the present invention as the sample polymer-cyclodextrin-lipid conjugate.
- the lengths of each partions of the conjugate are estamated by ChemBioDraw® Ultra 10 (CambridgeSoft, Waltham, MS, USA)
- Figure 2(a) showed the solubility comparision of 1% propofol in (1) 3.5% of Cholesteryl-lactobionate-mPEG12; (2) 35% of 2-Hydroxypropyl- -CD; (3) a mixture of 2% Cholesteryl-lactobionate-mPEG12 and 15% 2-Hydroxypropyl- -CD and (4) 2% of mPEG 12 -p- cyclodextrin-cholesterol and Figure 2(b) showsed the same sample solutions at day 5.
- PCL polymer-carbohydrate-lipid
- the present invention comprises the cyclic oligosaccharide portion of the polymer-cyclodextrin-lipid conjugates while those conjugates remains a basic structure having a backbone and three or four appended functional groups: one or two lipophilic vitamins or sterols or fatty acids, one or two hydrophilic polymers.
- the chemical and physical characters of cyclic oligosaccharides are significantly different from the linear oligosaccharides that were utilized in the previous invention.
- the hydrophobic compounds may be also solublized by either encapsulation or microemulsion with the PEG-lipid portion of the conjugate.
- the new conjugates act as a solubility enhancer of poor water soluble agents resulting in either a true solution or a very stable emulsified suspension with those of active agents.
- the degree of substitution of the cyclic oligosaccharides may be from 0.5 to 3.
- fatty acids 4(2), 130-136 may reduce the hemolytic effects of fatty acids alone similar to sterols or sterol-like compounds that may also significantly reduce potential hemolytic activity induced by fatty acids [Mimura, T. "Fatty acids and sterols of the tunicate, Salpa thompsoni, from the Antarctic Ocean: chemical composition and hemolytic activity” . Chemical & pharmaceutical bulletin, 34 (1986) 4562] . Unlike sterols, water soluble steroid acids (bile acids) are more likely inducing hemolytic anemia [Hani, A. "The pH dependence of the hemolytic potency of bile salts". Biochimica et biophysica acta, 1027 (1990) 199] .
- nonwater soluble sterols are preferable to be selected as the primary lipophilic carrier in the conjugates.
- the present invention comprises cyclodextrins to significantly reduce potential hemolytic activity of fatty acids as compared to commercial available PEG-lipids including polyethylene glycol sorbites, polyoxyethylated castor oil (Cremophor) and mono/diglycerides of caprylic/capric acid in glycerol (Capmul®) polyglycolized glycerides (Labrafac®), PEG-6 glyceryl monoleate or PEG-6 glyceryl linoleate (Labrafil®), PEG- 8 glyceryl caprylate/caprate (Labrasol®).
- PEG-lipids including polyethylene glycol sorbites, polyoxyethylated castor oil (Cremophor) and mono/diglycerides of caprylic/capric acid in glycerol (Capmul®) polyglycolized glycerides (Labrafac®), PEG-6 glyceryl monoleate or PEG-6 glyceryl
- the present invention comprises large a cyclic oligosaccharide ringe which are a rigid component in the conjugate construction, not having the same freedom of movement that the linear oligosaccharide based conjugates possess.
- This creates two different spaces in the conjugates if adjacent polymer-lipid substitutant of cyclodextrin is i.e., PEG-cholesterol, both "spaces" are rigid. If the polymer-lipid is PEG-oleate, than the second phase is more flexible than cyclodextrin.
- the size of a cyclodextrin is about one third (1/3) of the PEG- lipid substituent which provides an easy access for a solute "walking" between the two spaces. It is especially useful to have a two-phase/space structure in a single conjugate; there may be two concided solubilizing processes, inclusion comlexation of cyclodextrin based on a "host-quest” mechanism and microencapsulation of PEG-lipids based on a micellar solubilization.
- Voriconazole 1.82 200 349.3 sulfobutyl ether ⁇ -cyclodextrin 2242 16 2 2.5 Telavancin HC1 6.91 250 1755.6 hydroxypropyl-P-cyclodextrin 1396 10 2 12.6
- the polymer-CD-lipid conjugates in the present invention discloses a novel molecule(s) with two apolar centers or cores wherein hydrophophic interactions between the polymer-CD-lipid conjugate and a lipophilic solute may be largely increased, thus the water solubility of the solute may be significantly enhanced.
- cyclodextrin derivatives such as CD sulfoalkyl ether or hydroxypropyl-CD and CD copolymers
- increasing compositions or the polymer sizes may only increase the water solutibility themselves, not a hydrophobic interaction to a solute.
- a co-polymer may change cyclodextrin complexity efficiency
- the "host-guest" solubilization process underneath may be remained the same in contrast to the polymer-CD-lipid conjugates in the present invention, wherein a different microencapsulation process is introduced into or combined with the "host-guest" solubilization process.
- the present invention significantly improved the solubilizing power of cyclodextrins.
- cyclodextrins form complexes with many drugs through a process in which water molecules located in the center cavity are replaced by either the whole drug molecule or more frequently, by some lipophilic portion of the drug.
- the hydrophobic effect which involves breakdown and removal of the structured water molecules inside CD cavity and around the non-polar substrate.
- the drug-cyclodextrin complex formation is a dynamic equilibrium with free drug and cyclodextrin [R. Arun, et al (2008). Scientia Pharmaceutica. 76(4), 567-598; M. E. Brewster and T. Loftsson (2007). Advanced Drug Delivery Review.
- the CE of cyclodextrin is also largely influenced by the molecule shape of a solute in additional to its hydrophobicity as showed in the Tale 1. Hydrophobicity may be estimated by the oil/water phase partition coefficient (LogP). In the Tale 1 , where the Log Ps were calculated with a computer program of Marvin Sketch (ChemAxon Kft, Budapest, Hungary). A positive value indicates more oil soluble and a negative value indicates more water soluble.
- CD complexation is built on a temporal physical entrapment which may explain why high concentrations (or molar ratio) of CD typically required in the solubilization process, a simple 1/1 or 2/1 (CD/drug) complexation may not be sufficient to retain the solute in an aqueous environment.
- a PEG-lipid substituent is included (through the center backbone) to enhance the stability of CDs by providing a more lipophilic core and the conjugate encapsulated with a drug then will be fully soluble in water at room temperature.
- the binding positions to the CD with the PEG-lipid substituent may not be considered as critical and positional isomers may be produced during synthesis of the polymer-CD-lipid conjugates, while such isomers may be functionally equivalent.
- the choice of isomer may have implications in a variety of delivery process such as intracellular transport of lipophilic molecules as well as their use as vehicles in pharmaceutical applications.
- isomers may differ in the ability to stabilize a compound during solubilizing and storage.
- CDs cyclodextrins
- the hydrophobic interaction may be increased significantly by incorporating a CD group into the polymer-lipid conjugates.
- the water solubility is enhanced for those hydrophobes where the encapsulation of the lipophilic molecules into the cage-hydrophobic core of the conjugates is improved.
- the current invention presents a double-functional enhancer having stronger hydrophobic interactions with lipophilic solutes.
- the same hydrophobic interaction may not be achieved with CD alone due to the poor lipophilic character (Table 2) or PEG-linear carbohydrate-lipid alone due to the two solubilzing processes may compensate each other.
- the polymer-lipid substitutants of CDs support noninclusion-based drug solubilization such as micelle-like effects and molecular aggregation.
- the latter may result in a precipitation.
- novel polymer-CD-lipid conjugates having two apolar inner sites and outer sites with abounding hydroxyls and expendable polymer chains are good solubility enhancers. They may aid in the formation of stable solution or emulsions or blends of water and lipophilic agents. These conjugates provide an extended center apolar core which stabilizes hydrophobic molecules in water by maximizing the retaining power and reducing the interface energy at the liquid-liquid interface.
- the hydrophobic interaction is defined as an entropic effect generating from the disruption of highly dynamic hydrogen bonds between molecules of liquid water by the hydrophobic solute [T.P. Silverstein, "The Real Reason Why Oil and Water Don't Mix”. Journal of Chemical Education. 75(1998) 1 16-346].
- hydrophobic solute When a hydrophobic solute is mixed in an aqueous medium, hydrogen bonds between water molecules will be broken to make room for the hydrophobic solute; since water molecules do not react with the hydrophobic solute.
- Such hydrophobic effect may be quantified by measuring the partition coefficients of non-polar molecules between water and non- polar solvents. The partition coefficients may be transformed to free energy (AG) of transfer which includes enthalpy (AH) and entropic (AS) components.
- AG free energy
- AH enthalpy
- AS entropic
- the hydrophobic effect has been found to be entropy (AS ⁇ -driven at room temperature because of the reduced mobility of water molecules in solvation shell of the non-polar solute.
- the change in enthalpy (AH) of the system may be zero, negative or positive because the formation of the new hydrogen bonds may partially, completely, or over compensate for the hydrogen bonds broken by the entrance of the hydrophobic solute.
- the change in enthalpy may be insignificant in determining the spontaneity of mixing hydrophobic molecules and water because the change in entropy (AS) is very large.
- AG AH - T AS, with a small unknown value of AH and a large negative value of AS, the value of AG will turn out to be positive.
- a positive AG indicates that the mixing of the hydrophobe and water molecules is not spontaneous which results in a phase separation or precipitation.
- hydrophilic-lipophilic interaction is well balanced with the polymer-CD-lipid conjugates [Griffin WC. "Calculation of HLB Values of Non- Ionic Surfactants," Journal of the Society of Cosmetic Chemists. 5 (1954) 259].
- hydrophilic-lipophilic balance number remains greater than 15 due to the large polar portion in the conjugates to form translucent microemulsions spontaneously (Table 2).
- the polymer-CD-lipid conjugates in the present invention have optimized logP values which are able to form transparent solution or nanoemulsions spontaneously by a single polymer-CD-lipid conjugate and typically without co- solvent and external high energy input [Mason TG, Wilking JN, Meleson K, Chang CB, Graves SM. "Nanoemulsions: formation, structure, and physical properties", Journal of Physics: Condensed Matter, 18 (2006) R635-R666].
- a stable aqueous solution may be formed with smaller polymer-CD-lipid conjugates. This is superior over conventional CDs or CD derivatives or surfactants or other lipid-polymers since many undesirable side effects caused by CDs or surfactants or lipid-polymers, higher concentrations of CDs or CD derivatives are disadvantageous or prohibitive in many applications.
- the stability of a microemulsion or mechanically formed nanoemulsion by surfactants or CDs is often easily compromised by dilution, by heating, or by changing pH levels.
- polyethylene glycol PEG
- GRAS GRAS
- the backbone, "B” may be selected from a compound comprises at least three available binding positions or sites for the conjugation of a first carrier, a second carrier and a third carrier, each available binding position or site comprising an expendable amino, hydroxyl, or carboxylic group.
- the backbone may be selected from the group consisting of glycerol or glycerol-like analogues, polyamines, diamines, triamines, tetramines, aminodiol, aminotriols, aminoalcohols and amino acids having three available binding positions or sites, triols, tetraols, erythritol, triacids, tetracid, tetraacetic acid, glucoheptonic acid, and tartaric acid, including but not limited to ethanediamine, propanediamine, butanediamine, pentanediamine, hexanediamine, diethylenetriamine, 1 ,2-diaminoethane, 1 ,3-diaminopropane (propane- 1 ,3 -diamine), 4-amino-3- hydroxybutyric acid, N-(2-hydroxyethyl)ethylenediamine, 4-amino-2-hydroxybutyric acid, 2- hydroxy-4-
- the "Lipid” is a lipophilic compound or their diesters including but not limited to fatty acids or steroids or sterols or sterol-like compound or lipo-vitamin.
- the CD is a large carrier, it is still considered as one of the three carriers attached to the center backbone though the same or different linkers of alkylation or esterification or etherification or amidation between carrier groups and center backbones.
- Each linker may be as simple as oxygen or nitrogen or sulfur or other single atom to form an ester or ether or amide or thiol bond or alike between the carrier and center backbone.
- each linker may be single or replicate linkers selected from amino, succinylamino, acetamido, aminopentanamido, aminoacetyl, acryloyl, thiopropanoayl, N- (mercaptomethyl)propionamido, mercaptopropylthiopropanoyl, (1 ,2-dihydroxy-3-mercapto- propylthio)propanoyl, succinyl, acetyl, oxopentanoyl, carbamoyl, aminoalkyl, glutaramido, aminoethanethiol, mercaptopropanol, (hydroxypropylthio)propanoayl, 3-((2-propionamidoethyl)- disulfanyl)propanoayl, (((acetamido-ethyl)disulfanyl)propanoyloxy)glutaramido, aminoethanet- hioate
- Typical coupling reaction of the conjugates involves with one or more or combination or in series of alkylation including JV-alkylation or O-alkylation, etherification, esterification and amidation chemical processes.
- the general structure is meant to include all racemers or structural isomers of the structure, as they may be functionally equivalent.
- the PEG chain preferably consists of between about 5 and 1 15 subunits, and is preferably substantially monodisperse. 3 ⁇ 4 is the terminal group on the PEG chain may be selected from a wide variety of chemical moieties. Hydroxyl or methoxy is commonly selected as the terminal groups. R; preferably has a molecular weight of less than about 650.
- Commercially available PEG-lipid monoesters may be used to formulate many compounds by directly linking new moieties to the available positions on the center backbone.
- no drug or peptide or biomolecule will be selected as the center backbone.
- one of major applications of the present invention is for drug delivery, therefore the conjugates themselves as a delivery vehicle are chemically stable and preferably having less or no toxic to the body.
- the terminal group on the PEG chain may be selected from a wide variety of chemical moieties.
- Such moieties preferably have a molecular weight of less than 650.
- the terminal group may be a functional group that facilitates linking therapeutic or targeting agents to the surface of lipid vesicle aggregates.
- Linked therapeutic and targeting agents may include Fab fragments, cell surface binding agents, and the like. Additionally, the terminal group may include functional cell-targeting ligands such as folate, transferrin and molecules such as monoclonal antibodies, ligands for cellular receptors or specific peptide sequences may be attached to the liposomal surface to provide specific binding sites.
- functional cell-targeting ligands such as folate, transferrin and molecules such as monoclonal antibodies, ligands for cellular receptors or specific peptide sequences may be attached to the liposomal surface to provide specific binding sites.
- the terminal group may be neutral or include either negatively or positively charged head- groups such as decanolamine, octadecylolamine, octanolamine, butanolamine, dodecanolamine, hexanolamine, tetradecanolamine, hexadecanolamine, oleylamine, decanoltrimethylaminium, octadecyloltrimethylaminium, octanoltrimethylaminium, butanoltrimethylaminium, dodecanol- trimethylaminium, hexanoltrimethylaminium, tetradecanoltrimethylaminium, hexadecanol- trimethylaminium, oleyltrimethylaminium, for example.
- head- groups such as decanolamine, octadecylolamine, octanolamine, butanolamine, dodecanolamine
- R groups include fatty acids or alkyl groups such as alkoxy moieties, amino acids, and sugars including monosaccharides, disaccharides, trisaccharides and the oligosaccharides containing 1 , 2, 3, and 4 or more monosaccharide units respectively.
- targeting moieties such as antibody fragments and vitamins may also be used as R groups.
- the molecular weight of the R group is preferably less than about 650, and for most applications the R group is preferably easily polarized, in order to increase the binding and interaction with proteins at the targeted sites.
- well balanced ionic R groups are advantageously employed for certain modes of administrations such as topical gels and oral solutions targeting the mouth and throat.
- the present invention includes linking chemical groups that may be selected to optimize and improve PEG-CD-lipid based formulations. Selecting an appropriate linker between lipo- portion or PEG or CD and backbone may be important for several reasons, as described below.
- any inherit property of the molecules may be inactive. It is therefore an object of the invention to use less biodegradable linkers for stabilizing the bond between the center backbone and the carrier groups, especially when a portion of the conjugates alone may be relatively toxic.
- the present invention involves coupling reactions of the conjugates with one or more or combination or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. For practical and economic reasons, it is preferable making those conjugates from simple processes whenever possible at low costs.
- Retaining power of a solubilzing enhancer may be important in drug formulations and preventing drug precipitation from dilution or circulation in the body fluids.
- the present invention provides the means of enhancing retaining power by inclusion more hydrophobic carrier groups into polymer-CD-lipid conjugates.
- the use of preservative may be eliminated for parenteral products since the sterile filtration is possible with a relative low concentration of the polymer conjugates in the dosage forms which typically form a true solution product.
- the CD groups in the conjugates of the present invention have larger surface polarity than polymer chains or lipophilic carriers.
- those PEG-CD-lipid conjugates provide a better drug dispersion for their applications in nano- suspension or nanoparticles, especially for some amphiphatic drugs or other compounds; this provides a better equilibrium for the drug or other compounds to partition into apolar cavity or the lipophilic core of the conjugates.
- PEG-lipids such as Capmul®, Centrophase®, Cremophor®, Labrafac®, Labrafil®, Labrasol® and Myverol®
- a taste masking agent may be used which may have additional issues for manufacturing processes and costs.
- PEG- CD-lipid conjugates generally taste better than other types of PEG-lipids conjugates, and elimination of the need for taste making agents may be possible.
- PEG-CD-lipid conjugates in the present invention may be formulated into injectable preparations free from sugars which are commonly used to stabilize lyophilized proteins and peptides for injectables. Injectables prepared with PEG-CD-lipid conjugates are very stable even under high temperature or high humidity conditions. Reducing or eliminating the use of sugars in pharmaceutical preparation is especially beneficial for patients with diabetes mellitus.
- the polymer chains in the conjugates of the present invention are preferably monodisperse or narrow-disperse PEG.
- Materials and methods for synthesizing such monodisperse PEG chains are disclosed in United States patent application 12/802,197, which is hereby incorporated by reference in its entirety.
- Preferably more than 30% of the PEG chains in a particular conjugate have the same molecular weight. More preferably, more than 50% have the same molecular weight. Most preferably, more than 80% have the same molecular weight.
- the general structure is meant to include all racemers or structural isomers of the structure, as they may be functionally equivalent.
- the polyethylene glycol is used as the polymer
- the PEG chain preferably consists of between about 5 and 1 15 subunits, and is preferably substantially monodisperse.
- R is the terminal group on the PEG chain may be selected from a wide variety of chemical moieties.
- R preferably has a molecular weight of less than about 650.
- the present invention includes compositions and methods for synthesizing PEG- CD-lipid conjugates comprising a center backbone with one PEG chain and one lipophilic group bonded to the backbone, the PEG-lipid may then attach to one of activated hydroxyl group of CDs, likewise the activated CDs may be attached to the center backbone by the similar processes as other carriers.
- the conjugation undergoes alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes.
- Selected linkers may be used to form ester or ether or amide bonds between the backbone and the PEG chain or the CD or the lipophilic group or prior to the conjugation to the center backbones.
- the backbone comprises glycerol or glycerol-liking having three available binding positions or diamines, triamines, tetramine and polyamines or diaminoalcohol or amino acids having three available binding positions and the lipophilic carrier group comprises fatty acids or sterols or cholesterol or cholesterol-like having a single hydroxyl group or tocopherol or tocotrienol or cholecalciferol or retinol, retinal, and retinoic acid.
- Variations of the invention include a variety of compounds as for the center backbone with at least three available binding positions. Molecules having two available binding positions, such as diamines, aminoalcohols or amino acids may be chemically extended to three binding sites.
- positional isomers may be produced during synthesis of the polymer-carbohydrate - lipid conjugates, such isomers may be functionally equivalent.
- the choice of isomer may have implications in a variety of delivery process such as intracellular transport of lipophilic molecules as well as their use as vehicles in pharmaceutical applications.
- isomers may differ in the ability to stabilize a compound during solubilizing and storage.
- the backbone may be selected from glycerol or glycerol-like analogues, polyamines (di- or tri-or tetra- or penta- amines), amino acids having three available binding sites, and triols and triacids such as glucoheptonic acid and tartaric acid.
- the lipophilic component may be selected from a group of compounds including but not limited to cholesterol, stigmasterol, ergosterol, hopanoids, phytosterol, sitosterol, campesterol, brassicasterol, avenasterol adosterol, and stanols (saturated steroid alcohols or hydrogenated sterols), retinoids, , retinals, retinoic acid, tretinoin, carotenoids, ⁇ -carotene, a-tocopherol, tocotrienols, cholecalciferol, ergocalciferol, astaxanthin, auroxanthin, capsanthin, capsorubin, chrysanthemaxanthin, cryptoxanthin, fucoxanthin, lutein, neoxanthin, rubixanthin, violaxanthin, zeaxanthin.
- stanols saturated steroid alcohols or hydrogenated sterols
- retinoids , retina
- the CD may be a-cyclodextrin or ⁇ -cyclodextrin or ⁇ - cyclodextrin.
- the same or different linkers may be used through alkylation or etherification or esterification or amidation process between carrier groups and center backbones. Each linker may be as simple as oxygen or sulfur or other single atom.
- each linker may be single or replicate linkers selected from amino, succinylamino, acetamido, aminopentanamido, aminoacetyl, acryloyl, thiopropanoayl, N-(mercaptomethyl)-propionamido, mercaptopropylthiopropanoyl, (1 ,2- dihydroxy-3-mercaptopropylthio)propanoyl, succinyl, acetyl, oxopentanoyl, carbamoyl, aminoalkyl, glutaramido, aminoethanethiol, mercaptopropanol, (hydroxypropylthio)propanoayl, 3- ((2-propionamidoethyl)disulfanyl)propanoayl, (((acetamido-ethyl)disulfanyl)propanoyloxy)- glutaramido, aminoethanethioate, and 2-
- the linker may be co-extensive with or a part of the backbone or functional group component used to synthesize the conjugate.
- the invention also includes compounds in which the carbohydrate is in the center position of the backbone. However, it is more practical to have carbohydrates at the terminus instead of the center of the backbones due to the routes of synthetic chemistry.
- the general structure is meant to include all racemers or structural isomers of the structure, as they may be functionally equivalent.
- the PEG chain preferably consists of between about 5 and 1 15 subunits, and is preferably substantially monodisperse.
- R is the terminal group on the PEG chain may be selected from a wide variety of chemical moieties. R preferably has a molecular weight of less than about 650.
- the myristoleic acid, palmitoleic acid, oleic acid, lauric acid, myristic acid, palmitic acid and stearic acid may be more commonly used.
- Myristoleic acid, palmitoleic acid, oleic acid palmitic acid and stearic acid may be more preferable..
- preferable amino acid linkers are proline, glycine, alanine, lysine, cysteine, valine, isoleucine, leucine, methionine, phenylalanine, histidine, tryptophan, tyrosine, selenocysteine, and arginine
- preferable amino acid linkers are proline, glycine, alanine, lysine, cysteine, valine, isoleucine, leucine, methionine
- a linker in the general structure 2, even though it may not show in the chemical drawing, a linker may comprise one or more carbon atoms in addition to the linker forming an N-alkylation or O-alkylation, ester or ether or amide bond between the carriers and center backbone.
- a simple and low cost coupling process should be chosen to void multiple linkers such as forming a peptide and the linker is preferably oriented so that the backbone is readily coupling to the carrier groups.
- the present invention may be practiced using a variety of center backbones void drug moieties.
- Preferable backbones have at least three available or two expandable positions for carbohydrate or lipid or PEG attachments through alkylation, esterification, etherification or amidation.
- suitable molecules may be used as the backbone including but not limited to the group consisting of ethylenediamine (1 ,2-diaminoethane, 1 ,3-diaminopropane (propane- 1 ,3- diamine), putrescine (butane- 1 ,4-diamine), cadaverine (pentane-l ,5-diamine), hexamethylene- diamine (hexane-l ,6-diamine), ethylenediamine, 1 ,3-diaminopropane, 1 ,2-diaminopropane, 1 ,4- diaminobutane, diphenylethylenediamine, diaminocyclohexane, 3-amino-l ,2-propanediol, 3- bromo-l ,2-propanediol, 3-chloro-l ,2-propanediol, 3-fluoro-l ,2-propaned
- a suitable center backbone may be selected from 4- (hydroxymethyl)cyclopentane-l ,3-diol, deoxyfuconojirimycin, deoxynojirimycin, prostaglandins, hydroxymethylpiperidinol, dihydroxy(hydroxymethyl)aminocyclopentane, diaminophenol, benzene-tetracarboxylic acid, benzenetricarboxylic acid, aminobenzenediol, dihydroxybenzoic acid, aminohydroxybenzoic acid, trihydroxyaniline, benzenetriol, dimethoxybenzenediamine, trihydroxyphenol, (diaminophenoxy)-benzene-diamine or aminobromophenol.
- polymer-CD-lipid conjugates of the present invention may be used for many applications. Formulation and delivery of pharmaceutical and cosmetic agents have been described. Additionally, the polymer-CD-lipid conjugates of the present invention may be used in other contexts where water soluble vehicles are advantages, for example industrial and food processes
- the terminal group on the PEG chain may be selected from a wide variety of chemical moieties.
- Such moieties preferably have a molecular weight of less than 650.
- the terminal group may be a functional group that facilitates linking therapeutic or targeting agents to the surface of micro vesicle aggregates.
- Linked therapeutic and targeting agents may include Fab fragments, cell surface binding agents, and the like. Additionally, the terminal group may include functional cell-targeting ligands such as folate, transferrin and molecules such as monoclonal antibodies, ligands for cellular receptors or specific peptide sequences may be attached to the liposomal surface to provide specific binding sites.
- functional cell-targeting ligands such as folate, transferrin and molecules such as monoclonal antibodies, ligands for cellular receptors or specific peptide sequences may be attached to the liposomal surface to provide specific binding sites.
- the terminal group may be neutral or include either negatively or positively charged head-groups such as decanolamine, octadecylolamine, octanolamine, butanolamine, dodecanolamine, hexanolamine, tetra-decanolamine, hexadecanolamine, oleylamine, decanoltrimethylaminium, octadecyloltri- methylaminium, octanoltrimethylaminium, butanoltrimethylaminium, dodecanoltrimethyl- aminium, hexanoltrimethylaminium, tetradecanoltrimethylaminium, hexadecanoltrimethyl- aminium, oleyltrimethylaminium, for example.
- head-groups such as decanolamine, octadecylolamine, octanolamine, butanolamine,
- R; groups include alkyl groups such as alkoxy moieties, amino acids, and sugars including monosaccharides, ascorbic acid, gluconic acid, glucaric acid, glucuronic acid, galacturonic acid, disaccharides, trisaccharides and the oligosaccharides containing 1 , 2, 3, and 4 or more monosaccharide units respectively. Additionally, targeting moieties such as antibody fragments and vitamins may also be used as 3 ⁇ 4 groups.
- the R; group is highly soluble in water. The molecular weight of the R; group is preferably less than about 650, and for most applications the Ri group is preferably easily polarized, in order to increase the binding and interaction with proteins at the targeted sites.
- well balanced ionic Ri groups are advantageously employed for certain modes of administrations such as topical gels and oral solutions targeting the mouth and throat.
- the compounds of the invention may be categorized into several classes. These classes include and not limited to (a) sterol and "fat soluble" vitamin based: cholesterylglycerolcyclodextrin-polyethylene- (CGC- PEGs); tocopherylglycerolcyclodextrin-polyethyleneglycols (TGC-PEGs), cholesteryldiethylene- tetramine-cyclodextrin-polyethyleneglycols (CDC-PEGs), tocopheryldiethylenetetramine- cyclodextrinpolyethyleneglycols (TDC-PEGs), cholesteryltriethylenetetraminecyclodextrin- polyethyleneglycols (CTC-PEGs), and tocopheryltriethylenetetramine-cyclodextrin- polyethyleneglycols (TTC-PEGs); (b) fatty acid based: Olerylglycerolcyclodextrin-polyethylene- (
- a Polymer-CD-lipid conjugate composing a center backbone, a cyclodextrin, a polymer and a lipid is generally classified in Table 3.
- a polymer-CD-lipid conjugate includes and not limited to oleoyl-mPEG-(aminopropoxy)acetocyclodextrin, stearoyl-mPEG-(aminopropoxy)- acetocyclodextrin, palmitoyl-mPEG-(aminopropoxy)acetocyclodextrin, myristoyl-mPEG- (aminopropoxy)acetocyclodextrin, cholestery-mPEG-(aminopropoxy)acetocyclodextrin, cholestery-mPEG-(aminopropoxy)acetocyclodextrin, tocopheryl-mPEG-(aminopropoxy)aceto- cyclodextrin, retinoyl-mPEG-(aminopropoxy)acetocyclodextrin, retinoyl-mPEG-(aminopropoxy)acetocyclodextrin, reti
- the lipid may be selected from polyunsaturated fatty acids or polyunsaturated fatty alcohols including but not limited to Stearidonic acid, Eicosatrienoic acid, Eicosatetraenoic acid, Eicosapentaenoic acid, Heneicosapentaenoic acid, Docosapentaenoic acid, Docosahexaenoic acid, Tetracosapentaenoic acid, Tetracosahexaenoic acid, Docosadienoic acid, Adrenic acid, Docosapentaenoic acid, Rumenic acid, Rumenic acid, a- Calendic acid, ⁇ -Calendic acid, Jacaric acid, a-Eleostearic acid, ⁇ -Eleostearic acid, Catalpic acid, Punicic acid, Rumelenic acid, a-Parinaric acid, ⁇ -Parinaric acid,
- the invention includes a molecule comprising a compound represented by the following General Structure 3 :
- the bPEG is a branched PEG with 2 or more PEG chains and each PEG chain may consist of between about 5 and 1 15 subunits. Where 3 ⁇ 4 is the terminal group and may be selected from a wide variety of chemical moieties. R; preferably has a molecular weight of less than about 650.
- the PEG-carbohydrate conjugates are useful for applications other than liposomes, e.g., as a solubility enhancer in water solutions. All other components of the conjugates may remain the same as described under the General Structure 1 and 2.
- D is the fourth carrier which may a duplicate lipophilic carrier or PEG.
- Backbone is a molecule void of a drug moiety comprises glycerol or glycerol-liking having three available binding positions or diamines, triamines, tetramine or diaminoalcohol or aminoalcohols or aminodiol or aminotriols or amino acids having three available binding positions and polyamines having at least three available binding sites or positions. All other components may be the same as described under the General Structures 1 and 2.
- the third and fourth carriers of the PEG-CD-lipid conjugates may be formed through a linked conjugation as presented in the General Structure 5.
- D is a secondary lipophilic carrier or PEG
- L is a coupler selected from a group of molecules included but not limited to glycerol or glycerol-liking having three available binding positions or diamines, triamines, tetramine or diaminoalcohol or aminoalcohols or aminodiol or aminotriols or amino acids having three available binding positions.
- Another aspect of the invention includes a method of delivering a compound, where the method comprises preparing a PEG-CD-lipid conjugate based formulation of the compound, where the formulation comprises a PEG-CD-lipid conjugates having an amino acid linker and possible secondary linker(s) selected from the group consisting of amino, succinylamino, acetamido, aminopentanamido, aminoacetyl, acryloyl, thiopropanoayl, N-(mercaptomethyl)-propionamido, mercaptopropylthiopropanoyl, (l ,2-dihydroxy-3-mercaptopropylthio)propanoyl, succinyl, acetyl, oxopentanoyl, carbamoyl, aminoalkyl, glutaramido, aminoethanethiol, mercaptopropanol, (hydroxypropylthio)propanoayl, 3-((2-propiona) selected from
- the invention is a method of linking the center backbone to any of the three carrier groups via an amino acid linkage (alkylation or amidation process).
- the hydroxyl in the carrier groups may be activated by reaction with disucccimidylcarbonate (DCS) or mesylate or tosylate or acrylic acid or strong base (etherification or esterification).
- DCS disucccimidylcarbonate
- mesylate or tosylate or acrylic acid or strong base etherification or esterification
- allyl-cyclodextrin may be prepared according to modified method from published reports [Jindrich J., et al (19950. Carbohydr Res. 266(l):75-80; LI YingJie, et al (2010). Scientia Sinica Chimica, 40 (1 1): 1682-1687] and the PEG-Lipid portion may be synthesized according to out earlier publications [US20120202979 or US20120202890].
- This reaction scheme is suitable for carrier groups with all kinds of lipophilic compounds or PEG chains for the CD conjugation.
- the general structures shown in the application are meant to include all racemers and structural isomers of the structures, as they may be functionally equivalent.
- the present invention also demonstrated the using of a branched-PEG as the polymer carrier.
- Branched-PEGs are commercially available with relative large molecular weights.
- branched PEGs with smaller PEG chains may be prepared as the same as for a single PEG chain, consequentially, the activated branched PEG was used to make a branched PEG-carbohydrate conjugate as showed in the General Structure 3.
- the Reaction Scheme 1 there are multiple chemical processes of alkylation, etherification, esterification or amidation may be involved for making each final product, the steps of each conjugation were designed accordingly.
- the invention includes PEG-carbohydrate conjugates comprised of three carrier groups and a center backbone having at three positions available for the conjugation, and one or more linker(s) between one of the carrier groups and the center backbone.
- PEG- carbohydrate conjugates are represented by the General Structures 1 to 5, where the linker may be selected but not limited from a group consisting of amino, succinylamino, acetamido, aminopentanamido, aminoacetyl, acryloyl, thiopropanoayl, N-(mercaptomethyl)propionamido, mercaptopropylthio)-propanoyl, (1 ,2-dihydroxy-3-mercaptopropylthio)propanoyl, succinyl, acetyl, oxopentanoyl, carbamoyl, aminoalkyl, glutaramido, aminoethanethiol, mercaptopropanol, (
- the types of coupling reaction between the carriers and the center backbone as well as any chemical modification of cyclodextrin or a carrier or center backbone prior to the conjugation are alkylation including N-alkylation or 0-alkylation, esterification, etherification and amidation.
- alkylation including N-alkylation or 0-alkylation, esterification, etherification and amidation.
- a cyclodextrin may be modified with acryloyl chloride then reacted with center backbone, thus two types of reaction may be involved; esterification and N-alkylation (Michael addition).
- monotosylation of cyclodextrins may be prepared with l -(p-tosyl)-imidazole as described in the Reaction Scheme 2 [T. Tan, et al (201 1). Protocol Exchange, doi: 10.1038/protex.201 1.214] .
- Reaction Scheme 3 (R is a center backbone with or without attached PEG or lipid)
- Converting mono-6-tosyl-CD into mono-6-aminoacryloyl-6-deoxyl-CD may be achieved by the following steps in the Reaction Scheme 4 [W. Zhang, et al (2010). Applied Surface Science. 256: 3000-3005] .
- Reaction Scheme 5 (R is a center backbone)
- monosubstitution cyclodextrins may be preferable, while a number of modified cyclodextrins are commercially available, for simplicity and cost saving, nature or nonmodified cyclodextrins may be used as for the synthetic starting material since the final products of the polymer-CD-lipid conjugates are enhanced solubilizers, using expensive premodifed or substituted cyclodextrin may not be necessary.
- Embodiments of the present invention are described herein in the context of preparation of pharmaceutical compositions including polymer-cyclodextrin-lipid conjugates or polymer- cyclodextrin-lipid conjugates for increasing the solubility and enhancing the delivery of active agents.
- the approximate preferable compositions for formulated drug products are generally described herein, though different drugs typically have differing optimal formulations.
- Effective reagents for the deprotection of tert-butyl carbamates or tert-buty ⁇ esters include phosphoric acid and trifluoroacetic acid.
- the reactions give high yields and very convenient [Li, B. Kirk, M. etc, J. Org. Chem. , 2006; 71, 9045] .
- Equal volumes of trifluoroacetic acid were added to a solution of Boc-carbamate (10% of crude product) in CH 2 C1 2 .
- the resulting solution was stirred at room temperature for overnight and the solvent was evaporated and the residue was re-dissolved into CH 2 C1 2 , then washed with saturated NaHCOs and dried over MgS0 4 . Solvent was evaporated and was used in next step without further purification.
- Example 7 Preparation of a-cyclodextrinoleoyldiethylenetriamine-mPEG
- the active mPEG 2 4-NHS (0.01 mol) was dissolved in THF, and then mixed with the above reactants, stirred for overnight at room temperature. After the completion of the reaction, solvents were removed by vacuo and 50 mL of acetone was added to the crude product and filtered and washed with 30 mL of acetone three times. The reaction solution was precipitated into IPA and ACN was added to maximize the isolated yield of precipitate. The crude product was washed well with 20/80 (v/v) IPA/ACN and dried under vacuum at 30-40° C. The purity (> 95%) of the final product (Chemical Structure 9) was determined by 1H NMR and UPLC-MS.
- Example 8 Preparation of a-cyclodextrintriethylenetetramine
- Triethylenetetramine (0.02 mol) was dissolved in 50 mL of dry (molecular sieve) THF and mono-6-tosyl-a-cyclodextrin (0.01 mol) was added. The resulting mixture was stirred for 6 hours at 50-60 °C and allowed to cool to the room temperature when the reaction was completed. The reaction solution was precipitated into IPA and ACN was added to maximize the isolated yield of precipitate. The cake was washed well with acetone, then 20/80 (v/v) IPA/ACN and dried under vacuum at 30-40 °C. The crude product (Chemical Structure 10) was used in next step without further purification.
- the reaction was quenched with sodium hydroxide solution (100 mL of 5%, w/v) and concentrated by remove tetrahydrofuran under vacuo, then extracted with methylene chloride (50 mL).
- the aqueous layer was acidified with HC1 (36%) to pH 3-4.
- the aqueous phase was extracted with methylene chloride (25 mL) twice.
- the combined organic layers were dried over sodium sulfate for 1 hour.
- the salt was removed by paper filtration and the solvent was removed in vacuo to yield an oil products (45- 73%) as showed in Chemical Structure 14.
- Boc-Glycine (0.1 mol) and N,N'-Dicyclohexylcarbodiimide (0.1 mol) in methylene chloride (50 mL) was stirred for 30 minutes, and the mixture was added into a methylene chloride solution (50 mL) of (0.1 mol) slowly. The mixture was stirred for 2 hours. The solution was filtrated and solvent was removed under vacuo to yield a crude product of Boc-Gly-Ser which was transferred to the next step without further purification.
- Example 20 Preparation of PEG 17 -cholesterylglycinylserinyl-6-p-cyclodextrin
- NL -Gly-Ser-Chol- PEG 17 (0.1 mol) and dried mono-6-aminoacryloyl-6-deoxyl- -cyclodextrin (0.1 mol) was mixed in TGF (100 mL) and the reaction was initiated by adding triethylamine (3%, v/v). The reaction was reflux in a water bath of 60-65 °C for 16 hours under constant stirring and solvent was removed under vacuo. The resulting waxy crude product was washed with hexanes and dried under vacuo to yield a pale to yellowish solid (80 to 95%) as showed in Chemical Structure 18.
- the predried reaction mixture was placed on the top of the column and the column was eluted with acetone/hexanes 200 mL of acetone/ Isopropyl alcohol (1/5) and 500 mL of 100% acetone.
- the eluents containing compound was concentrated in vacuo to N £ - -cyclodextrin-N a -cholesterol-mPEG-lysinate (yield -80%).
- the polymer chain may be replaced by other polymer(s) such as polymethylene glycol or polypropylene glycol or a mixture of the repeating units of methylene glycol, ethylene glycol and propylene glycol.
- Hydrophilic polymers useful in forming the polymer- carbohydrate conjugates of the invention include polyethylene glycol (PEG) and other polyalkene oxide polymers, polyoxyethylene alkyl ethers, polyvinylpyrrolidone, Poly(allylamine), Poly(l - glycerol methacrylate), Poly(2-ethyl-2-oxazoline), Poly(2-hydroxyethyl methacrylate/-methacrylic acid)/poly(2-hydroxyethyl methacrylate), Poly(2-vinylpyridine), Poly(acrylamide/-acrylic acid), Poly(acrylic acid), Poly(butadiene/maleic acid), Poly(ethyl acrylate/acrylic acid) , Poly(ethylene oxide-b-propylene
- Cop-olymers and block copolymers based on the list above may also be used.
- the free polymers are water-soluble at room temperature, as well as non-toxic. They do not elicit an appreciable immunogenic response in mammals.
- Hydrophilic polymers with narrow molecular weight distributions are preferable. Because of already existing acceptance in the pharmaceutical business, PEG is the preferred hydrophilic polymer.
- a PEG-CD-lipid conjugate solution suitable for drug delivery is prepared as follows. 4% (w/v) of PEG-CD-lipid in Saline was added to a vessel equipped with a mixer propeller and 2% (w/v) of an active pharmaceutical ingredient (API) is pre-dissolved in ethanol (1 % of total volume, v/v) and charged into the vessel with constant mixing at ambient room temperature. Mixing is continued until the solution is visually homogeneous. Equal volume of Saline is added to the vessel with adequate mixing. Mixing continued for another 30 minutes or until a homogenous solution is achieved. The finish product is place under vacuum overnight to remove ethanol.
- a sample formulation is described in Table 5.
- the PEG-carbohydrate conjugate may be any of PEG-CD-lipid conjugates described in the invention with a PEG chain consisting of between about 10 and 45 subunits.
- the API may be etomidate, propofol, alfaxalone, docetaxel, voriconazole, posaconaole, gemcitabine, platins, tacrolimus, cytarabine, ifosfamide, streptozocin, plicamycin, paclitaxel, omeprazole, alprostadil, mitomycin, ziprasidone.
- Sodium hydroxide is used to prepare a 10% w/w solution in purified water. The targeted pH is in a range of 4.0 to 7.5. Diluted NaOH or HC1 may be used to adjust pH if necessary.
- the invention comprises a method of solubilizing a water-insoluble agent, i.e., a drug compound that, because of low solubility in water, typically requires formulation with a pharmaceutically acceptable carrier for effective delivery to an intended site of action.
- a water-insoluble agent i.e., a drug compound that, because of low solubility in water, typically requires formulation with a pharmaceutically acceptable carrier for effective delivery to an intended site of action.
- Such delivery may be intravenous, oral, topical, subdermal, sublingual, or any other mode of drug delivery.
- the invention also includes compositions for such delivery. Both the methods and the compositions related to delivery of water-insoluble agents employ the PEG-CD-lipid conjugates of the present invention and the methods and materials described above.
- 1% (w/v) of voriconazole was prepared in a saline based solution with different PEG- lipid conjugates and a modified cyclodextrin.
- Table 7 listed the minimum concentrations of the conjugates required to solublize voriconazole as a solubility test reference. While it demonstrated that the lowest polymer to drug concentration ratio was N,N, V-oleoylpropanediamine-p- cyclodextrin-mPEG(12) for solubilizating voriconazole, much high concentration of sulfobutyl ether- -cyclodextrin sodium was required for the same concentration of voriconazole.
- the conjugates of the present invention do not have a critical micellar concentration (CMC). Micelles only form when the concentration of surfactants is greater than the CMC, and the temperature of the system is greater than the critical micelle temperature.
- the present polymer-CD-lipid conjugates may form aggregates spontaneously at any given concentration.
- Present invention discloses a novel polymer-CD-lipid conjugate system having at least one of polymer-lipid substituent (through a center backbone structurally) that may be used as a safe and biocompatible vehicle for drug or molecule delivery.
- a therapeutic, diagnostic or cosmetic agent may be solubilized or encapsulated in those polymer-CD-lipid conjugates to form a solution or micro-suspension.
- the invention includes compositions and methods for synthesizing polymer- CD-lipid conjugates comprising a glycerol backbone or a multiamine or amino acid with a polymer (PEG) chain, a cyclodextrin and a fatty acid or a sterol or a "fat soluble” vitamin or alike group bonded to the backbone.
- PEG polymer
- Spacer or linker groups including amino acids may be included between the backbone and the PEG chains, CDs or lipophilic groups.
- the terminal end of PEG chain may be a charged or polar moiety.
- a chemical compound carrier for improving the biocompatibility of a therapeutic agent and for increasing the solubility of a hydrophobic or lipophilic agent in water.
- the carrier may comprise a molecular structure represented by the formula:
- Lipid is a lipophilic carrier including steroid acids and fatty acids, sterols and fat soluble vitamins.
- CD is a cyclodextrin comprises ⁇ -, ⁇ -. ⁇ -cyclodextrins;
- PEG is a polymer of polyethylene glycols;
- D is a secondary fatty acid, sterol or lipophilic vitamin or PEG;
- Backbone is a molecule having three or four available binding positions and being void of a drug moiety, said Backbone comprising at least one of glycerol, glycerol-like analogues, diamines, triamines, tetramine, diaminoalcohol, aminoalcohols, aminodiol, aminotriols, amino acids, and polyamines; and
- L is a coupler comprising at least one of glycerol or glycerol-like analogues having three available binding positions, diamines, triamines, diaminoalco
- the permeation enhancement properties of PEG-CD-lipid conjugates may increase the in vivo targeted delivery of drugs, reduce toxicity and improve oral bioavailability of various drugs.
- Still another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound wherein suitable molecules may be used as the backbone including glycerol or glycerol-like analogues or diamines, triamines or multiamines or aminoalcohols or amino acids or triols or diols with a carboxyl group or amine or diamines with a hydroxyl or carboxyl group and extensible amines or alcohols, wherein the hydrophobic carrier is a sterol or lipophilic vitamin.
- the PEG chain may consist of between about 5 and 1 15 subunits. More preferably the PEG chain consists of between about 8 and 1 15 subunits. Still more preferably the PEG chain consists of between about 8 and 45 subunits.
- a further feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound having a acyclic carrier group wherein the hydrophobic group is selected from fatty acids including lauric acid, myristic acid, palmitic acid, oleic acid and stearic acids or sterols including cholesterol, stigmasterol, ergosterol, hopanoids, phytosterol, sitosterol, campesterol, brassicasterol, avenasterol adosterol) excluding steroid acids, stanols (saturated steroid alcohols or hydrogenated sterols) or lipophilic vitamins: Vitamin E including and not limited to tocopherols and tocotrienols, Vitamin D including and not limited to cholecalciferol and ergocalciferol, and Vitamin A including and not limited to retinoids, retinol, retinal, retinoic acid, and carotenoids,
- the hydrophobic groups may be selected from saturated fatty acids and unsaturated fatty acids or xanthophylls, astaxanthin, auroxanthin, capsanthin, capsorubin, chrysanthemaxanthin, crocetin, crocin, cryptoxanthin, fucoxanthin, kryptoxanthin, lutein, neoxanthin, rubixanthin, violaxanthin, zeaxanthin and polyunsaturated fatty acids or polyunsaturated fatty alcohols including native polyunsaturated alcohols such as farnesol, solanesol and dodecaprenol. It is preferable to have the cholesterol as the primary lipophilic carrier which may reduce or suppress the hemolytic activity of a fatty acids or xanthophylls, astaxanthin, auroxanthin, capsanthin, capsorubin, chrysanthemaxanthin, crocetin, crocin, cryptoxanthin, fucoxanthin
- linker is selected from the group consisting of -S-, -0-, -N-, - OCOO-, and to form covalent bonds of ester or ether or amide between carriers and center backbones. While a conjugation reaction of alkylation or etherification or esterification or amidation is preferable with or without adding linker group, the carriers or center backbones may be chemically modified prior to the final coupling reactions. Those of chemical modifications may be carried out with one or more of the linker groups.
- terminal (R) group is preferably easily polarized or negatively or positively charged head-groups such as alkoxy moieties, amines, amino acids, and oligosaccharides.
- a further feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a polymer-CD-lipid conjugate wherein it is used for the composition in delivery of an active agent especially for a poorly water soluble compound of Biopharmaceutics classification II or IV including but not limited to alfaxalone, propofol, docetaxel, paclitaxel, voriconazole and posaconazole.
- Another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a method of delivering a compound, the method comprising preparing a polymer-CD-lipid conjugate(s) based formulation of the compound, where the PEG-CD-lipid comprises a PEG, a lipid, a CD and a center backbone selecting from ethylenediamine, diaminopropane, ethanolamine, aminopropanol, aminobutanol, aminopentanol, amino- 1-hexanol, the center backbone may be chemically extended and modified to provide said third or a fourth available binding position or site.
- Lipid is a lipophilic carrier of fatty acids, sterols, stanols, cholecalciferols, ergocalciferol, retinoids, carotenoids, tocopherols, and tocotrienols;
- CD is a cyclodextrin comprising a- cyclodextrin.
- mPEG is a polymer of polyethylene glycols
- D is a duplicate of the Lipid or the mPEG
- Backbone is a center Backbone having a molecule with three or four available binding positions or sites and being void of a drug moiety, the backbone comprising at least one of glycerol, glycerol-like analogues having three binding positions, diamines, triamines, tetraamines, polyamines, diaminoalcohols, aminoalcohols, aminodiols, aminotriols, amino acids having three or four available binding positions, triols, tetraols, triacids, tetracids, halogen-containing diols, halogen-containing amines, and carboxyl- containing diols.
- the Backbone comprises at least three available binding positions or sites for the conjugation of a first carrier, a second carrier, and a third carrier, each the available binding position or site comprising an expendable amino, hydroxyl, acryloyl or carboxylic group; the first carrier having an expendable amino, hydroxyl, acryloyl, or carboxylic group and the Lipid bound thereto; the second carrier comprising having an expendable amino, hydroxyl, acryloyl or carboxylic group and the mPEG bound thereto; the third carrier comprising having an expendable amino, hydroxyl, acryloyl or carboxylic group and the CD bound thereto.
- Still another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein the backbone comprises three available binding positions or sites for the conjugation of a first carrier, a second carrier, and a third carrier, each the available binding position or site comprising an expendable amino, hydroxyl, acryloyl or carboxylic group, wherein: the first carrier has the Lipid bound thereto; the second carrier has the mPEG bound thereto; the mPEG comprising a terminal (R) group; and the third carrier has the CD bound thereto.
- a further feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein the Backbone is one of a) through d): a) selected from the group consisting of glycerol or glycerol- like analogues, polyamines, diamines, triamines, tetraamines, aminodiols, aminotriols, aminoalcohols, amino acids having three available binding positions or sites, triols, tetraols, erythritol, triacids, tetracid, tetraacetic acid, and tartaric acid; b) selected from the group consisting of ethanediamine, propanediamine, butanediamine, pentanediamine, hexanediamine, diethylenetriamine, diethylenetriamine, bis(3-aminopropyl)-amine, bis(3-aminopropyl)-l ,3-
- Another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein two of the accessible binding positions or sites are selected from the group consisting of aminoalcohols, diamines, ethylenediamine, diaminopropane, ethanolamine, aminopropanol, aminobutanol, aminopentanol, and amino- 1 -hexanol; and the chemical compound being chemically extended and modified to provide the third or a fourth available binding position or site.
- Still another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein the mPEG comprises a single PEG chain having between 5 and 1 15 subunits or a branched PEG having 2 or more subchains, wherein each the subchain has between 5 and 1 15 subunits, and a terminal group (R) comprising methoxy, hydroxyl or biotin.
- the center Backbone is selected from the group consisting of glycerol, polyamines, diamines, triamines, tetraamines, aminodiol, aminotriols, aminoalcohols, triols, tetraols, erythritol, triacids, tetracid, tetraacetic acid, glucoheptonic acid, tartaric acid, and amino acids having three available binding positions or sites
- the CD is selected from the group consisting of ⁇ , ⁇ , and ⁇ cyclodextrin having an averaged number of substituent per glucopyranose repeat unit ranging from 0.6 to 3
- the Lipid is selected from the group consisting of myristic acid, palmitic acid, stearic acid myristoleic acid, palmitoleic acid, sapienic acid, e
- Yet another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a method for treating a disease or health condition in a mammal with a chemical compound carrier as disclosed above, the method comprising treating a condition that comprises general anesthesia or procedural sedation.
- Another feature or aspect of an embodiment is to differentiate the present invention chemically and physically from the previous patent publications US2012/202,979 and US2012/202,890; in the present invention, a cyclodextrin is incorporated. As demonstrated in Tables 4, such structures increased lipophilic properties was not mentioned or utilized in the previous inventions. For instance, the PEG-CD-fatty acid conjugates, the PEG-CD-cholesterol conjugates and PEG-CD-lipo-vitamin conjugates were demonstrated for the first time.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention comprises compounds, methods of making, and methods of using. A group of polymer-cyclodextrin-lipid conjugates having a center backbone and three or four appended functional groups are disclosed, wherein one of the hydrophilic components is cyclodextrin. The compounds may have a backbone with three or four appended functional groups: one or two lipophilic compounds including sterols or "fat soluble" vitamins or fatty acids, one or two hydrophilic polymer and one cyclodextrin. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the center backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.
Description
SPECIFICATION
TITLE OF INVENTION
POLYMER-CYCLODEXTRIN-LIPID CONJUGATES
[001] This application claims priority to the provisional patent application serial number: 62/183,400, entitled "Polymer-Cyclodextrin-Lipid Conjugates" filed in the U.S. Patent and Trademark Office on June 23, 2015, by Nian Wu and nonprovisional patent application serial number: 15/184,014, entitled "Polymer-Cyclodextrin-Lipid Conjugates" filed in the U.S. Patent and Trademark Office on June 16, 2016, by Nian Wu.
FIELD OF THE INVENTION
[002] The present invention relates to polymer-cyclodextrin-lipid Conjugates, detailed and specific disclosures are given for synthetic polyethylene glycol (PEG)-cyclodextrin-lipid conjugates with fatty or sterols or so called "fat soluble" vitamins ("lipo-vitamin") as the lipophilic carriers in the conjugates and preferably having substantially monodisperse PEG chains if used for intravenous drug administration. More particularly, the present invention relates to novel polymer-cyclodextrin-lipid conjugates having cyclic oligosaccharides to replace linear oligosaccharides as for the carbohydrate component in our previous inventions. Such combination of the core characters of lipophilic solubilization wherein polymer-lipids and inclusion comlexation wherein cyclodextrins may maximize the ability of the conjugates for delivering poor water soluble therapeutic agents and reduction of toxicity in pharmaceutical products as well use for cosmetics or foods and other purposes.
BACKGROUND OF INVENTION
[003 Over last three decades, some of promising drug carriers that have been investigated in systemic delivery systems includes liposomes, polymeric nanoparticles, polymeric micelles, ceramic nanoparticles and dendrimers (Cherian et id. Drug. Dev. Lid. Pharm, 26: (2000) 459-463; Lian and Ho. J. Pharm. Sci, 90 (2001 ) 667-680; Adams et ai. Pharm. Sci, 92 (2003) 1343-1355; Na et ai. Eur. J. Med. Chem. 41 (2006) 670-674; Kaur et al. J. Control. Rel 127(2008) 97-109). Systemic drug delivery may be achieved by intravenous or intraperiplieral injection and therefore is non-invasive. The drugs may be administered repeatedly as needed. However, in order to achieve therapeutic concentrations at. the target site, systemic administration requires large dosages with relatively high vehicle contents which may cause side effects such as allergic reactions ["Cremophor-based paclitaxel 'chemo' drug triggers fatal allergic reactions," The Medical News. 9 June 2009],
|ΌΘ4| In the design of safe and biocompatible delivery systems, several important factors may be taken into account including high solubilization properties and retaining power of the carrier and appropriate surface characteristics to permit interactions with potential targeting tissue sites or cell m embrane perm eati on s .
[005] Cyclodextrins (CDs) are cyclic oligosaccharides (Chemical Structure 1) that have been studied for several decades and as one of the leading pharmaceutical excipients approved by the US FDA (Food and Drug administration) for dozens of marketed pharmaceutical products, they are continued being utilized as an important vehicle for poor water soluble agents. Unlike polymer excipients, CDs are biological active and their solubilizing ability achieved through forming water- soluble complexes with many hydrophobic agents.
[006] Chemical Structure 1 : 6 (a), 7 (β) and 8 (γ) member rings of cyclodextrins used in the present invention
[007] Lipids are a group of naturally occurring molecules including fatty acids, sterols and fat- soluble vitamins (vitamin A, D and E), monoglycerides, diglycerides, triglycerides, phospholipids, and others. The main biological functions of lipids include storing energy, signaling, and acting as structural components of cell membranes [Fahy E, Subramaniam S, Brown HA, et al. (2005). "A comprehensive classification system for lipids". J Lipid Res. 46 (5): 839-61]. The lipid classification scheme is chemically based and driven by the distinct hydrophobic and hydrophilic elements that compose the lipid. Lipids such as sterols and related compounds play essential roles in the physiology of eukaryotic organisms are a subgroup of the steroids. They occur naturally in plants, animals, and fungi, the most familiar type of animal sterol is cholesterol. Cholesterol is vital to animal cell membrane structure and function and forms part of the cellular membrane in animals, where it affects the cell membrane's fluidity and serves as secondary messenger in developmental signaling [Alberts B, Johnson A, Lewis J, Raff M, Roberts K, and Walter P (2002). Molecular biology of the cell. 4th Edition, New York: Garland Science, p. 1874].
[008] The present invention compromises one of the three carrier groups consisting of a lipid including but not limited to fatty acids, sterols including but not limited to cholesterol, stigmasterol, ergosterol, hopanoids, phytosterol, sitosterol, campesterol, brassicasterol, avenasterol adosterol, and stanols (saturated steroid alcohols or hydrogenated sterols). Sterols are biological importance as a highly compatible vehicle for drug delivery, for instance cholesterol makes up about 10-50 percent of the total lipid in natural cell membranes, the conjugates containing sterols or fat soluble vitamins may increase the drug permeation for cell targeted delivering.
[009] The human body has a natural tendency to maintain homeostasis, and may be elaborated from substances present in the diet, sometimes exclusively, for vitamins, minerals, essential amino-acids and essential fatty acids including polyunsaturated fatty acids which play a significant role in the prevention of cardiovascular disease in human. Vitamin E is the general term for all tocopherols and tocotrienols, of which alpha-tocopherol is the natural and biologically most active form. The antioxidant function of vitamin E is considered to be critical for the prevention of oxidation of tissue. While these molecules are essential for the human body, they may be utilized as safer ingredients to design for an ideal carbohydrate-lipid conjugate.
[0010] The present invention compromises one of the three carrier groups consisting of a sterol or fat soluble vitamin. Another carrier group is a cyclodextrins containing a number of glucose monomers ranging from six to eight units in a ring. The third carrier is a water soluble polymer such as polyethylene glycol. The three carrier groups are attached covalently to a center backbone where at least three bonding positions or sites available. The conjugation may be achieved via one or more types of reactions or combination of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation.
[0011] The solubility of organic molecules is often summarized by the phrase, "like dissolves like." This means that molecules with many polar groups are more soluble in polar solvents, and molecules with few or no polar groups (i.e., nonpolar molecules) are more soluble in nonpolar solvents (R. Casiday and R. Frey, "Maintaining the Body's Chemistry: Dialysis in the Kidneys,"
http://wwwxhemistrv.wustl.edu/~edudev/LabTutorials/Dialvsis/Kidneys.html, Department of Chemistry, Washington University, St. Louis, MO, accessed on December 3, 2013).
[0012] Vitamins are either water-soluble or fat-soluble (soluble in lipids and nonpolar compounds), depending on their molecular structures. Water-soluble vitamins have many polar groups and are hence soluble in polar solvents such as water. In contrast fat-soluble vitamins are predominantly nonpolar and hence are soluble in nonpolar solvents such as the fatty (nonpolar) tissue of the body.
[0013] Solubility is a complex phenomenon that depends on the change in free energy (AG) of the process. For a process, i.e., a vitamin dissolving in a solvent, to be spontaneous, the change in free energy may be negative (i.e., AG<0) [M. Traverso, "Vitamin Solubility," http://www.chemistrv.wustl.edu/~edudev/LabTutorials/CourseTutorials/Tutorials/Vitamins/molec ularbasis.htm,Washington University, St. Louis, MO, accessed on December 3, 2013].
[0014] Narrow molecular weight distribution of drug delivery polymers is crucially important for biomedical applications, especially if used for intravenous injections. For instance, PEG-8 Caprylic/Capric Glycerides are mixtures of monoesters, diesters, and triesters of glycerol and monoesters and diesters of polyethylene glycols with a mean relative molecular weight between 200 and 400. Partially due to allergic reactions observed in animals, the application of PEG-8 CCG for paranteral administration of many water-insoluble drugs is restricted and hence is limited usable for human drug formulations.
BRIEF SUMMARY OF THE INVENTION
[0015] The present invention comprises compounds having a polymer-lipid conjugate comprising a backbone and three or four appended functional groups as showed in Figure 1 : one or two lipophilic vitamins or sterols or alike, one or two hydrophilic polymers, the polymer-lipid conjugates are then further attached to a cyclodextrin, the number of polymer-lipid conjugates attached to the cyclodextrin may be dependent on the available primary hydroxyl groups. As showed in the Chemical Structure 2, the primary hydroxyl groups on the C-6 (denoted by an open arrow) have the highest reactivity, especially when bulky substitution reagents are used, and the secondary hydroxyl groups on C-2 and C-3 (denoted by a solid arrow) have least reactivity. This is attributed to the hydrogen bonding between the protons of the hydroxyl group on C-3 and the oxygen atom of the hydroxyl group on the C-2, a hydrogen bond with the C-3 hydroxyl group of the neighboring glucopyranose unit [F. M. Menger and M. A. Dulany (1985). Tetrahedron Lett. 26: 267]. The C-2 hydroxyl group of one glucopyranose unit can form a hydrogen bond with the C-3 hydroxyl group of the neighboring glucopyranose unit [B. Gillet, D. J. Nicole and J. J. Delpuech, Tetrahedron Lett., 1982, 23, 65] and hydrogen-deuterium exchange in the secondary hydroxyl groups of a-cyclodextrin, β-cyclodextrin and γ-cyclodextrin showed that the strongest hydrogen bond system is formed in the β-cyclodextrin [B. Casu, G. G. Gallo, M.Reggiani and A. Vigevani, J. Chem. Soc. Spec, publ., 1968, 23, 217]. While a complete secondary belt is formed by these hydrogen bonds in β-cyclodextrin, thus making it a rigid structure and the hydrogen ring is incomplete in the α-cyclodextrin because one of the glucopyranose units is in a distorted position and only four can be formed instead of the six possible hydrogen bonds [D. A. Rees, J. Chem. Soc. (B), 1970, 877; B. P. Schonberger, A. C. A. Jansen and L. H. M. Janssen, in 'Proceedings of the 4th International Symposium on Cyclodextrins, Munich, 1988', eds. O. Huber and J. Szejtli, Kluwer, Dordrecht, 1988, p. 61]. In the Chemical Structure 2, (a) and (b) symbolize the same basic structure of cyclodextrins and "n" represents a number of glucopyranose units with the truncated circle line in (a). Howver only (b) will be used in the specification to simplify the drawings and to express the cyclodextrin molecular structures entirely.
[0016] Chemical Structure 2: Potential reactive hydroxyl sites in cyclodextrins (n = 6 to 8)
[0017] In one aspect of the present invention, while multiple polymer-lipid substitutants to a cyclodextrin may be possible as showed in the General Structure 1 , a few substitutants of cyclodextrin may be preferable. The most popular common method for a monomodification at 6- position of cyclodextrin is so called nucleophilic substitution of a reagent containing appropriate group on mono-6-tosyl cyclodextrin or mono-6-mesosyl cyclodextrin. The monotosylated cyclodextrin derivatives are synthesized by reacting molar equivalent of benzene or p-toluene- sulfonyl chloride with cyclodextrin in pyridine or DMF containing a base [R. C. Petter, J. S. Salek, C. T. Sikorsky, G. Kumaravel and F. T. Lin, J. Am. Chem. Soc, 1990, 1 12, 3860; X. M. Gao, L. H. Tong, Y. Inoue, and A. Tai, Synth. Commun., 1995, 25, 703; K. A. Martin and A. W. Czarnik, Tetrahedron Lett., 1994, 35, 6781]. The monosubstituted 6-tosylcyclodextrins and mono-6- mesosylcyclodextrins are important precursors for a variety of modified cyclodextrins. A nucleophilic displacement of the tosyl or mesoyl group by suitable nuleophiles such as iodide, azide, thioacetate, alkyl, hydroxylamine or polyalkylamines yields monoiodo-, azido-, thio-, hydroxylamino-, or alkylamino-cyclodextrins [L. E. Fikes, D. T. Winn, R. W. Sweger, M. P. Johnson and A. W. Crarnik, J. Am. Chem. Soc, 1992, 1 14, 1493; A. Ueno, F. Moriwaki, T. Osa, F. Hamada and K. Murai, Tetrahedron, 1987, 43, 1571 ; K. Tsujihara, H. Kurita and M. Kawazu (1977). Bull. Chem. Soc. Jpn., 50, 1567; D. W. Griffiths and M. L. Bender, Adv. Catal., 1973, 54, 625; B. Siegel (1979). J. Inorg. Nucl. Chem. 41 , 609]. Further purification may be achieved by recycystallation in a mixture of methanol and water [M. Popr (2014). Beilstein J. Org. Chem., 10, 1390-1396].
[0018] General Structure 1
[0019] Where "n" is a number of the glucopyranose rings of cyclodextrins ranging from 6 to 8 and "i" is the averaged number of substituents (molar degree of substitution) of PEG-lipid per glucopyranose repeat unit ranging from 0.5 to 3. Specific polymer or liphophilic groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutraceuticals, and the like. A variety of linkers between the backbone and functional groups may also be selected to
optimize performance. The coupling reaction is one or combination or series of alkylation, esterification, etherification and amidation chemical process.
BRIEF DESCRIPTION OF THE FIGURES
[0020] Figure 1 shows a representation of PEG-p-cyclodextrin-cholesteryl- diaminopropane in the present invention as the sample polymer-cyclodextrin-lipid conjugate. The lengths of each partions of the conjugate are estamated by ChemBioDraw® Ultra 10 (CambridgeSoft, Waltham, MS, USA)
[0021] Figure 2(a) showed the solubility comparision of 1% propofol in (1) 3.5% of Cholesteryl-lactobionate-mPEG12; (2) 35% of 2-Hydroxypropyl- -CD; (3) a mixture of 2% Cholesteryl-lactobionate-mPEG12 and 15% 2-Hydroxypropyl- -CD and (4) 2% of mPEG12-p- cyclodextrin-cholesterol and Figure 2(b) showsed the same sample solutions at day 5.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[0022] Embodiments of the present invention are described herein in the context of varying polymer-cyclodextrin-lipid conjugates for drug delivery. Those of ordinary skill in the art will realize that the following detailed description of the present invention is illustrative only and is not intended to be in any way limiting. Other embodiments of the present invention will readily suggest themselves to such skilled persons having the benefit of this disclosure. Reference will now be made in detail to implementation of the present invention.
[0023] In the interest of clarity, not all of the routine features of the implementations herein are described. It will be appreciated that in the development of such actual implementation, numerous implementation-specific details may need to be made in order to achieve the developer's specific goals, and that these specific goals may vary.
[0024] United States Patent Publication 20150157721 and 20120202890, which are hereby incorporated by reference, teach the aqueous formulations of poor water soluble agents by employing certain polymer-carbohydrate-lipid (PCL) conjugates. The patents described how to prepare the polymer-carbohydrate-lipid conjugates and its applications by simply adding the conjugate to an aqueous solution. It has been demonstrated that PCLs are useful for solubilizing hydrophobic drugs without the formation of liposomes or microemulsions.
[0025] Differentiating from the previous inventions published in US20150157721 and US20120202890, the present invention comprises the cyclic oligosaccharide portion of the polymer-cyclodextrin-lipid conjugates while those conjugates remains a basic structure having a backbone and three or four appended functional groups: one or two lipophilic vitamins or sterols or fatty acids, one or two hydrophilic polymers. The chemical and physical characters of cyclic oligosaccharides are significantly different from the linear oligosaccharides that were utilized in the previous invention. While poor water soluble agents may be solubilized by forming inclusion complexes with the cyclodextrin portion of the conjugates, the hydrophobic compounds may be also solublized by either encapsulation or microemulsion with the PEG-lipid portion of the conjugate. By combining these two functionalities of inclusion and encapsulation or microemulsion all into one compound, it is possible to achieve improved formulations of many active (pharmaceutical) agents. The general structure of the family of compounds is shown as General Structure 1 , where "B" indicates the backbone, "PEG" indicates the polymer, "Lipid" indicates lipophilic vitamin or sterol or fatty acid. In aqueous solutions, the new conjugates act as a solubility enhancer of poor water soluble agents resulting in either a true solution or a very stable emulsified suspension with those of active agents. Where the cyclodextrin has 6 or 7 or 8 member rings, the degree of substitution of the cyclic oligosaccharides may be from 0.5 to 3.
[0026] Another differentiation from our previous inventions published in US20150157721 and US20120202890, the present invention comprises cyclodextrins [Brigandi, RA., et al (2014). Clinical Pharm in Drug Dev. 4(2), 130-136] may reduce the hemolytic effects of fatty acids alone similar to sterols or sterol-like compounds that may also significantly reduce potential hemolytic activity induced by fatty acids [Mimura, T. "Fatty acids and sterols of the tunicate, Salpa thompsoni, from the Antarctic Ocean: chemical composition and hemolytic activity" . Chemical & pharmaceutical bulletin, 34 (1986) 4562] . Unlike sterols, water soluble steroid acids (bile acids) are more likely inducing hemolytic anemia [Hani, A. "The pH dependence of the hemolytic potency of bile salts". Biochimica et biophysica acta, 1027 (1990) 199] . For this particular reason, nonwater soluble sterols are preferable to be selected as the primary lipophilic carrier in the conjugates. In case there are two lipophilic carriers, one may be cholesterol or a non-hemolytic sterol or "fat soluble" vitamin.
[0027] In one aspect of the present invention, the present invention comprises cyclodextrins to significantly reduce potential hemolytic activity of fatty acids as compared to commercial available PEG-lipids including polyethylene glycol sorbites, polyoxyethylated castor oil (Cremophor) and mono/diglycerides of caprylic/capric acid in glycerol (Capmul®) polyglycolized glycerides (Labrafac®), PEG-6 glyceryl monoleate or PEG-6 glyceryl linoleate (Labrafil®), PEG- 8 glyceryl caprylate/caprate (Labrasol®). While these fatty acid based lipid-polymers may increase poor water soluble agents, hemolysis is induced at higher lipid-drug ratios [G.D. Noudeh, P. Khazaeli and P. Rahmani. "Study of the Effects of Polyethylene Glycol Sorbitan Esters Surfactants Group on Biological Membranes." International Journal of Pharmacology, 4 (2008) 27-33; A.O. Nornooa, D.W. Osborneb, D.S.L. Chow (2008). "Cremophor-free intravenous microemulsions for paclitaxel: I: Formulation, cytotoxicity and hemolysis." International Journal of Pharmaceutics. 349, 108-1 16] .
[0028] Further differentiation from our previous inventions published in US 20150157721 and US20120202890, the present invention comprises large a cyclic oligosaccharide ringe which are a rigid component in the conjugate construction, not having the same freedom of movement that the linear oligosaccharide based conjugates possess. This creates two different spaces in the conjugates, if adjacent polymer-lipid substitutant of cyclodextrin is i.e., PEG-cholesterol, both "spaces" are rigid. If the polymer-lipid is PEG-oleate, than the second phase is more flexible than cyclodextrin. As showed in Figure 1 , the size of a cyclodextrin is about one third (1/3) of the PEG- lipid substituent which provides an easy access for a solute "walking" between the two spaces. It is especially useful to have a two-phase/space structure in a single conjugate; there may be two concided solubilizing processes, inclusion comlexation of cyclodextrin based on a "host-quest" mechanism and microencapsulation of PEG-lipids based on a micellar solubilization. While the two processes are physically different, the unique combination would result in enhanced solubility than those of single phases since the complexation efficiency (CE) of "host" molecules is very limited due to the cage capacity of cyclodextrins; ideally the solubility of a drug in the presence of cyclodextrins can be achieved by a 1 : 1 inclusion complexation. It is important to recognize that aqueous solubility enhancement by cyclodextrins is limited, often required much higher concentrations or molar/molar ratio of a cyclodextrin to solublize a hydrophobic agent (Table 1). Conjugating polymer-lipids into cyclodextrins compensate or provide additional solubilization power to the "host" molecules.
[0029] Table 1. Solubility of marketed Drug Products
Dose Drug CD C D/1)
Drug LogP1 CD
(mg) (Mw) (Mw) (w/w) (mol/mol)
Itraconazole 7.31 10 705.6 hydroxypropyl-P-cyclodextrin 1396 402 20.2
Voriconazole 1.82 200 349.3 sulfobutyl ether β-cyclodextrin 2242 162 2.5
Telavancin HC1 6.91 250 1755.6 hydroxypropyl-P-cyclodextrin 1396 102 12.6
Carfilzomib 4.20 60 719.9 sulfobutyl ether β-cyclodextrin 2242 502 16.1
Posaconazole 5.41 200 700.8 sulfobutyl ether β-cyclodextrin 2242 223 6.9
Alphaxalone 3.06 10 332.5 sulfobutyl ether β-cyclodextrin 2242 144 2.1
Diazepam 3.08 5 284.7 hydroxypropyl-P-cyclodextrin 1396 905 18.4
Haloperidol 3.66 0.4 375.9 hydroxypropyl-P-cyclodextrin 1396 1 125s 302.9
Methotrexate -0.24 8 454.4 hydroxypropyl-P-cyclodextrin 1396 565 18.3
Propranolol 2.58 8 259.3 hydroxypropyl-P-cyclodextrin 1396 565 10.4
Ranitidine HC1 0/99 7 314.4 hydroxypropyl-P-cyclodextrin 1396 645 14.5 logarithm of partition coefficient = a measure of lipophilicity or hydrophobicity
http://www.rxlist.com
3 http://aac.asm.org/content/earlv/2014/04/08/AAC.02686-13.full.pdf
4 http ://www.j urox .com
5 http://www.sigmaaldrich.com/life-science/cell-culture/learning-center/cyclodextrin.html
[0030] Unlike other known linear cyclodextrin derivatives or copolymers [Y. Ping, et al (201 1) Biomaterials. 32(32): 8328-8341 ; ME. Davis et al. US 7091 192], the polymer-CD-lipid conjugates in the present invention discloses a novel molecule(s) with two apolar centers or cores wherein hydrophophic interactions between the polymer-CD-lipid conjugate and a lipophilic solute may be largely increased, thus the water solubility of the solute may be significantly enhanced. For those of cyclodextrin derivatives such as CD sulfoalkyl ether or hydroxypropyl-CD and CD copolymers, increasing compositions or the polymer sizes may only increase the water solutibility themselves, not a hydrophobic interaction to a solute. While a co-polymer may change cyclodextrin complexity efficiency, the "host-guest" solubilization process underneath may be remained the same in contrast to the polymer-CD-lipid conjugates in the present invention, wherein a different microencapsulation process is introduced into or combined with the "host-guest" solubilization process.
[0031] In one aspect, the present invention significantly improved the solubilizing power of cyclodextrins. In aqueous solutions, cyclodextrins form complexes with many drugs through a process in which water molecules located in the center cavity are replaced by either the whole drug molecule or more frequently, by some lipophilic portion of the drug. The hydrophobic effect which involves breakdown and removal of the structured water molecules inside CD cavity and around the non-polar substrate. The drug-cyclodextrin complex formation is a dynamic equilibrium with free drug and cyclodextrin [R. Arun, et al (2008). Scientia Pharmaceutica. 76(4), 567-598; M. E. Brewster and T. Loftsson (2007). Advanced Drug Delivery Review. 59(7): 645-666; M. Jug and M. B. Lacan (2008). Rad. Medical Sciences, 32(499), 9-26]. The CE of cyclodextrin is also largely influenced by the molecule shape of a solute in additional to its hydrophobicity as showed in the Tale 1. Hydrophobicity may be estimated by the oil/water phase partition coefficient (LogP). In the Tale 1 , where the Log Ps were calculated with a computer program of Marvin Sketch (ChemAxon Kft, Budapest, Hungary). A positive value indicates more oil soluble and a negative value indicates more water soluble. Thus the stability of CD complexation is built on a temporal physical entrapment which may explain why high concentrations (or molar ratio) of CD typically required in the solubilization process, a simple 1/1 or 2/1 (CD/drug) complexation may not be sufficient to retain the solute in an aqueous environment. Thus a PEG-lipid substituent is included (through the center backbone) to enhance the stability of CDs by providing a more lipophilic core and the conjugate encapsulated with a drug then will be fully soluble in water at room temperature.
[0032] In one aspect of the present invention, the binding positions to the CD with the PEG-lipid substituent may not be considered as critical and positional isomers may be produced during
synthesis of the polymer-CD-lipid conjugates, while such isomers may be functionally equivalent. The choice of isomer may have implications in a variety of delivery process such as intracellular transport of lipophilic molecules as well as their use as vehicles in pharmaceutical applications. For example, isomers may differ in the ability to stabilize a compound during solubilizing and storage.
[0033] While cyclodextrins (CDs) can enhance the drug bioavailability. For the solute with a large LogP value, much high concentration of cyclodextrin is required as showed in the Table 1. As compared to polymer-CD-lipid conjugates, even though CDs have a very large negative LogP values (Table 2), their solubility enhancement in water is weak which may be mainly due to lack of lipophilicity. In forming the inclusion complex, the physicochemical and biological properties of the drug may be also altered to affect its therapeutic functions. When a high concentration of CDs is required to improve aqueous solubility of drugs and the metabolism and pharmacokinetics of those drugs may be altered. The renal toxicity of a-CD and β-CD for parenteral administration was found in animal model [Frank DW, et al (1976). Cyclodextrin nephrosis in the rat. Am J Pathol 83 :367-82] as well as problems with a number of modified CDs have been well documented [Irie T, et al (1997). J P harm Sci. 86: 147-62; Thompson DO (1997). Crit Rev Ther Drug Carrier Syst. 14: 1-104; Gould S, et al (2005). Food Chem Toxicol. 43 : 1451-9]. In addition, as severe renal impairment prolongs the elimination rate of cyclodextrin with high CD contents.
[0034] In one aspect of the present invention, the hydrophobic interaction may be increased significantly by incorporating a CD group into the polymer-lipid conjugates. The water solubility is enhanced for those hydrophobes where the encapsulation of the lipophilic molecules into the cage-hydrophobic core of the conjugates is improved. Differentiated from previous described lipid-(linear) carbohydrate-polymer conjugates, the current invention presents a double-functional enhancer having stronger hydrophobic interactions with lipophilic solutes. The same hydrophobic interaction may not be achieved with CD alone due to the poor lipophilic character (Table 2) or PEG-linear carbohydrate-lipid alone due to the two solubilzing processes may compensate each other. The polymer-lipid substitutants of CDs support noninclusion-based drug solubilization such as micelle-like effects and molecular aggregation.
[0035] In one aspect of the present invention comprise CD molecules with polymer-lipids available for equilibrium of a solute between the apolar cavity of a CD and the hydrophobic core of lipids instead of the equilibrium between the apolar cavities of a CD or the hydrophobic core of PEG-lipids and aqueous phase. The latter may result in a precipitation.
[0036] In watery-aqueous environment, the interior of polymer-lipid conjugates or the cavity of CDs is largely non-polar and the principle to use when determining hydrocarbon solubility is "like dissolves like." In additional caged complexation, noninclusion interaction between CDs or polymer-lipids and lipophilic solutes are clumped together "like dissolves like." On the outside of the polymer-lipids or CDs are largely polar groups which are able to interact with the polar water molecule, thus the entire polymer-cyclodextrin-lipid conjugate incorporating a lipophilic solute is then water soluble.
[0037] In the novel polymer-CD-lipid conjugates having two apolar inner sites and outer sites with abounding hydroxyls and expendable polymer chains are good solubility enhancers. They may aid in the formation of stable solution or emulsions or blends of water and lipophilic agents. These conjugates provide an extended center apolar core which stabilizes hydrophobic molecules in water by maximizing the retaining power and reducing the interface energy at the liquid-liquid interface.
[0038] The hydrophobic interaction is defined as an entropic effect generating from the disruption of highly dynamic hydrogen bonds between molecules of liquid water by the hydrophobic solute [T.P. Silverstein, "The Real Reason Why Oil and Water Don't Mix". Journal of Chemical Education. 75(1998) 1 16-346]. When a hydrophobic solute is mixed in an aqueous medium, hydrogen bonds between water molecules will be broken to make room for the hydrophobic solute;
since water molecules do not react with the hydrophobic solute. Such hydrophobic effect may be quantified by measuring the partition coefficients of non-polar molecules between water and non- polar solvents. The partition coefficients may be transformed to free energy (AG) of transfer which includes enthalpy (AH) and entropic (AS) components. The hydrophobic effect has been found to be entropy (AS^-driven at room temperature because of the reduced mobility of water molecules in solvation shell of the non-polar solute. The change in enthalpy (AH) of the system may be zero, negative or positive because the formation of the new hydrogen bonds may partially, completely, or over compensate for the hydrogen bonds broken by the entrance of the hydrophobic solute. The change in enthalpy, however, may be insignificant in determining the spontaneity of mixing hydrophobic molecules and water because the change in entropy (AS) is very large. According to the Gibbs free energy Equation, AG = AH - T AS, with a small unknown value of AH and a large negative value of AS, the value of AG will turn out to be positive. A positive AG indicates that the mixing of the hydrophobe and water molecules is not spontaneous which results in a phase separation or precipitation.
[0039] In another aspect of the current invention, the hydrophilic-lipophilic interaction is well balanced with the polymer-CD-lipid conjugates [Griffin WC. "Calculation of HLB Values of Non- Ionic Surfactants," Journal of the Society of Cosmetic Chemists. 5 (1954) 259]. For example, hydrophilic-lipophilic balance number remains greater than 15 due to the large polar portion in the conjugates to form translucent microemulsions spontaneously (Table 2). Unlike microemulsions formed by a mixture of surfactants or lipid polymers, co-surfactants and/or co-solvents which a surfactant or lipid polymer concentration is several times higher that significantly exceeds the concentration of the dispersed phase or mechanically produced translucent microemulsions which specialized equipment is required, as showed in Table 2, the polymer-CD-lipid conjugates in the present invention have optimized logP values which are able to form transparent solution or nanoemulsions spontaneously by a single polymer-CD-lipid conjugate and typically without co- solvent and external high energy input [Mason TG, Wilking JN, Meleson K, Chang CB, Graves SM. "Nanoemulsions: formation, structure, and physical properties", Journal of Physics: Condensed Matter, 18 (2006) R635-R666].
[0041] In one aspect of the current invention, a stable aqueous solution may be formed with smaller polymer-CD-lipid conjugates. This is superior over conventional CDs or CD derivatives or surfactants or other lipid-polymers since many undesirable side effects caused by CDs or
surfactants or lipid-polymers, higher concentrations of CDs or CD derivatives are disadvantageous or prohibitive in many applications. In addition, the stability of a microemulsion or mechanically formed nanoemulsion by surfactants or CDs is often easily compromised by dilution, by heating, or by changing pH levels. As showed in Figure 2, simply mixing a PEG-carbohydrate-lipid conjugate (cholestoryllactobionate-mPEG-12) and ΗΡ-β-CD (2-hydroxypropyl- -cyclodextrin) will only product an opaque emulsion. Thus a chemical conjugation is necessary in order to achieve the solubility enhancement instead of physical mixing of a CD with a PEG-lipid.
[0042] Though it is possible to use a variety of hydrophilic polymers in practicing the invention, polyethylene glycol (PEG) is preferred because of its long history of effectiveness and its status of being generally regarded as safe (GRAS). Incorporating PEG, the General Structure 2 of the new polymer-CD-lipid conjugate is:
[0043] General Structure 2
[0044] In General Structure 2, where "i" is a number of substituent comprising polymer and lipid that are conjugated to CDs through the center backbone, "i" may be equal to the available hydroxyl groups of a CD, it is preferable ranging from 1 to 7 and more preferable ranging from 1 to 5, most preferable ranging from 1 to 3. Where and R2 may be the same or different, Rl and R2 may be hydrogen or carboxyl or alkyl ether including but not limited to -CH2CHOHCH3 or - (CH2)4S03-Na+ or -CH3. The backbone, "B" may be selected from a compound comprises at least three available binding positions or sites for the conjugation of a first carrier, a second carrier and a third carrier, each available binding position or site comprising an expendable amino, hydroxyl, or carboxylic group. The backbone may be selected from the group consisting of glycerol or glycerol-like analogues, polyamines, diamines, triamines, tetramines, aminodiol, aminotriols, aminoalcohols and amino acids having three available binding positions or sites, triols, tetraols, erythritol, triacids, tetracid, tetraacetic acid, glucoheptonic acid, and tartaric acid, including but not limited to ethanediamine, propanediamine, butanediamine, pentanediamine, hexanediamine, diethylenetriamine, 1 ,2-diaminoethane, 1 ,3-diaminopropane (propane- 1 ,3 -diamine), 4-amino-3- hydroxybutyric acid, N-(2-hydroxyethyl)ethylenediamine, 4-amino-2-hydroxybutyric acid, 2- hydroxy-4-aminobutylic acid, l-B-homoserine, 1-threonine, JV-B-aminoethylglycine, putrescine (butane- 1 ,4-diamine), cadaverine (pentane-l ,5-diamine), hexamethylenediamine (hexane- 1 ,6- diamine), 1 ,2-diaminopropane, diphenylethylenediamine, diaminocyclohexane. Diethylenetriamine, bis(3-aminopropyl)amine, triethylenetetramine, tris(2-aminoethyl)amine, spermine, spermidine, norspermidine, bis(3-aminopropyl)- 1 ,3 -propanediamine, l ,2-bis(3-aminopropyl- amino)ethane, V,JV'-bis(3-aminopropyl)- 1 ,3 -propanediamine, tris(hydroxylmethyl)amino-methane, diaminobenzidine, V-ethyl-JV'-(3 -dimethylaminopropyl)carbodiimide, meso-erythritol, triazacyclononane, tetraazacyclododecane, threitol, dithiothreitol, trimethylcyclo-hexane- 1 ,3,5- tricarboxylic acid, trimethylbis(hexamethylene)triamine, bis(hexamethylene)-triamine, arginine, oxylyldiaminopropionic acid, 3-amino- l ,2-propanediol, 3-bromo- l ,2-propanediol, 3-chloro- l ,2- propanediol, 3-fluoro-l ,2-propanediol, DL-glyceric acid, diaminopropionic acid, glucoheptonic acid and, 1 ,2,4-butanetriol, 2,2-bis(hydroxymethyl)butyric acid, l ,3-diamino-2-propanol and 2-
(3-aminopropylamino)ethanol, and 3-((3-aminopropyl)amino)propanol; aspartic acid, glutamic acid, asparagine, glutamine, lysine, ornithine, serine, and threonine or benzyl triols or aminohydroxybenzoic acids or benzenetriol, dihydroxybenzoic acid, diaminobenzoic acid, diaminophenol, diaminobenzoic acid, aminohydroxybenzoic acid, aminosalicylic acid, hydroxyanthranilic acid, hydroxyisophthalic acid, aminoisophthalic acid, 4-(hydroxyl- methyl)cyclopentane-l ,3-diol, deoxyfuconojirimycin, deoxynojirimycin, prostaglandins, hydroxylmethylpiperidinol, dihydroxy(hydroxymethyl)aminocyclopentane, diaminophenol, benzenetetracarboxylic acid, benzenetricarboxylic acid, aminobenzenediol, dihydroxybenzoic acid, aminohydroxybenzoic acid, trihydroxyaniline, benzenetriol, dimethoxybenzenediamine, trihydroxyphenol, (diaminophenoxy)benzenediamine and aminobromophenol. The cyclodextrin consist of (n =) six, seven, and eight glucopyranose units or branched with glucosyl or maltosyl group. The "Lipid" is a lipophilic compound or their diesters including but not limited to fatty acids or steroids or sterols or sterol-like compound or lipo-vitamin. Although the CD is a large carrier, it is still considered as one of the three carriers attached to the center backbone though the same or different linkers of alkylation or esterification or etherification or amidation between carrier groups and center backbones. Each linker may be as simple as oxygen or nitrogen or sulfur or other single atom to form an ester or ether or amide or thiol bond or alike between the carrier and center backbone. Alternatively, each linker may be single or replicate linkers selected from amino, succinylamino, acetamido, aminopentanamido, aminoacetyl, acryloyl, thiopropanoayl, N- (mercaptomethyl)propionamido, mercaptopropylthiopropanoyl, (1 ,2-dihydroxy-3-mercapto- propylthio)propanoyl, succinyl, acetyl, oxopentanoyl, carbamoyl, aminoalkyl, glutaramido, aminoethanethiol, mercaptopropanol, (hydroxypropylthio)propanoayl, 3-((2-propionamidoethyl)- disulfanyl)propanoayl, (((acetamido-ethyl)disulfanyl)propanoyloxy)glutaramido, aminoethanet- hioate, 2-hydroxyacetic proprionic anhydride, glycerol or glycerol-like analogues, polyamines, diamines, triamines, tetraamines, aminodiol, aminotriols, aminoalcohols and amino acids having three available binding positions or sites, triols, tetraols, erythritol, triacids, tetracid, tetraacetic acid, glucoheptonic acid, and tartaric acid, including but not limited to ethanediamine, propanediamine, butanediamine, pentanediamine, hexanediamine, diethylenetriamine, 1 ,2- diaminoethane, 1 ,3-diaminopropane (propane- 1 ,3 -diamine), 4-amino-3-hydroxybutyric acid, N-(2- hydroxyethyl)ethylenediamine, 4-amino-2-hydroxybutyric acid, 2-hydroxy-4-aminobutylic acid, 1- β-homoserine, 1-threonine, JV-B-aminoethylglycine, putrescine (butane- 1 ,4-diamine), cadaverine (pentane-l ,5-diamine), hexamethylenediamine (hexane- l ,6-diamine), 1 ,2-diaminopropane, diphenylethylenediamine, diaminocyclohexane. Diethylene-triamine, bis(3-aminopropyl)amine, triethylenetetramine, tris(2-aminoethyl)amine, spermine, spermidine, norspermidine, bis(3- aminopropyl)-l ,3 -propanediamine, 1 ,2-bis(3-amino-propylamino)ethane, JV, JV'-bis(3 -amino- propyl)- 1 ,3 -propanediamine, tris(hydroxyl-methyl)aminomethane, diaminobenzidine, N-ethyl-N'- (3-dimethylaminopropyl)-carbodiimide, meso-erythritol, triazacyclononane, tetraazacyclo- dodecane, threitol, dithiothreitol, trimethylcyclo-hexane-l ,3,5-tricarboxylic acid, trimethylbis(hexamethylene)triamine, bis(hexamethylene)-triamine, arginine, oxylyldiamino- propionic acid, 3-amino- l ,2-propanediol, 3-bromo- l ,2-propanediol, 3-chloro- l ,2-propanediol, 3- fluoro-l ,2-propanediol, DL-glyceric acid, diaminopropionic acid, glucoheptonic acid and, 1 ,2,4- butanetriol, 2,2-bis(hydroxymethyl)butyric acid, l ,3-diamino-2-propanol and 2-(3-aminopropyl- amino)ethanol, and 3-((3-aminopropyl)-amino)propanol; aspartic acid, glutamic acid, asparagine, glutamine, lysine, ornithine, serine, and threonine or benzyl triols or aminohydroxybenzoic acids or benzenetriol, aminosalicylic acid. In some cases, the linker may be co-extensive with or a part of the backbone or functional group component used to synthesize the conjugates.
[0045] Typical coupling reaction of the conjugates involves with one or more or combination or in series of alkylation including JV-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. The general structure is meant to include all racemers or structural isomers of the structure, as they may be functionally equivalent. The PEG chain preferably
consists of between about 5 and 1 15 subunits, and is preferably substantially monodisperse. ¾ is the terminal group on the PEG chain may be selected from a wide variety of chemical moieties. Hydroxyl or methoxy is commonly selected as the terminal groups. R; preferably has a molecular weight of less than about 650. Commercially available PEG-lipid monoesters may be used to formulate many compounds by directly linking new moieties to the available positions on the center backbone.
[0046] In one aspect of the present invention, no drug or peptide or biomolecule will be selected as the center backbone. Unlike prodrugs modified from bioactive agents, one of major applications of the present invention is for drug delivery, therefore the conjugates themselves as a delivery vehicle are chemically stable and preferably having less or no toxic to the body.
[0047] The terminal group on the PEG chain may be selected from a wide variety of chemical moieties. Such moieties preferably have a molecular weight of less than 650. Such moieties include -OH, -OCH3, -NH2, -COOH, -OCH2CH3, -OCH2CH2OH, -COCH=CH2, -OCH2CH2NH2, -OS02CH3, -OCH2C6H6, -OCH2COCH2CH2COONC4H402, -CH2CH2=CH2, Ci0Hi6N2O3S and - OC6H6. The terminal group may be a functional group that facilitates linking therapeutic or targeting agents to the surface of lipid vesicle aggregates. Amino acids, amino alkyl esters, biotins, maleimide, diglycidyl ether, maleinimido propionate, methylcarbamate, tosylhydrazone salts, azide, propargylamine, propargyl alcohol, succinimidyl (NHS) esters (e.g., propargyl NHS ester, NHS-biotin, sulfo-NHS-LC-biotin, or NHS carbonate), hydrazide, succinimidyl ester, succinimidyl tartrate, succinimidyl succinate, and toluenesulfonate salt are useful for such linking. Linked therapeutic and targeting agents may include Fab fragments, cell surface binding agents, and the like. Additionally, the terminal group may include functional cell-targeting ligands such as folate, transferrin and molecules such as monoclonal antibodies, ligands for cellular receptors or specific peptide sequences may be attached to the liposomal surface to provide specific binding sites. The terminal group may be neutral or include either negatively or positively charged head- groups such as decanolamine, octadecylolamine, octanolamine, butanolamine, dodecanolamine, hexanolamine, tetradecanolamine, hexadecanolamine, oleylamine, decanoltrimethylaminium, octadecyloltrimethylaminium, octanoltrimethylaminium, butanoltrimethylaminium, dodecanol- trimethylaminium, hexanoltrimethylaminium, tetradecanoltrimethylaminium, hexadecanol- trimethylaminium, oleyltrimethylaminium, for example. Other useful R groups include fatty acids or alkyl groups such as alkoxy moieties, amino acids, and sugars including monosaccharides, disaccharides, trisaccharides and the oligosaccharides containing 1 , 2, 3, and 4 or more monosaccharide units respectively. Additionally, targeting moieties such as antibody fragments and vitamins may also be used as R groups. The molecular weight of the R group is preferably less than about 650, and for most applications the R group is preferably easily polarized, in order to increase the binding and interaction with proteins at the targeted sites. However, well balanced ionic R groups are advantageously employed for certain modes of administrations such as topical gels and oral solutions targeting the mouth and throat.
[0048] The present invention includes linking chemical groups that may be selected to optimize and improve PEG-CD-lipid based formulations. Selecting an appropriate linker between lipo- portion or PEG or CD and backbone may be important for several reasons, as described below.
[0049] Of the three linked PEG, CD and lipophilic components or lipo-vitamins are digestible by humans while cyclodextrins are partially digestible and PEG is not. Breaking the linkage among the three components may result in increased clearance for all. It is therefore an object of the invention to use varying biodegradable linkers for optimizing clearance rates of lipid vesicles and lipids used for drug delivery.
[0050] When attached to a polymer, any inherit property of the molecules may be inactive. It is therefore an object of the invention to use less biodegradable linkers for stabilizing the bond between the center backbone and the carrier groups, especially when a portion of the conjugates alone may be relatively toxic.
[0051] In one aspect of the present invention involves coupling reactions of the conjugates with one or more or combination or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. For practical and economic reasons, it is preferable making those conjugates from simple processes whenever possible at low costs.
[0052] Retaining power of a solubilzing enhancer may be important in drug formulations and preventing drug precipitation from dilution or circulation in the body fluids. The present invention provides the means of enhancing retaining power by inclusion more hydrophobic carrier groups into polymer-CD-lipid conjugates. In addition, with increased retaining power of the conjugates, the use of preservative may be eliminated for parenteral products since the sterile filtration is possible with a relative low concentration of the polymer conjugates in the dosage forms which typically form a true solution product.
[0053] The CD groups in the conjugates of the present invention have larger surface polarity than polymer chains or lipophilic carriers. For instance, those PEG-CD-lipid conjugates provide a better drug dispersion for their applications in nano- suspension or nanoparticles, especially for some amphiphatic drugs or other compounds; this provides a better equilibrium for the drug or other compounds to partition into apolar cavity or the lipophilic core of the conjugates.
[0054] When using existing PEG-lipids such as Capmul®, Centrophase®, Cremophor®, Labrafac®, Labrafil®, Labrasol® and Myverol® for oral liquid formulations, a taste masking agent may be used which may have additional issues for manufacturing processes and costs. PEG- CD-lipid conjugates generally taste better than other types of PEG-lipids conjugates, and elimination of the need for taste making agents may be possible.
[0055] PEG-CD-lipid conjugates in the present invention may be formulated into injectable preparations free from sugars which are commonly used to stabilize lyophilized proteins and peptides for injectables. Injectables prepared with PEG-CD-lipid conjugates are very stable even under high temperature or high humidity conditions. Reducing or eliminating the use of sugars in pharmaceutical preparation is especially beneficial for patients with diabetes mellitus.
[0056] The polymer chains in the conjugates of the present invention are preferably monodisperse or narrow-disperse PEG. Materials and methods for synthesizing such monodisperse PEG chains are disclosed in United States patent application 12/802,197, which is hereby incorporated by reference in its entirety. Preferably more than 30% of the PEG chains in a particular conjugate have the same molecular weight. More preferably, more than 50% have the same molecular weight. Most preferably, more than 80% have the same molecular weight.
[0057] In one aspect of the current invention, the general structure is meant to include all racemers or structural isomers of the structure, as they may be functionally equivalent. When the polyethylene glycol is used as the polymer, the PEG chain preferably consists of between about 5 and 1 15 subunits, and is preferably substantially monodisperse. R is the terminal group on the PEG chain may be selected from a wide variety of chemical moieties. R preferably has a molecular weight of less than about 650.
[0058] Generally, the present invention includes compositions and methods for synthesizing PEG- CD-lipid conjugates comprising a center backbone with one PEG chain and one lipophilic group bonded to the backbone, the PEG-lipid may then attach to one of activated hydroxyl group of CDs, likewise the activated CDs may be attached to the center backbone by the similar processes as other carriers. The conjugation undergoes alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. Selected linkers may be used to form ester or ether or amide bonds between the backbone and the PEG chain or the CD or the lipophilic group or prior to the conjugation to the center backbones. The backbone comprises glycerol or glycerol-liking having three available binding positions or diamines, triamines, tetramine and polyamines or diaminoalcohol or amino acids having three available binding positions and the lipophilic carrier group comprises fatty acids or sterols or cholesterol or
cholesterol-like having a single hydroxyl group or tocopherol or tocotrienol or cholecalciferol or retinol, retinal, and retinoic acid.
[0059] Variations of the invention include a variety of compounds as for the center backbone with at least three available binding positions. Molecules having two available binding positions, such as diamines, aminoalcohols or amino acids may be chemically extended to three binding sites.
[0060] While positional isomers may be produced during synthesis of the polymer-carbohydrate - lipid conjugates, such isomers may be functionally equivalent. However, the choice of isomer may have implications in a variety of delivery process such as intracellular transport of lipophilic molecules as well as their use as vehicles in pharmaceutical applications. For example, isomers may differ in the ability to stabilize a compound during solubilizing and storage.
[0061] Though it is possible to use a variety of center backbone for the preparation of a polymer-CD-lipid conjugates, incorporating linear or cyclic molecule in practicing the invention is demonstrated to be very powerful. In one hand is because of a sterol or tocopherol or cholecalciferol may largely increase handling ability of "like dissolves like," In other hand, the apolar cavity of CDs provide the "host" site for "guest" molecules. General Structure 2, the backbone may be selected from glycerol or glycerol-like analogues, polyamines (di- or tri-or tetra- or penta- amines), amino acids having three available binding sites, and triols and triacids such as glucoheptonic acid and tartaric acid. The lipophilic component may be selected from a group of compounds including but not limited to cholesterol, stigmasterol, ergosterol, hopanoids, phytosterol, sitosterol, campesterol, brassicasterol, avenasterol adosterol, and stanols (saturated steroid alcohols or hydrogenated sterols), retinoids, , retinals, retinoic acid, tretinoin, carotenoids, β-carotene, a-tocopherol, tocotrienols, cholecalciferol, ergocalciferol, astaxanthin, auroxanthin, capsanthin, capsorubin, chrysanthemaxanthin, cryptoxanthin, fucoxanthin, lutein, neoxanthin, rubixanthin, violaxanthin, zeaxanthin. The CD may be a-cyclodextrin or β-cyclodextrin or γ- cyclodextrin. The same or different linkers may be used through alkylation or etherification or esterification or amidation process between carrier groups and center backbones. Each linker may be as simple as oxygen or sulfur or other single atom. Alternatively, each linker may be single or replicate linkers selected from amino, succinylamino, acetamido, aminopentanamido, aminoacetyl, acryloyl, thiopropanoayl, N-(mercaptomethyl)-propionamido, mercaptopropylthiopropanoyl, (1 ,2- dihydroxy-3-mercaptopropylthio)propanoyl, succinyl, acetyl, oxopentanoyl, carbamoyl, aminoalkyl, glutaramido, aminoethanethiol, mercaptopropanol, (hydroxypropylthio)propanoayl, 3- ((2-propionamidoethyl)disulfanyl)propanoayl, (((acetamido-ethyl)disulfanyl)propanoyloxy)- glutaramido, aminoethanethioate, and 2-hydroxyacetic proprionic anhydride.
[0062] . In some cases, the linker may be co-extensive with or a part of the backbone or functional group component used to synthesize the conjugate. Though not shown, the invention also includes compounds in which the carbohydrate is in the center position of the backbone. However, it is more practical to have carbohydrates at the terminus instead of the center of the backbones due to the routes of synthetic chemistry. The general structure is meant to include all racemers or structural isomers of the structure, as they may be functionally equivalent. The PEG chain preferably consists of between about 5 and 1 15 subunits, and is preferably substantially monodisperse. R is the terminal group on the PEG chain may be selected from a wide variety of chemical moieties. R preferably has a molecular weight of less than about 650.
[0063] In another aspect of the present invention, while various fatty acids may be utilized for the preparation of the polymer-CD-lipid conjugates, the myristoleic acid, palmitoleic acid, oleic acid, lauric acid, myristic acid, palmitic acid and stearic acid may be more commonly used. Myristoleic acid, palmitoleic acid, oleic acid palmitic acid and stearic acid may be more preferable..
[0064] In one aspect of the present invention, whenever applicable, preferable amino acid linkers are proline, glycine, alanine, lysine, cysteine, valine, isoleucine, leucine, methionine, phenylalanine, histidine, tryptophan, tyrosine, selenocysteine, and arginine, more preferable are
proline, glycine, alanine, lysine, cysteine, valine, isoleucine, leucine, methionine, most preferable are proline, glycine, and alanine
[0065] In this aspect of the invention, in the general structure 2, even though it may not show in the chemical drawing, a linker may comprise one or more carbon atoms in addition to the linker forming an N-alkylation or O-alkylation, ester or ether or amide bond between the carriers and center backbone. Whenever suitable, a simple and low cost coupling process should be chosen to void multiple linkers such as forming a peptide and the linker is preferably oriented so that the backbone is readily coupling to the carrier groups.
[0066] The present invention may be practiced using a variety of center backbones void drug moieties. Preferable backbones have at least three available or two expandable positions for carbohydrate or lipid or PEG attachments through alkylation, esterification, etherification or amidation. For those suitable molecules may be used as the backbone including but not limited to the group consisting of ethylenediamine (1 ,2-diaminoethane, 1 ,3-diaminopropane (propane- 1 ,3- diamine), putrescine (butane- 1 ,4-diamine), cadaverine (pentane-l ,5-diamine), hexamethylene- diamine (hexane-l ,6-diamine), ethylenediamine, 1 ,3-diaminopropane, 1 ,2-diaminopropane, 1 ,4- diaminobutane, diphenylethylenediamine, diaminocyclohexane, 3-amino-l ,2-propanediol, 3- bromo-l ,2-propanediol, 3-chloro-l ,2-propanediol, 3-fluoro-l ,2-propanediol, DL-glyceric acid, diaminopropionic acid, tartaric acid, glucoheptonic acid and, 1 ,2,4-butanetriol, 2,2- Bis(hydroxymethyl)butyric acid, l ,3-diamino-2-propanol and 2-(3-aminopropylamino)ethanol, 3- ((3-aminopropyl)amino)propanol, diethylenetriamine, spermidine, triethylenetetramine, spermine, norspermidine, bis(3-aminopropyl)-l ,3-propanediamine, and bis(hexamethylene)triamine, aspartic acid, glutamic acid, asparagine, glutamine, ornithine, serine and threonine, benzyl triols or aminohydroxybenzoic acids or phenol-like analogues, phenyl diols with a carboxyl group or amine, and diamines with a hydroxyl or carboxyl group, diaminobenzoic acid, aminohydroxybenzoic acid, aminosalicylic acid, hydroxyanthranilic acid, hydroxyisophthalic acid, aminoisophthalic acid. For example, a suitable center backbone may be selected from 4- (hydroxymethyl)cyclopentane-l ,3-diol, deoxyfuconojirimycin, deoxynojirimycin, prostaglandins, hydroxymethylpiperidinol, dihydroxy(hydroxymethyl)aminocyclopentane, diaminophenol, benzene-tetracarboxylic acid, benzenetricarboxylic acid, aminobenzenediol, dihydroxybenzoic acid, aminohydroxybenzoic acid, trihydroxyaniline, benzenetriol, dimethoxybenzenediamine, trihydroxyphenol, (diaminophenoxy)-benzene-diamine or aminobromophenol.
[0067] The polymer-CD-lipid conjugates of the present invention may be used for many applications. Formulation and delivery of pharmaceutical and cosmetic agents have been described. Additionally, the polymer-CD-lipid conjugates of the present invention may be used in other contexts where water soluble vehicles are advantages, for example industrial and food processes
[0068] The terminal group on the PEG chain may be selected from a wide variety of chemical moieties. Such moieties preferably have a molecular weight of less than 650. Such moieties include -NH2, -COOH, -OCH2CH3, -OCH2CH2OH, -COCH=CH2, -OCH2CH2NH2, -OS02CH3, - OCH2C6H6, -OCH2COCH2CH2COONC4H402, -CH2CH2=CH2, Ci0Hi6N2O3S and -OC6H6. The terminal group may be a functional group that facilitates linking therapeutic or targeting agents to the surface of micro vesicle aggregates. Amino acids, amino alkyl esters, biotins, maleimide, diglycidyl ether, maleinimido propionate, methylcarbamate, tosylhydrazone salts, azide, propargyl- amine, propargyl alcohol, succinimidyl (NHS) esters (e.g., propargyl NHS ester, NHS-biotin, sulfo-NHS-LC-biotin, or NHS carbonate), hydrazide, succinimidyl ester, succinimidyl tartrate, succinimidyl succinate, and toluenesulfonate salt are useful for such linking. Linked therapeutic and targeting agents may include Fab fragments, cell surface binding agents, and the like. Additionally, the terminal group may include functional cell-targeting ligands such as folate, transferrin and molecules such as monoclonal antibodies, ligands for cellular receptors or specific peptide sequences may be attached to the liposomal surface to provide specific binding sites. The
terminal group may be neutral or include either negatively or positively charged head-groups such as decanolamine, octadecylolamine, octanolamine, butanolamine, dodecanolamine, hexanolamine, tetra-decanolamine, hexadecanolamine, oleylamine, decanoltrimethylaminium, octadecyloltri- methylaminium, octanoltrimethylaminium, butanoltrimethylaminium, dodecanoltrimethyl- aminium, hexanoltrimethylaminium, tetradecanoltrimethylaminium, hexadecanoltrimethyl- aminium, oleyltrimethylaminium, for example. Other useful R; groups include alkyl groups such as alkoxy moieties, amino acids, and sugars including monosaccharides, ascorbic acid, gluconic acid, glucaric acid, glucuronic acid, galacturonic acid, disaccharides, trisaccharides and the oligosaccharides containing 1 , 2, 3, and 4 or more monosaccharide units respectively. Additionally, targeting moieties such as antibody fragments and vitamins may also be used as ¾ groups. Generally, the R; group is highly soluble in water. The molecular weight of the R; group is preferably less than about 650, and for most applications the Ri group is preferably easily polarized, in order to increase the binding and interaction with proteins at the targeted sites. However, well balanced ionic Ri groups are advantageously employed for certain modes of administrations such as topical gels and oral solutions targeting the mouth and throat.
[0069] Depending on the choice of backbone, functional groups and linkers, the compounds of the invention may be categorized into several classes. These classes include and not limited to (a) sterol and "fat soluble" vitamin based: cholesterylglycerolcyclodextrin-polyethylene- (CGC- PEGs); tocopherylglycerolcyclodextrin-polyethyleneglycols (TGC-PEGs), cholesteryldiethylene- tetramine-cyclodextrin-polyethyleneglycols (CDC-PEGs), tocopheryldiethylenetetramine- cyclodextrinpolyethyleneglycols (TDC-PEGs), cholesteryltriethylenetetraminecyclodextrin- polyethyleneglycols (CTC-PEGs), and tocopheryltriethylenetetramine-cyclodextrin- polyethyleneglycols (TTC-PEGs); (b) fatty acid based: Oleoylglycerol-cyclodextrin-polyethylene- glycols (OGC-PEGs); oleoyldiethylenetetramine-cyclodextrin-polyethyleneglycols (ODC-PEGs), oleoyltriethylenetetramine-cyclodextrin-polyethyleneglycols (OTC-PEGs) and myristoylglycerol- cyclodextrin-polyethyleneglycols (MGC-PEGs); myristoyl-diethylenetetramine-cyclodextrin- polyethyleneglycols (MDC-PEGs); myristoyltriethylene-tetraminecyclodextrin-polyethylene- glycols (MTC-PEGs).
[0070] In one aspect of the present invention, a Polymer-CD-lipid conjugate composing a center backbone, a cyclodextrin, a polymer and a lipid is generally classified in Table 3.
[0071] Table 3 Typical Composition of Polymer-CD-lipid Conjugate
[0077] In further detail of the classification, a polymer-CD-lipid conjugate includes and not limited to oleoyl-mPEG-(aminopropoxy)acetocyclodextrin, stearoyl-mPEG-(aminopropoxy)- acetocyclodextrin, palmitoyl-mPEG-(aminopropoxy)acetocyclodextrin, myristoyl-mPEG-
(aminopropoxy)acetocyclodextrin, cholestery-mPEG-(aminopropoxy)acetocyclodextrin, cholestery-mPEG-(aminopropoxy)acetocyclodextrin, tocopheryl-mPEG-(aminopropoxy)aceto- cyclodextrin, retinoyl-mPEG-(aminopropoxy)acetocyclodextrin, retinoyl-mPEG-(aminopropoxy)- acetocyclodextrin, cholecalciferol-mPEG(aminopropoxy)acetocyclodextrin, oleoylpropane- diaminecyclodextrin-mPEG, £N-cyclodextrin-aN-oleoyl-mPEG-lysinate, £N-cyclodextrin-aiV- myristoyl-mPEG-lysinate, £N-cyclodextrin-aN-stearoyl-mPEG-lysinate, stearoylpropanediamine- cyclodextrin-mPEG, oleoyldiethylenetriamine-bismPEG-cyclodextrin, palmitoyldiethyletriamine- bismonomethoxyl-PEG-ether-cyclodextrin, oleoyltriethylenetetramine-p-cyclodextrin-bismPEG, palmitoyl-propanediamine-cyclodextrin-bismPEG, myristoylpropanediamine-cyclodextrin-mPEG, palmitoylpropane-diamine-cyclodextrin-mPEG, cholesterypropanediamine-cyclodextrin-mPEG, N£-cyclodextrin-Na-cholesterol-mPEG-lysinate, cholesterydiethylenetriamine-cyclodextrin-mPEG, a-tocopheroltriethylene-tetramine-bismonomethoxyl-PEG-ether-cyclodextrin, cholester-triethyl- enetetramine-bismPEG-cyclodextrin, cholesterytriethylenetetramine-cyclodextrin-bismPEG, cholesterytriethylenetetramine- -cyclodextrin-mPEG, tocopherylpropanediamine-cyclodextrin- mPEG, retinoylpropanediamine- cyclodextrin-mPEG, retinoyldiethylenetriamine-cyclodextrin- mPEG, cholecalciferoldiethylenetriamine-cyclodextrin-mPEG, cholecalciferoldiethylenetriamine- bismPEG-cyclodextrin, cyclodextrin-tocopherylethylene-bismPEG-aminosalicylate, choleca- lciferoldiethylenetriaminemono-bismPEG-cyclodextrin, cholesterylascorbyldiethylenetriamine- tryptophanyl-mPEG-cyclodextrin, cholesterolascorbyl-mPEG-propanediaminocyclodextrin, cholesterolaspartate-mPEG-cyclodextrin, cholesteryloleoylascorbyl-diethylenetriamine-mPEG- cyclodextrin, cholesteryl-retinoyldiethylenetriamine-mPEG-cyclodextrin, cholesterolascorbyl- triethylenetetramine-bismonomethoxy-PEG-ether-cyclodextrin, cyclodextrin-tocopherol-mPEG- lysinate, cholesteroltriethylenetetramine-bismPEG-cyclodextrin, cholesterololeoyl-cyclodextrin- diethylenetriamine-mPEG, bismPEG-propanediamine-serinol-iV-cholesterol-iV'-cyclodextrin, cyclodextrindiamino-2-propanolcholesterolmPEG-ascorbate, cholecalciferolascorbyldiethylene- triamine-cyclodextrin-mPEG, £N-cyclodextrin-£N-cholesteryl-aN-acetyl-mPEG-lysinate, cholecal- ciferoldipropylenetriamine-mPEG-cyclodextrin, cholesteryldiethylenetriaminetryptophanyl- mPEG-cyclodextrin, N-cyclodextrin-cholesterolaspartate-mPEG, cholesterylretinoyltriethylene- tetramine-mPEG-cyclodextrin, cholesteryltriethylenetetramine-bis-mPEG cyclodextrin, EiV- cyclodextrin-£iV-a-tocopherol-aiV-acetyl-monomethoxyl-PEG-ether-lysinate, a-tocopherol- triethylenetetramine-bismPEG-cyclodextrin, cholesterolascorboyldiethylenetriamine-mPEG- cyclodextrin, cholecalciferololeoylascorboyldiethylenetriamine-mPEG-cyclodextrin and cholesteryloleoylascorboyldiethylenetriamine-mPEG-cyclodextrin.
[0078] In another aspect of the present invention, the lipid may be selected from polyunsaturated fatty acids or polyunsaturated fatty alcohols including but not limited to Stearidonic acid, Eicosatrienoic acid, Eicosatetraenoic acid, Eicosapentaenoic acid, Heneicosapentaenoic acid, Docosapentaenoic acid, Docosahexaenoic acid, Tetracosapentaenoic acid, Tetracosahexaenoic acid, Docosadienoic acid, Adrenic acid, Docosapentaenoic acid, Rumenic acid, Rumenic acid, a- Calendic acid, β-Calendic acid, Jacaric acid, a-Eleostearic acid, β-Eleostearic acid, Catalpic acid, Punicic acid, Rumelenic acid, a-Parinaric acid, β-Parinaric acid, Bosseopentaenoic acid and native polyunsaturated alcohols such as farneol, solanesol and dodecaprenol. Hexadecatrienoic acid.
[0079] In another aspect the invention includes a molecule comprising a compound represented by the following General Structure 3 :
[0080] General Structure 3
[0081] where the bPEG is a branched PEG with 2 or more PEG chains and each PEG chain may consist of between about 5 and 1 15 subunits. Where ¾ is the terminal group and may be selected from a wide variety of chemical moieties. R; preferably has a molecular weight of less than about 650. The PEG-carbohydrate conjugates are useful for applications other than liposomes, e.g., as a solubility enhancer in water solutions. All other components of the conjugates may remain the same as described under the General Structure 1 and 2.
[0082] In one aspect of the current invention, coupling reactions of alkylation, etherification, esterification or amidation between the carriers and center backbone may be achieved with or without added-on linker groups depending on particular center backbones and carrier groups of the conjugates as summarized in the General Structure 4:
[0083] General Structure 4
[0084] where D is the fourth carrier which may a duplicate lipophilic carrier or PEG. Backbone is a molecule void of a drug moiety comprises glycerol or glycerol-liking having three available binding positions or diamines, triamines, tetramine or diaminoalcohol or aminoalcohols or aminodiol or aminotriols or amino acids having three available binding positions and polyamines having at least three available binding sites or positions. All other components may be the same as described under the General Structures 1 and 2.
[0085] A further aspect of the invention, the third and fourth carriers of the PEG-CD-lipid conjugates may be formed through a linked conjugation as presented in the General Structure 5.
[0087] Where D is a secondary lipophilic carrier or PEG; L is a coupler selected from a group of molecules included but not limited to glycerol or glycerol-liking having three available binding
positions or diamines, triamines, tetramine or diaminoalcohol or aminoalcohols or aminodiol or aminotriols or amino acids having three available binding positions. As showed in Chemical Structure 3, N-bis-monomethoxy-PEG-ether-serinol-N-cholesterol-iV'-a-cyclodextrin-propane- diamine, the coupler is 3-amino-l , 2-propanediol (serinol) and the "D' is a secondary mPEG.
[0088] Chemical Structure 3
[0089] Another aspect of the invention includes a method of delivering a compound, where the method comprises preparing a PEG-CD-lipid conjugate based formulation of the compound, where the formulation comprises a PEG-CD-lipid conjugates having an amino acid linker and possible secondary linker(s) selected from the group consisting of amino, succinylamino, acetamido, aminopentanamido, aminoacetyl, acryloyl, thiopropanoayl, N-(mercaptomethyl)-propionamido, mercaptopropylthiopropanoyl, (l ,2-dihydroxy-3-mercaptopropylthio)propanoyl, succinyl, acetyl, oxopentanoyl, carbamoyl, aminoalkyl, glutaramido, aminoethanethiol, mercaptopropanol, (hydroxypropylthio)propanoayl, 3-((2-propionamidoethyl)disulfanyl)propanoayl, (((acetamido- ethyl)disulfanyl)propanoyloxy)glutaramido, aminoethanethioate, and 2-hydroxyacetic proprionic anhydride; and providing a release agent, where the release agent causes the linker to degrade. The release agent may be an acid, light, hypoxia, or a catalyst.
[0090] In one aspect, the invention is a method of linking the center backbone to any of the three carrier groups via an amino acid linkage (alkylation or amidation process). The hydroxyl in the carrier groups may be activated by reaction with disucccimidylcarbonate (DCS) or mesylate or tosylate or acrylic acid or strong base (etherification or esterification).
[0091] Example of the synthesis of the PEG-CD-lipid conjugates from mono-aminoacrylate-6- deoxy- -cyclodextrin with a PEGylatedcholesteryldiethylediamine is shown below in Reaction Scheme 1.
[0092] Reaction Scheme 1
[0093] The preparations of allyl-cyclodextrin may be prepared according to modified method from published reports [Jindrich J., et al (19950. Carbohydr Res. 266(l):75-80; LI YingJie, et al (2010).
Scientia Sinica Chimica, 40 (1 1): 1682-1687] and the PEG-Lipid portion may be synthesized according to out earlier publications [US20120202979 or US20120202890]. This reaction scheme is suitable for carrier groups with all kinds of lipophilic compounds or PEG chains for the CD conjugation. The general structures shown in the application are meant to include all racemers and structural isomers of the structures, as they may be functionally equivalent.
[0094] The present invention also demonstrated the using of a branched-PEG as the polymer carrier. Branched-PEGs are commercially available with relative large molecular weights. Thus branched PEGs with smaller PEG chains may be prepared as the same as for a single PEG chain, consequentially, the activated branched PEG was used to make a branched PEG-carbohydrate conjugate as showed in the General Structure 3. As demonstrated in the Reaction Scheme 1 , there are multiple chemical processes of alkylation, etherification, esterification or amidation may be involved for making each final product, the steps of each conjugation were designed accordingly.
[0095] In another aspect, the invention includes PEG-carbohydrate conjugates comprised of three carrier groups and a center backbone having at three positions available for the conjugation, and one or more linker(s) between one of the carrier groups and the center backbone. Such PEG- carbohydrate conjugates are represented by the General Structures 1 to 5, where the linker may be selected but not limited from a group consisting of amino, succinylamino, acetamido, aminopentanamido, aminoacetyl, acryloyl, thiopropanoayl, N-(mercaptomethyl)propionamido, mercaptopropylthio)-propanoyl, (1 ,2-dihydroxy-3-mercaptopropylthio)propanoyl, succinyl, acetyl, oxopentanoyl, carbamoyl, aminoalkyl, glutaramido, aminoethanethiol, mercaptopropanol, (hydroxypropylthio)propanoayl, 3-((2-propionamidoethyl)disulfanyl)-propanoayl, (((acetamido- ethyl)disulfanyl)propanoyloxy)glutaramido, amino-ethanethioate, and 2-hydroxyacetic proprionic anhydride. The Table 4 shows certain samples of the PEG-CD-lipid conjugates and in the event of variations of chemical names, the structures shown are meant to be controlling.
[0097] In Table 4 the types of coupling reaction between the carriers and the center backbone as well as any chemical modification of cyclodextrin or a carrier or center backbone prior to the conjugation are alkylation including N-alkylation or 0-alkylation, esterification, etherification and amidation. For example, a cyclodextrin may be modified with acryloyl chloride then reacted with center backbone, thus two types of reaction may be involved; esterification and N-alkylation (Michael addition). As one of the key intermediates for the preparation of the conjugate, monotosylation of cyclodextrins may be prepared with l -(p-tosyl)-imidazole as described in the Reaction Scheme 2 [T. Tan, et al (201 1). Protocol Exchange, doi: 10.1038/protex.201 1.214] .
[0098] Reaction Scheme 2. Preparation of mono-6-tosyl-cyclodextrin
[0099] A sample of the CD conjugation with mono-6-tosyl-cyclodextrin is demonstrated in the Reaction scheme 3. The yield product may be further purified with a mixture of methanol and acetonitril
[00100] Reaction Scheme 3 (R is a center backbone with or without attached PEG or lipid)
[00101] Converting mono-6-tosyl-CD into mono-6-aminoacryloyl-6-deoxyl-CD may be achieved by the following steps in the Reaction Scheme 4 [W. Zhang, et al (2010). Applied Surface Science. 256: 3000-3005] .
[0096] Reaction Scheme 4. Mono-N-aminoacryloyl-6-deoxylcyclodextrin
[0097] Similar acrylation may be applicable to the PEG or lipid carriers with fewer steps as demonstrated in the Reaction Scheme 5.
[0098] Reaction Scheme 5 (R is a center backbone)
[0099] In one aspect of the present invention, monosubstitution cyclodextrins may be preferable, while a number of modified cyclodextrins are commercially available, for simplicity and cost saving, nature or nonmodified cyclodextrins may be used as for the synthetic starting material since the final products of the polymer-CD-lipid conjugates are enhanced solubilizers, using expensive premodifed or substituted cyclodextrin may not be necessary.
[00100] Embodiments of the present invention are described herein in the context of preparation of pharmaceutical compositions including polymer-cyclodextrin-lipid conjugates or polymer- cyclodextrin-lipid conjugates for increasing the solubility and enhancing the delivery of active agents. The approximate preferable compositions for formulated drug products are generally described herein, though different drugs typically have differing optimal formulations.
EXAMPLES
[00101] Chemicals and Reagents: N, N'-dicyclohexylurea, N, N'-dicyclohexylcarbo-diimide (DCC), oleic acid, ascorbic acid, α-, β-, γ-cyclodextrins, cholecalciferol, cholesteryl choloformate, cholesterol, glucuronic acid, polyethylene glycol (PEG), retinoic acid, a-tocopherol and other chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA) or Alfa Aesar (Ward Hill, MA, USA) or TCI America (Portland, OR, USA). Activated PEGs were obtained from Quanta BioDesign (Powell, Ohio, USA) or Thermo Fisher Scientific (Rockford, IL) or were provided by LipoSeutics LLC (North Brunswick, New Jersey, USA).
[00102] Example 1. Preparation of tert-Butyl Carbamates (Boc)-Protected Amino Groups
[00103] A high yield and effective synthetic method under a catalyst-free and room temperature was reported previously [Chankeshwara, SV and Chakraborti, AK. Org. Lett. , (2006); 8, 3259] and used with slightly modification. To a solution of starting compound containing amino benzoate in MeOH, di-i-butyl dicarbonate was added as one to one molar ratio. The resulting mixture was stirred overnight at room temperature. When the reaction was done, solvent was removed under vacuum; the residue was dissolved into ethyl acetate and washed with saturated NH4C1 aqueous solution once, then dried over Na2S04 and condensed to yield the expected product (> 90%). Example of this reaction is demonstrated in Reaction Scheme 4, where R is a main structure of the center backbone. This method gives N-t-Boc derivatives chemoselectively without any side products (such as isocyanate, urea, JV, JV-di-i-Boc).
H
O
[00104] Reaction Scheme 4
[00105] Example 2. Deprotection of Boc-Protected Amino Groups
[00106] Effective reagents for the deprotection of tert-butyl carbamates or tert-buty\ esters include phosphoric acid and trifluoroacetic acid. The reactions give high yields and very convenient [Li, B. Berliner, M. etc, J. Org. Chem. , 2006; 71, 9045] . Equal volumes of trifluoroacetic acid were added to a solution of Boc-carbamate (10% of crude product) in CH2C12. The resulting solution was stirred at room temperature for overnight and the solvent was evaporated and the residue was re-dissolved into CH2C12, then washed with saturated NaHCOs and dried over MgS04. Solvent was evaporated and was used in next step without further purification.
[00107] Example 3. Preparation of JV-Boc-cholesterylserinate
[00108] 0.03 moles of JV-Boc-serine was constantly stirred under nitrogen in 100 mL of chloroform. 0.03 mole of cholesteryl choloformate was dissolved with 100 mL of chloroform and added to this heterogeneous mixture of N-tert-butyloxycarbonylserine and followed by adding 10 mL of anhydrous pyridine. The reaction for 30 minutes under constantly stirring at room temperature, the mixture turned to homogeneous and the reaction was completed when no
detectable cholesteryl chloroformate was in the mixture. The bulk solvent was removed under vacuum and the crude product was used to next step without further purification. The resulting product (% of yields 70-80) is showed in Chemical Structure 5.
[00109] Chemical Structure
[00110] Example 4. Preparation of N-Boc-cholesterylmonomethoxyldodecaethylene glycol ether serinate
[00111] 0.01 moles of monomethoxyldodeeacthySene glycol ether (0.01 mmol) was dissolved with 50 mL of anhydrous CH2CI2, 0.01 mole of dicyclohexylcarbodiimide and cholesterylserinate were added. The resulting mixture was stirred at 0 °C for 2 hours, then allowed to warm up to room temperature and stirred for additional 48 hours. When the reaction was complete, the white precipitate was filtered off over celite. The residue was rinsed with small amount of CH2CI2 twice and washed with sutured NH4CI, then dried over MgS04. Solvent was evaporated to afford pale yellowish oil as showed in Chemical Structure 6. The crude product's purity was determined by 1H NMR and UPLC-MS, ESI-MS (>70%).
[00112] Chemical Structure 6
[00113] Example 5. Preparation of cholesterylserinylmonomethoxyldodecaethylene-glycol eilier- P-cyclodextrin
[00114] The protection group of tert-butylcarbonyl on the amino group was removed according to the method described in Example 2. 0.01 moles of N-Boc-cholesterylserinylmonomethoxyl- dodecaethylene glycol ether (0.01 mol) from Example 4 was dissolved with 50 mL of anhydrous tetrahydrofuran (THF), 0.01 mole of Mono-N-aminoacryloyl-6- -deoxylcyclodextrin and 3% of triethylamine were added. The resulting mixture was stirred at 50-60 °C for overnight, and allowed to cool to the room temperature. The reaction solution was precipitated into isopropyl alcohol (IPA)-Acetonitrile (ACN, 1/4, v/v) and methyl t-butyl ether (MTBE) was added to maximize the isolated yield of precipitate. The crude product was washed with 20/80 (v/v) IPA/ACN and dried under vacuum at 30-40° C. The purity (> 95%) of the final product (Chemical Structure 4) was determined by 1H NMR and UPLC-MS.
[00115] Chemical Structure 7
[00116] Example 6. Preparation of Cyclodextrindiethylenetriamine
[00117] Diethylenetriamine (0.01 mol) was dissolved in 50 mL of dry (molecular sieve) THF and mono-6-tosyl-a-cyclodextrin (0.005 mol) was added. The resulting mixture was stirred for 6 hours at 50-60 °C and allowed to cool to the room temperature when the reaction was completed. The reaction solution was precipitated into IPA and ACN was added to maximize the isolated yield of precipitate. The cake was washed well with 20/80(v/v) IPA/ACN and dried under vacuum at 30-40° C. The crude product (Chemical Structure 8) and was used in next step without further purification.
[00118] Chemical Structure 8
[00119] Example 7. Preparation of a-cyclodextrinoleoyldiethylenetriamine-mPEG
[00120] 0.01 mole of the starting material from Example 6, a-cyclodextrindiethylenetriamine, was dissolved in 20 mL of THF at 20 to 30° C. The slightly excess active oleic acid N- hydroxysuccinimide ester (0.01 1 mol) was dissolved in 20 mL of tetrahydrofuran (THF), then mixed with a-cyclodextrindiethylenetriamine and adding triethylamine (TEA, 3%, v/v) as a base, stirred for 2 hrs at room temperature. An assay was performed to verify the yield and moves to next step without purification. The active mPEG24-NHS (0.01 mol) was dissolved in THF, and then mixed with the above reactants, stirred for overnight at room temperature. After the completion of the reaction, solvents were removed by vacuo and 50 mL of acetone was added to the crude product and filtered and washed with 30 mL of acetone three times. The reaction solution was precipitated into IPA and ACN was added to maximize the isolated yield of precipitate. The crude product was washed well with 20/80 (v/v) IPA/ACN and dried under vacuum at 30-40° C. The purity (> 95%) of the final product (Chemical Structure 9) was determined by 1H NMR and UPLC-MS.
[00121] Example 8. Preparation of a-cyclodextrintriethylenetetramine
[00122] Triethylenetetramine (0.02 mol) was dissolved in 50 mL of dry (molecular sieve) THF and mono-6-tosyl-a-cyclodextrin (0.01 mol) was added. The resulting mixture was stirred for 6 hours at 50-60 °C and allowed to cool to the room temperature when the reaction was completed. The reaction solution was precipitated into IPA and ACN was added to maximize the isolated yield of precipitate. The cake was washed well with acetone, then 20/80 (v/v) IPA/ACN and dried under vacuum at 30-40 °C. The crude product (Chemical Structure 10) was used in next step without further purification.
[00123] Example 9. Preparation of a-cyclodextrincholesteryltriethylenetetramine
[00124] 0.01 mole of a-cyclodextrintriethylenetetramine from Example 8 was dissolved with 50 mL of anhydrous THF, 0.01 mole of cholesteryl chloroformate was added. The resulting mixture was stirred at 45-50 °C for overnight, and allowed to cool to the room temperature. The reaction solution was precipitated into IPA and ACN was added to maximize the isolated yield of precipitate. The crude product was washed well with 20/80 (v/v) IPA/ACN and dried under vacuum at 30-40 °C. The purity (> 80%) of the final product (Chemical Structurel l) was determined by 1H NMR and UPLC-MS.
[00125] Chemical structure 9
[00126] Chemical Structure 10
[00127] Chemical Structure 1 1
[00128] Example 10. Preparation of a-cyclodextrin triethylenetetraminecholesteryl-mPEG
[00129] 0.01 mole of the starting material from Example 9, a-cyclodextrincholesteryl- triethylenetetramine, was dissolved in 20 mL of THF at 20 to 30° C, a slightly excess of the active mPEG24-NHS (0.021 mol in 10 mL THF) was added, stirred for overnight at room temperature. 300 mL of acetone was added at the end of the reaction and solvents were removed by vacuo. The crude product washed with acetone and filtered. The wet product (60-65%) was further lyophilized to a wax as showed in Chemical Structure 12.
\ iM\ Chemical Structure 12
[00131] Example 1 1 Preparation of cholesterylethylylene glycol ether
[00132] Cholesteryl tosylate (0.1 mol) in tetrahydrofuran (100 mL) was mixed with ethylene glycol (1 mol) a round-bottomed flask equipped with a mechanic stirrer and heating mantle. The reaction mixture was stirred under reflux for 12 hours under protection of nitrogen and solvent was removed in vacuo, the residual was redissolved in 200 mL of methylene chloride and washed with 200 mL of water three times. The crude product in methylene chloride was dried in vacuo to yield a solid (90-105%) as showed C
[00133] Chemical Structure 13
[00134] Example 12. Preparation of cholesteryl ethylene glycol acetic acid
(00135] Product of cholesteryl ethylene glycol ether from Example 1 1 (0.02 mol) in tetrahydrofuran (100 mL) was placed into a round-bottomed flask equipped with a mechanic stirrer and a heating mantle. The solution was sparged with nitrogen (50- 100 psi). Sodium strip (0.05g) is added slowly at ambient room temperature. After the addition was completed, the reaction mixture was heated up gradually to 60 °C under constant stirring for 6 hours and sodium chloroacetate (0.03 mol) and Nal (0.005 mol) was added into the reaction flask and the reaction mixture was allowed to continue at 55-60 °C under constant stirring overnight. The reaction was quenched with sodium hydroxide solution (100 mL of 5%, w/v) and concentrated by remove tetrahydrofuran under vacuo, then extracted with methylene chloride (50 mL). The aqueous layer was acidified with HC1 (36%) to pH 3-4. The aqueous phase was extracted with methylene chloride (25 mL) twice. The combined organic layers were dried over sodium sulfate for 1 hour. The salt was removed by paper filtration and the solvent was removed in vacuo to yield an oil products (45- 73%) as showed in Chemical Structure 14.
[00138] 1 , 3-diaminepropane (0.01 mol) was dissolved in 50 mL of dry (molecular sieve) THF and mono-6-tosyl-y-cyclodextrin (0.005 mol) was added. The resulting mixture was stirred for 6 hours at 50-60 °C and allowed to cool to the room temperature when the reaction was completed. The reaction solution was precipitated into IPA and ACN was added to maximize the isolated yield of precipitate. The cake was washed well with 20/80 (v/v) IPA/ACN and dried under vacuum at 30-40° C. The crude product (Chemical Structure 15) was used in next step without further purification.
[00139] Chemical Structure 15
[00140] Example 14. Preparation of γ-Cyclodextrindiaminepropanyl-mPEG
[00141] 0.01 mole of the starting material from Example 14, γ-Cyclodextrindiaminepropane, was dissolved in 20 mL of THF at 20 to 30° C. The active mPEG24-tosylate (0.01 mol) was dissolved in THF, and then mixed with the above reactants, stirred for overnight at room temperature. After the completion of the reaction, solvents were removed by vacuo and 50 mL of acetone was added to the crude product and filtered and washed with 30 mL of acetone three times. The wet product (40-55%) was further lyophilized to a wax as showed in Chemical Structure 16.
[00143] Example 15. Preparation of γ-Cyclodextrincholesteryldiaminepropyl-mPEG
[00144] 0.01 moles of γ-Cyclodextrindiaminepropanyl-mPEG (0.01 mol) from Example 14 was dissolved with 50 mL of anhydrous N-methyl-2-pyrrolidinone, cholesteryl ethylene glycol acetic acid (0.01 mol) from Example 12 in tetrahydrofuran (50 mL) and slightly excess active N- hydroxysuccinimide ester (0.01 1 mol) dissolved in 20 mL of tetrahydrofuran (THF) were mixed with of lactobionyldiethylenetriamine-mPEG and adding triethylamine (TEA, 3%, v/v) as a base, stirred for 2 hrs at room temperature. Assays were performed to verify the yield periodly. The resulting mixture was stirred at 45-50 °C for overnight, and allowed to cool to the room temperature. The reaction solution was precipitated into isopropyl alcohol (IPA) and methyl t-butyl ether (MTBE) was added to maximize the isolated yield of precipitate. The crude product was washed well with 50/50 (v/v) IPA/MTBE and dried under vacuum at 30-40° C. The purity (> 93%) of the final product (Chemical Structure 17) was determined by 1H NMR and UPLC-MS.
[00145] Example 16. Preparation of Boc-Glycinylserinate (Boc-Gly-Ser)
[00146] Boc-Glycine (0.1 mol) and N,N'-Dicyclohexylcarbodiimide (0.1 mol) in methylene chloride (50 mL) was stirred for 30 minutes, and the mixture was added into a methylene chloride solution (50 mL) of (0.1 mol) slowly. The mixture was stirred for 2 hours. The solution was
filtrated and solvent was removed under vacuo to yield a crude product of Boc-Gly-Ser which was transferred to the next step without further purification.
[00149] Mesyl chloride (0.1 mol) was added to a mixture of cholesterol (0.1 mol) and triethylamine (0.1 mol) in methylene chloride (100 mL) placed in an ice-bath. The mixture was stirred for 1 hour and the resulting product was washed with saline and dried over sodium sulfate. The solution was filtered and solvent was removed under vacuo to yield the crude product (oMvChol) which was directly used with Boc-Gly-Ser from Example 16.
[00150] Example 18. Preparation of Cholesterylglycinylserinate (Boc-gly-ser-chol)
[00151] Potassium tert-butoxide (0.1 mol) was added into a tetrahydrofuran solution (100 mL) of Boc-Gly-Ser and Cholesterol mesylate (0.1 mol) from Example 17. The mixture was stirred for 6 hours at about 65 °C. The resulting solution was washed with saline and methylene chloride layer was isolated, dried over sodium sulfate and solvent removed under vacuo to yield an intermediate product of Boc-gly-ser-chol and was used directly without further purification.
[00152] Example 19. Preparation of PEG-cholesterylglycinylserinate (Boc-glyserchol-PEG)
[00153] Heptaethylene glycol monomethoxyl ether (0.1 mol) and Boc-gly-ser-chol (0.1 mol) from the Example 18 was mixed with N,iV'-Dicyclohexylcarbodiimide (0.1 mol) in tetrahydrofuran (100 mL). The mixture was kept at ambient room temperature under content stirring for overnight (about 16 hours) and the reaction was checked for completion by TLC or HPLC. The solution was filtered and solvent was removed under reduced vacuo. The crude product was purified using a silica gel column with the eluent of hexanes/ethyl acetate (1 : 1 , v/v). This intermediate product of Boc-glyserchol-PEG17 was used for the final synthetic step.
[00154] Example 20. Preparation of PEG17-cholesterylglycinylserinyl-6-p-cyclodextrin
[00155] The intermediate product of Boc-Gly-Ser-Chol-PEG17 (0.1 mol) from Example 19 was dissolved in methylene chloride (50 mL) and trifluoroacetic acid (1 mol) was added. The mixture was stirred for 2 hours to remove the amino-protecting group. The reaction was quenched by adding saturated sodium bicarbonate solution (-10%) and the organic layer was dried over sodium sulfate and solvent was removed under vacuo. The resulting intermediate of NH2-Gly-Ser-Chol- PEG17 was directly transferred to the next step without further purification. NL -Gly-Ser-Chol- PEG17 (0.1 mol) and dried mono-6-aminoacryloyl-6-deoxyl- -cyclodextrin (0.1 mol) was mixed in TGF (100 mL) and the reaction was initiated by adding triethylamine (3%, v/v). The reaction was reflux in a water bath of 60-65 °C for 16 hours under constant stirring and solvent was removed under vacuo. The resulting waxy crude product was washed with hexanes and dried under vacuo to yield a pale to yellowish solid (80 to 95%) as showed in Chemical Structure 18.
[00156] Example 21. Preparation of Νε- tert-butyloxycarbonyl(Boc)-lysine-cholesterol
[00157] N£-tert-butyloxycarbonyl(Boc)-lysine (0.2 mol) in 150mL of methylene chloride was transferred to a round-bottomed flask equipped with a mechanical stirrer. Triethylamine (0.4 mol) is added to the flask and the reaction mixture is cooled down to 0 and 10 oC in an ice-water bath under constant stirring. Cholesteryl chloride (0.18 mol) in 100 mL of methylene chloride was added dropwise. The reaction mixture was allowed to continue under constant stirring for 2 hours
after the addition of Cholesteryl chloride was completed. The solution was concentrated to give the crude product of Νε- tert-butyloxycarbonyl(Boc)-Na-cholesterol lysine(yield ~ 60%), which was used directly for the next step
[00158] Chemical structure 18
[00159] Example 22. Preparation of N£-Boc-lysine-cholesterol-mPEG
[00160] Equivalent amount of monomethoxyPEG was mixed with N£-Boc-Na-cholesterol-lysine (from Example 21) in 200 mL THF/DCM (1/1. v/v) and the reaction was started with adding equal amounts of DCC as the catalyst at room temperature under constantly stirring for overnight. The completion of the reaction was monitored by TLC or HPLC. The solid was filtered out and the solution was concentrated under reduced pressure. The crude product was purified by column chromatography with silica gel (eluent: hexanes/ethyl acetate) with a yield of 50% or higher which was used directly for the next step.
[00161] Example 23. Preparation of N£-lysine-Na-cholesterol-mPEG
[00162] Trifluoroacetic acid (10 equivalents) was added to the DCM solution of N£-Boc-lysine- cholesterol-mPEG intermediate (from Example 22) and the mixture was stirred for 2 hours. The mixture was carefully quenched by adding sodium bicarbonate solution and the organic layer was dried over sodium sulfate and concentrated after removed the salt to quantitatively yield the intermediate N£-lysine-cholesterol-mPEG, which was used directly at the next step.
[00163] Example 24. Preparation N£- -cyclodextrin-Na-cholesterol-mPEG-lysinate
[00164] mono-6-aminoacryloyl-6-deoxyl- -cyclodextrin was mixed with equal molar quantity of N£-lysine-Na-cholesterol-mPEG reacted 60-65°C in THF in the presence of 3% of TEA overnight to obtain N£- -cyclodextrin -Na-cholesterol-mPEG-lysinate (Chemical structure 19), The reaction mixture was loaded on a layer of silica gel and air dried. A silica gel column was prepared in a frit filter funnel to give a column volume of about 1 L. The predried reaction mixture was placed on the top of the column and the column was eluted with acetone/hexanes 200 mL of acetone/ Isopropyl alcohol (1/5) and 500 mL of 100% acetone. The eluents containing compound was concentrated in vacuo to N£- -cyclodextrin-Na-cholesterol-mPEG-lysinate (yield -80%).
[00165] Similar synthetic methods from the Examples 1 to 24 may be utilized for the preparations of other PEG-CD-lipid conjugates; It also further demonstrated that selected molecules may be chemically extended and modified to provide said third or fourth available binding position or site, appropriate molecules include and not limited to aminoalcohols and diamines consisting of ethylenediamine, diaminopropane, ethanolamine, and aminopropanol, aminobutanol, aminopentanol, aminohexanol.
[00166] In one aspect of the present invention, while some of these PEG-CD-lipid conjugates showed in Table 4 only monosubstituted PEG-CD-lipid conjugates, due to complexicity of CDs, a mixture of varied substitutions may exist. For quality control and pharmaceutical application, fewer substituent per glucopyranose repeat unit may be preferable. However multiple substituent per glucopyranose may not affect the solubility enhancement or implicate any safety issue since the major advantage with these modified CDs is significant reduction in the quantity of the excipient (solubilizer) used per dose unit as compare to those of non-PEG-lipid modified CDs.
[00167] Chemical structure 19
[00168] In another aspect, the polymer chain may be replaced by other polymer(s) such as polymethylene glycol or polypropylene glycol or a mixture of the repeating units of methylene glycol, ethylene glycol and propylene glycol. Hydrophilic polymers useful in forming the polymer- carbohydrate conjugates of the invention include polyethylene glycol (PEG) and other polyalkene oxide polymers, polyoxyethylene alkyl ethers, polyvinylpyrrolidone, Poly(allylamine), Poly(l - glycerol methacrylate), Poly(2-ethyl-2-oxazoline), Poly(2-hydroxyethyl methacrylate/-methacrylic acid)/poly(2-hydroxyethyl methacrylate), Poly(2-vinylpyridine), Poly(acrylamide/-acrylic acid), Poly(acrylic acid), Poly(butadiene/maleic acid), Poly(ethyl acrylate/acrylic acid) , Poly(ethylene oxide-b-propylene oxide), Poly(ethylene/ acrylic acid), Poly(methacrylic acid) , Poly(maleic acid), Poly(N-iso-propylacrylamide), Poly(N-vinylpyrrolidone/vinyl acetate), Poly(styrenesulfonic acid), Poly(styrenesulfonic acid/maleic acid), Poly(vinyl acetate), Poly(vinyl phosphoric acid), Poly(vinylamine), Polyacrylamide, Polyacrylic Acid, Polyaniline, Polyethylenimine, Pullulan, Polymethacrylamide. Cop-olymers and block copolymers based on the list above may also be used. The free polymers are water-soluble at room temperature, as well as non-toxic. They do not elicit an appreciable immunogenic response in mammals. Hydrophilic polymers with narrow molecular weight distributions are preferable. Because of already existing acceptance in the pharmaceutical business, PEG is the preferred hydrophilic polymer.
[00169] Example 25, Preparation of Pharmaceutical Solutions
[00170] A PEG-CD-lipid conjugate solution suitable for drug delivery is prepared as follows. 4% (w/v) of PEG-CD-lipid in Saline was added to a vessel equipped with a mixer propeller and 2% (w/v) of an active pharmaceutical ingredient (API) is pre-dissolved in ethanol (1 % of total volume, v/v) and charged into the vessel with constant mixing at ambient room temperature. Mixing is continued until the solution is visually homogeneous. Equal volume of Saline is added to the vessel with adequate mixing. Mixing continued for another 30 minutes or until a homogenous solution is achieved. The finish product is place under vacuum overnight to remove ethanol. A sample formulation is described in Table 5.
[00171] Table 5
[00172] The PEG-carbohydrate conjugate may be any of PEG-CD-lipid conjugates described in the invention with a PEG chain consisting of between about 10 and 45 subunits. The API may be
etomidate, propofol, alfaxalone, docetaxel, voriconazole, posaconaole, gemcitabine, platins, tacrolimus, cytarabine, ifosfamide, streptozocin, plicamycin, paclitaxel, omeprazole, alprostadil, mitomycin, ziprasidone. nimesulide, sulfomethiazole, lorazepam, griseofulvin, praziquantel, chlorthalidon, exodolac, piroxicam, itraconazole, ibuprofen, praziquantel, praziquantel, omeprazole, digoxin, albendazole, levemopamil HC1, sulfomethiazole, ketoprofen, griseofulvin, itraconazole, carbamazepine Zolpidem, phenytoin, rutin, camptothesin, danazol, fluasterone, spiranolactone, rapamycin. Sodium hydroxide is used to prepare a 10% w/w solution in purified water. The targeted pH is in a range of 4.0 to 7.5. Diluted NaOH or HC1 may be used to adjust pH if necessary.
[00173] Example 26: Solubility Study of Propofol
1% (w/v) of propofol was prepared in a saline based solution with different PEG-carbohydrate conjugates. Table 6 listed the minimum concentration of the conjugates required to solublize propofol as a solubility test reference. While PEG-carbohydrate-lipid conjugates demonstrated a lower molar concentration for solublizing propofol, much high conjugate concentration was required for hydroxypropyl- -cyclodextrin and only about 2% of a PEG-CD-lipid was needed. Mixing 2% of cholesterypropanediaminelactobionate-mPEG12 and 2-hydroxypropyl- - cyclodextrin resulted in a milky emulsion (Figure 2).
[00174] Table 6
[00175] In another aspect, the invention comprises a method of solubilizing a water-insoluble agent, i.e., a drug compound that, because of low solubility in water, typically requires formulation with a pharmaceutically acceptable carrier for effective delivery to an intended site of action. Such delivery may be intravenous, oral, topical, subdermal, sublingual, or any other mode of drug delivery. The invention also includes compositions for such delivery. Both the methods and the compositions related to delivery of water-insoluble agents employ the PEG-CD-lipid conjugates of the present invention and the methods and materials described above.
[00176] Example 27: Solubility Study of Voriconazole
[00177] 1% (w/v) of voriconazole was prepared in a saline based solution with different PEG- lipid conjugates and a modified cyclodextrin. Table 7 listed the minimum concentrations of the conjugates required to solublize voriconazole as a solubility test reference. While it demonstrated that the lowest polymer to drug concentration ratio was N,N, V-oleoylpropanediamine-p- cyclodextrin-mPEG(12) for solubilizating voriconazole, much high concentration of sulfobutyl ether- -cyclodextrin sodium was required for the same concentration of voriconazole. This is largely due to a relative stronger hydrophobic interactions of when combined an apolar cavity and a hydrophobic core to the solute than those of modified cyclodextrin or PEG-carbohydrate-lipid. The example further demonstrated a significant enhancement in solubilizating hydrophobic compounds with the PEG-lipid modified cyclodextrin, even though sulfobutyl ether- -cyclodextrin sodium has more negative values of LogP or water soluble, however the solubilizing efficiency of lipophilic agents also depends on the retaining power of the solubilizer.
[00178] Table 7
Solubilizing Voriconazole
Polymer LogP HLB1
(w/w)
sulfobutyl ether-P-cyclodextrin sodium -1 1.94 - 16
NNN-oleoyllactobionoyl-mPEG(12)-propanediamine -1.94 16.0 12
NNN-oleoyl P-cyclodextrin-mPEG(12)-propanediamine -6.68 17.8 5
[00179] Unlike nature occurring lipids such as phospholipids, the conjugates of the present invention do not have a critical micellar concentration (CMC). Micelles only form when the concentration of surfactants is greater than the CMC, and the temperature of the system is greater than the critical micelle temperature. The present polymer-CD-lipid conjugates may form aggregates spontaneously at any given concentration.
[00180] Present invention discloses a novel polymer-CD-lipid conjugate system having at least one of polymer-lipid substituent (through a center backbone structurally) that may be used as a safe and biocompatible vehicle for drug or molecule delivery. A therapeutic, diagnostic or cosmetic agent may be solubilized or encapsulated in those polymer-CD-lipid conjugates to form a solution or micro-suspension.
[00181] Another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly a chemical compound or a method of making a compound wherein the PEG-CD-lipid conjugate is a compound represented by the formulas of the General Structure 1 trough 5.
[00182] Generally, the invention includes compositions and methods for synthesizing polymer- CD-lipid conjugates comprising a glycerol backbone or a multiamine or amino acid with a polymer (PEG) chain, a cyclodextrin and a fatty acid or a sterol or a "fat soluble" vitamin or alike group bonded to the backbone. Spacer or linker groups including amino acids may be included between the backbone and the PEG chains, CDs or lipophilic groups. Furthermore, the terminal end of PEG chain may be a charged or polar moiety. For example, in at least one aspect of the present disclosure, a chemical compound carrier for improving the biocompatibility of a therapeutic agent and for increasing the solubility of a hydrophobic or lipophilic agent in water is disclosed. The carrier may comprise a molecular structure represented by the formula:
CD ^ CD
B ackbone mPEC kbone lipid
I and/or / \
Li id D mPEG
D Lip Ty mPEG
[00183] Wherein: Lipid is a lipophilic carrier including steroid acids and fatty acids, sterols and fat soluble vitamins. CD is a cyclodextrin comprises α-, β-. γ-cyclodextrins; PEG is a polymer of polyethylene glycols; D is a secondary fatty acid, sterol or lipophilic vitamin or PEG; Backbone is a molecule having three or four available binding positions and being void of a drug moiety, said Backbone comprising at least one of glycerol, glycerol-like analogues, diamines, triamines, tetramine, diaminoalcohol, aminoalcohols, aminodiol, aminotriols, amino acids, and polyamines; and L is a coupler comprising at least one of glycerol or glycerol-like analogues having three available binding positions, diamines, triamines, diaminoalcohol, aminoalcohols, aminodiols, aminotriols, and amino acids having three available binding positions.
[00184] The compounds of the present invention are effective to formulate compositions of active agents, such gemcitabin or platinum drugs, whereby side effects and toxicities associated with therapeutic treatments are reduced.
[00185] In the present invention, the permeation enhancement properties of PEG-CD-lipid conjugates may increase the in vivo targeted delivery of drugs, reduce toxicity and improve oral bioavailability of various drugs.
[00186] Another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound wherein a polymer-CD-lipid conjugate with defined carriers is made by a method comprising the steps of:
a. selecting a center backbone void drug moieties with at least three available sites for the conjugations between the three carriers and the center backbone;
b. selecting a polymer as the first career;
c. selecting a terminal group on the polymer carrier
d. selecting a lipid as the second carrier;
e. selecting a cyclodextrin as the third carrier
f. selecting a polymer or lipid as the fourth carrier
g. alternatively selecting a hydrophobic compound other than sterol or lipophilic vitamin as the fourth carrier;
h. selecting a linker or linkers for coupling reactions of alkylation including N-alkylation or O- alkylation or esterification or etherification or amidation between carriers and center backbones.
[00187] Yet another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound where the order of each conjugation step is not restricted and may further comprise the steps of alkylation, etherification, esterification or amidation:
a. protecting the hydroxyl or amino group;
b. bonding the first carrier to the center backbone;
c. bonding the second carrier to the center backbone;
d. removing the hydroxyl or amino protecting group; and
e. bonding the third carrier to the center protecting group.
[00188] Still another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound wherein suitable molecules may be used as the backbone including glycerol or glycerol-like analogues or diamines, triamines or multiamines or aminoalcohols or amino acids or triols or diols with a carboxyl group or amine or diamines with a hydroxyl or carboxyl group and extensible amines or alcohols, wherein the hydrophobic carrier is a sterol or lipophilic vitamin.
[00189] Another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound wherein the polymer is a PEG having subunits between 5 and 1 15. The PEG chain may consist of between about 5 and 1 15 subunits. More preferably the PEG chain consists of between about 8 and 1 15 subunits. Still more preferably the PEG chain consists of between about 8 and 45 subunits.
[00190] Yet another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound where the polymer is a branched PEG having 2 or more subchains each chain having PEG subunits between 5 and 1 15.
[00191] A further feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound having a acyclic carrier group wherein the hydrophobic group is selected from fatty
acids including lauric acid, myristic acid, palmitic acid, oleic acid and stearic acids or sterols including cholesterol, stigmasterol, ergosterol, hopanoids, phytosterol, sitosterol, campesterol, brassicasterol, avenasterol adosterol) excluding steroid acids, stanols (saturated steroid alcohols or hydrogenated sterols) or lipophilic vitamins: Vitamin E including and not limited to tocopherols and tocotrienols, Vitamin D including and not limited to cholecalciferol and ergocalciferol, and Vitamin A including and not limited to retinoids, retinol, retinal, retinoic acid, and carotenoids,
[00192] Another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound having nonsterol or non "fat- soluble" vitamins as the fourth carrier group wherein the hydrophobic groups may be selected from saturated fatty acids and unsaturated fatty acids or xanthophylls, astaxanthin, auroxanthin, capsanthin, capsorubin, chrysanthemaxanthin, crocetin, crocin, cryptoxanthin, fucoxanthin, kryptoxanthin, lutein, neoxanthin, rubixanthin, violaxanthin, zeaxanthin and polyunsaturated fatty acids or polyunsaturated fatty alcohols including native polyunsaturated alcohols such as farnesol, solanesol and dodecaprenol. It is preferable to have the cholesterol as the primary lipophilic carrier which may reduce or suppress the hemolytic activity of a fatty acid.
[00193] Further feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound wherein the CD is a cyclodextrin including a-cyclodextrin, β-cyclodextrin and γ- cyclodextrin.
[00194] Yet another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound wherein the linker is selected from the group consisting of -S-, -0-, -N-, - OCOO-, and to form covalent bonds of ester or ether or amide between carriers and center backbones. While a conjugation reaction of alkylation or etherification or esterification or amidation is preferable with or without adding linker group, the carriers or center backbones may be chemically modified prior to the final coupling reactions. Those of chemical modifications may be carried out with one or more of the linker groups.
[00195] Yet another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound wherein the PEG chains are replaced by polymers selected from the group consisting of polymethylene glycol, polypropylene glycol, and copolymers comprised of a at least two of the monomers selected from the group consisting of methylene glycol, ethylene glycol and propylene glycol.
[00196] Still another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a compound wherein the terminal (R) group is preferably easily polarized or negatively or positively charged head-groups such as alkoxy moieties, amines, amino acids, and oligosaccharides.
[00197] A further feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a chemical compound or a method of making a polymer-CD-lipid conjugate wherein it is used for the composition in delivery of an active agent especially for a poorly water soluble compound of Biopharmaceutics classification II or IV including but not limited to alfaxalone, propofol, docetaxel, paclitaxel, voriconazole and posaconazole.
[00198] Another feature or aspect of an embodiment is demonstrated at the time of the filing of this patent application to possibly reside broadly in a method of delivering a compound, the method comprising preparing a polymer-CD-lipid conjugate(s) based formulation of the compound, where the PEG-CD-lipid comprises a PEG, a lipid, a CD and a center backbone selecting from ethylenediamine, diaminopropane, ethanolamine, aminopropanol, aminobutanol,
aminopentanol, amino- 1-hexanol, the center backbone may be chemically extended and modified to provide said third or a fourth available binding position or site.
[00199] One feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier for improving the biocompatibility of a therapeutic agent and for increasing the solubility of a hydrophobic or lipophilic agent in water, the carrier comprising a molecular structure represented by the formula:
[00200] Wherein: Lipid is a lipophilic carrier of fatty acids, sterols, stanols, cholecalciferols, ergocalciferol, retinoids, carotenoids, tocopherols, and tocotrienols; CD is a cyclodextrin comprising a- cyclodextrin. β-cyclodextrin, or γ-cyclodextrin; mPEG is a polymer of polyethylene glycols; D is a duplicate of the Lipid or the mPEG; Backbone is a center Backbone having a molecule with three or four available binding positions or sites and being void of a drug moiety, the backbone comprising at least one of glycerol, glycerol-like analogues having three binding positions, diamines, triamines, tetraamines, polyamines, diaminoalcohols, aminoalcohols, aminodiols, aminotriols, amino acids having three or four available binding positions, triols, tetraols, triacids, tetracids, halogen-containing diols, halogen-containing amines, and carboxyl- containing diols.
[00201] Another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein, the Backbone comprises at least three available binding positions or sites for the conjugation of a first carrier, a second carrier, and a third carrier, each the available binding position or site comprising an expendable amino, hydroxyl, acryloyl or carboxylic group; the first carrier having an expendable amino, hydroxyl, acryloyl, or carboxylic group and the Lipid bound thereto; the second carrier comprising having an expendable amino, hydroxyl, acryloyl or carboxylic group and the mPEG bound thereto; the third carrier comprising having an expendable amino, hydroxyl, acryloyl or carboxylic group and the CD bound thereto.
[00202] Yet another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein the backbone comprises at least four available binding positions or sites for the conjugation of a first carrier, a second carrier, a third carrier, and a fourth carrier, each the available binding position or site comprising an expendable amino, hydroxyl, acryloyl or carboxylic group.
[00203] Still another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein the backbone comprises three available binding positions or sites for the conjugation of a first carrier, a second carrier, and a third carrier, each the available binding position or site comprising an expendable amino, hydroxyl, acryloyl or carboxylic group, wherein: the first carrier has the Lipid bound thereto; the second carrier has the mPEG bound thereto; the mPEG comprising a terminal (R) group; and the third carrier has the CD bound thereto.
[00204] A further feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein the Backbone is one of a) through d): a) selected from the group consisting of glycerol or glycerol- like analogues, polyamines, diamines, triamines, tetraamines, aminodiols, aminotriols, aminoalcohols, amino acids having three available binding positions or sites, triols, tetraols, erythritol, triacids, tetracid, tetraacetic acid, and tartaric acid; b) selected from the group consisting of ethanediamine, propanediamine, butanediamine, pentanediamine, hexanediamine,
diethylenetriamine, diethylenetriamine, bis(3-aminopropyl)-amine, bis(3-aminopropyl)-l ,3- propanediamine or N, N'-bis(3-aminopropyl)- l ,3-propanediamine, triethylenetetramine, l ,2-bis(3- aminopropylamino)ethane, spermine, tris(2-aminoethyl)amine, spermidine, norspermidine, bis(hexamethylene)triamine, tris(hydroxymethyl)-aminomethane, diaminobenzidine, triazacyclononane, tetraazacyclododecane, threitol, meso-erythritol, dithiothreitol, trimethylcyclohexane-l ,3,5-tricarboxylic acid, 1 ,3,5-cyclohexane-tricarboxylic acid, trimethylbis(hexamethylene)triamine, arginine, oxylyldiaminopropionic acid having three or four available binding positions or sites, triols, triacids, glucoheptonic acid, and tartaric acid; c) selected from the group consisting of 3-amino-l ,2-propanediol, 3-bromo-l ,2-propanedol, 3-chloro- 1 ,2-propanediol, 3-fluoro- l ,2-propanediol, DL-glyceric acid, diamino-propionic acid, tartaric acid, glucoheptonic acid, 2,4-butanetriol, 2,2-bis(hydroxymethyl)butyric acid, l ,3-diamino-2-propanol and 2-(3-aminopropylamino)ethanol, and 3-((3-aminopropyl)-amino)propanol; and d) selected from the group consisting of aspartic acid, glutamic acid, asparagine, glutamine, lysine, ornithine, serine, and threonine.
[00205] Another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein two of the accessible binding positions or sites are selected from the group consisting of aminoalcohols, diamines, ethylenediamine, diaminopropane, ethanolamine, aminopropanol, aminobutanol, aminopentanol, and amino- 1 -hexanol; and the chemical compound being chemically extended and modified to provide the third or a fourth available binding position or site.
[00206] Yet another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein three of the available binding positions or sites of the centercenter Backbone are selected from the group consisting of glycerol or glycerol-like analogues, diamines, triamines, tetramines, polyamines, triols, animoalcohols, triacids, amino acids; and the center Backbone being chemically extended and modified to provide a fourth available binding position or site.
[00207] Still another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein the mPEG comprises a single PEG chain having between 5 and 1 15 subunits or a branched PEG having 2 or more subchains, wherein each the subchain has between 5 and 1 15 subunits, and a terminal group (R) comprising methoxy, hydroxyl or biotin.
[00208] Another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein the Lipid is selected from the group of a fatty acid having between 5 to 22 carbons.
[00209] Yet another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a chemical compound carrier wherein the center Backbone is selected from the group consisting of glycerol, polyamines, diamines, triamines, tetraamines, aminodiol, aminotriols, aminoalcohols, triols, tetraols, erythritol, triacids, tetracid, tetraacetic acid, glucoheptonic acid, tartaric acid, and amino acids having three available binding positions or sites, the CD is selected from the group consisting of α, β, and γ cyclodextrin having an averaged number of substituent per glucopyranose repeat unit ranging from 0.6 to 3, the Lipid is selected from the group consisting of myristic acid, palmitic acid, stearic acid myristoleic acid, palmitoleic acid, sapienic acid, elaidic acid, vaccenic acid, linoleic acid, tocopherols/tocotrienols, retinoids/carotenoids, cholecalciferol, steroids, and sterols, and the mPEG is mPEGnwith n being the number of ethylene glycol subunit ranging from 5 to 1 15.
[00210] Yet another feature or aspect of an illustrative example is believed at the time of the filing of this patent application to possibly reside broadly in a method for treating a disease or health condition in a mammal with a chemical compound carrier as disclosed above, the method comprising treating a condition that comprises general anesthesia or procedural sedation.
[00211] Another feature or aspect of an embodiment is to differentiate the present invention chemically and physically from the previous patent publications US2012/202,979 and US2012/202,890; in the present invention, a cyclodextrin is incorporated. As demonstrated in Tables 4, such structures increased lipophilic properties was not mentioned or utilized in the previous inventions. For instance, the PEG-CD-fatty acid conjugates, the PEG-CD-cholesterol conjugates and PEG-CD-lipo-vitamin conjugates were demonstrated for the first time.
[00212] While preferred embodiments of the present invention have been described, those skilled in the art will recognize that other and further changes and modifications may be made without departing from the spirit of the invention, and all such changes and modifications should be understood to fall within the scope of the invention.
Claims
1. A chemical compound carrier for improving the biocompatibility of a therapeutic agent and for increasing the solubility of a hydrophobic or lipophilic agent in water, said carrier comprising a molecular structure represented by the formula:
wherein:
Lipid is a lipophilic carrier of fatty acids, sterols, stanols, cholecalciferols, ergocalciferol, retinoids, carotenoids, tocopherols, and tocotrienols;
CD is a cyclodextrin comprising a- cyclodextrin. β-cyclodextrin, or γ-cyclodextrin;
mPEG is a polymer of polyethylene glycols;
D is a duplicate of the Lipid or the mPEG;
Backbone is a center Backbone having a molecule with three or four available binding positions or sites and being void of a drug moiety, said backbone comprising at least one of glycerol, glycerol-like analogues having three binding positions, diamines, triamines, tetraamines, polyamines, diaminoalcohols, aminoalcohols, aminodiols, aminotriols, amino acids having three or four available binding positions, triols, tetraols, triacids, tetracids, halogen-containing diols, halogen-containing amines, and carboxyl-containing diols.
2. The chemical compound of claim 1 wherein:
said Backbone comprises at least three available binding positions or sites for the conjugation of a first carrier, a second carrier, and a third carrier, each said available binding position or site comprising an expendable amino, hydroxyl, acryloyl or carboxylic group;
said first carrier having an expendable amino, hydroxyl, acryloyl, or carboxylic group and said Lipid bound thereto;
said second carrier comprising having an expendable amino, hydroxyl, acryloyl or carboxylic group and said mPEG bound thereto;
said third carrier comprising having an expendable amino, hydroxyl, acryloyl or carboxylic group and said CD bound thereto.
3. The chemical compound of claim 1 wherein said Backbone is one of a) through d):
a) selected from the group consisting of glycerol or glycerol-like analogues, polyamines, diamines, triamines, tetraamines, aminodiols, aminotriols, aminoalcohols, amino acids having three available binding positions or sites, triols, tetraols, erythritol, triacids, tetracid, tetraacetic acid, and tartaric acid;
b) selected from the group consisting of ethanediamine, propanediamine, butanediamine, pentanediamine, hexanediamine, diethylenetriamine, diethylenetriamine, bis(3- aminopropyl)-amine, bis(3-aminopropyl)- 1 ,3 -propanediamine or N, N'-bis(3-aminopropyl)- l ,3- propanediamine, triethylenetetramine, l ,2-bis(3-aminopropylamino)ethane, spermine, tris(2- aminoethyl)amine, spermidine, norspermidine, bis(hexamethylene)triamine, tris(hydroxymethyl)- aminomethane, diaminobenzidine, triazacyclononane, tetraazacyclododecane, threitol, meso- erythritol, dithio-threitol, trimethylcyclohexane-l ,3,5-tricarboxylic acid, 1 ,3,5-cyclohexane- tricarboxylic acid, trimethylbis(hexamethylene)triamine, arginine, oxylyldiaminopropionic acid having three or four available binding positions or sites, triols, triacids, glucoheptonic acid, and tartaric acid;
c) selected from the group consisting of 3-amino-l ,2-propanediol, 3-bromo-l ,2- propanediol, 3-chloro-l ,2-propanediol, 3-fluoro-l ,2-propanediol, DL-glyceric acid, diamino- propionic acid, tartaric acid, glucoheptonic acid, 2,4-butanetriol, 2,2-bis(hydroxymethyl)butyric acid, l ,3-diamino-2-propanol and 2-(3-aminopropylamino)ethanol, and 3-((3-aminopropyl)- amino)propanol; and
d) selected from the group consisting of aspartic acid, glutamic acid, asparagine, glutamine, lysine, ornithine, serine, and threonine.
4. The chemical compound of claim 1 wherein two of said accessible binding positions or sites are selected from the group consisting of aminoalcohols, diamines, ethylenediamine, diaminopropane, ethanolamine, aminopropanol, aminobutanol, aminopentanol, and amino- 1- hexanol; and
said chemical compound being chemically extended and modified to provide said third or a fourth available binding position or site.
5. The chemical compound of claim 1 wherein three of said available binding positions or sites of the center Backbone are selected from the group consisting of glycerol or glycerol-like analogues, diamines, triamines, tetramines, polyamines, triols, animoalcohols, triacids, amino acids; and
said center Backbone being chemically extended and modified to provide a fourth available binding position or site.
6. The chemical compound of claim 1 wherein said mPEG comprises a single PEG chain having between 5 and 1 15 subunits or a branched PEG having 2 or more subchains, wherein each said subchain has between 5 and 1 15 subunits, and a terminal group (R) comprising methoxy, hydroxyl or biotin.
7. The chemical compound of claim 1 wherein said Lipid is selected from the group consisting of sterols or stanols; cholesterol, stigmasterol, ergosterol, hopanoids, phytosterol, sitosterol, campesterol, brassicasterol, avenasterol adosterol, fatty soluble vitamins; retinols, retinoids, retinal, retinoic acid, tretinoin, carotenoids, β-carotene, tocopherols, tocotrienols, cholecalciferol, and ergocalciferol.
8. The chemical compound of claim 1 wherein said Lipid is selected from the group of a fatty acid having between 5 to 22 carbons.
9. The chemical compound of claim 1 , wherein said center Backbone is selected from the group consisting of glycerol, polyamines, diamines, triamines, tetraamines, aminodiol, aminotriols, aminoalcohols, triols, tetraols, erythritol, triacids, tetracid, tetraacetic acid, glucoheptonic acid, tartaric acid, and amino acids having three available binding positions or sites, said CD is selected from the group consisting of α, β, and γ cyclodextrin having an averaged number of substituent per glucopyranose repeat unit ranging from 0.6 to 3, said Lipid is selected from the group consisting of myristic acid, palmitic acid, stearic acid, myristoleic acid, palmitoleic acid, sapienic acid, elaidic acid, vaccenic acid, linoleic acid, tocopherols/tocotrienols, retinoids/carotenoids, cholecalciferol, steroids, and sterols, and said mPEG is mPEGn with n being the number of ethylene glycol subunit ranging from 5 to 1 15
10. The chemical compound of claim 1 being selected from the group consisting of oleoyl- mPEG-(aminopropoxy)acetocyclodextrin, stearoyl-mPEG-(aminopropoxy)acetocyclodextrin, palmitoyl-mPEG-(aminopropoxy)acetocyclodextrin, myristoyl-mPEG-(aminopropoxy)aceto-
cyclodextrin, cholestery-mPEG-(aminopropoxy)acetocyclodextrin, cholestery-mPEG-
(aminopropoxy)acetocyclodextrin, tocopheryl-mPEG-(aminopropoxy)acetocyclodextrin, retinoyl- mPEG-(aminopropoxy)acetocyclodextrin, retinoyl-mPEG-(aminopropoxy)-aceto-cyclodextrin, cholecalciferol-mPEG(aminopropoxy)acetocyclodextrin, oleoylpropanediamine-cyclodextrin- mPEG, A^-cyclodextrin-A^-oleoyl-mPEG-lysinate, A^-cyclodextrin-Na-myristoyl-mPEG-lysinate, N£-cyclodextrin-Na-stearoyl-mPEG-lysinate, stearoylpropanediamine-cyclodextrin-mPEG, oleoyl- diethylenetriamine-bismPEG-cyclodextrin, palmitoyldiethyletriamine-bismonomethoxyl-PEG- ether-cyclodextrin, oleoyltriethylenetetramine-p-cyclodextrin-bismPEG, palmitoylpropane- diamine-cyclodextrin-bismPEG, myristoylpropanediamine-cyclodextrin-mPEG, palmitoylpropane- diamine-cyclodextrin-mPEG, cholesterypropanediamine-cyclodextrin-mPEG, N£-cyclodextrin-Na- cholesterol-mPEG-lysinate, cholesterydiethylenetriamine-cyclodextrin-mPEG, a-tocopherol- triethylene-tetramine-bismonomethoxyl-PEG-ether-cyclodextrin, cholestertriethylenetetramine- bismPEG-cyclodextrin, cholesterytriethylenetetramine-cyclodextrin-bismPEG, cholestery- triethylenetetramine- -cyclodextrin-mPEG, tocopherylpropanediamine-cyclodextrin-mPEG, retinoylpropanediamine- cyclodextrin-mPEG, retinoyldiethylenetriamine-cyclodextrin-mPEG, cholecalciferoldiethylenetriamine-cyclodextrin-mPEG, cholecalciferoldiethylenetriamine- bismPEG-cyclodextrin, cyclodextrintocopherylethylene-bismPEG-aminosalicylate, cholecalci- feroldiethylenetriaminemono-bismPEG-cyclodextrin, cholesterylascorbyldiethylenetriamine- tryptophanyl-mPEG-cyclodextrin, cholesterolascorbyl-mPEG-propanediaminocyclodextrin, cholesterolaspartate-mPEG-cyclodextrin, cholesteryloleoylascorbyl-diethylenetriamine-mPEG- cyclodextrin, cholesteryl-retinoyldiethylenetriamine-mPEG-cyclodextrin, cholesterolascorbyl- triethylenetetramine-bismonomethoxy-PEG-ether-cyclodextrin, cyclodextrin-tocopherol-mPEG- lysinate, cholesteroltriethylenetetramine-bismPEG-cyclodextrin, cholesterololeoyl-cyclodextrin- diethylenetriamine-mPEG, bismPEG-propanediamine-serinol-iV-cholesterol-iV '-cyclodextrin, cyclodextrindiamino-2-propanolcholesterolmPEG-ascorbate, cholecalciferolascorbyldiethylene- triamine-cyclodextrin-mPEG, £N-cyclodextrin-£iV-cholesteryl-aiV-acetyl-mPEG-lysinate, cholecal- ciferoldipropylenetriamine-mPEG-cyclodextrin, cholesteryldiethylenetriaminetryptophanyl- mPEG-cyclodextrin, N-cyclodextrin-cholesterolaspartate-mPEG, cholesterylretinoyltriethylene- tetramine-mPEG-cyclodextrin, cholesteryltriethylenetetramine-bis-mPEG cyclodextrin, EiV- cyclodextrin-£iV-a-tocopherol-aiV-acetyl-monomethoxyl-PEG-ether-lysinate, a-tocopherol- triethylenetetramine-bismPEG-cyclodextrin, cholesterolascorboyldiethylenetriamine-mPEG- cyclodextrin, cholecalciferololeoylascorboyldiethylenetriamine-mPEG-cyclodextrin, and cholesteryloleoylascorboyldiethylenetriamine-mPEG-cyclodextrin.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2988587A CA2988587C (en) | 2015-06-23 | 2016-06-17 | Polymer-cyclodextrin-lipid conjugates |
CN201680036637.3A CN108026131B (en) | 2015-06-23 | 2016-06-17 | Polymer-cyclodextrin-lipid conjugates |
JP2017557414A JP7196378B2 (en) | 2015-06-23 | 2016-06-17 | Polymer-cyclodextrin-lipid conjugate |
EP16815095.1A EP3313857B1 (en) | 2015-06-23 | 2016-06-17 | Polymer-cyclodextrin-lipid conjugates |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562183400P | 2015-06-23 | 2015-06-23 | |
US62/183,400 | 2015-06-23 | ||
US15/184,014 US9605305B2 (en) | 2015-07-07 | 2016-06-16 | Method for reducing primer-dimer amplification |
US15/184,014 | 2016-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016209732A1 true WO2016209732A1 (en) | 2016-12-29 |
Family
ID=57585488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/038134 WO2016209732A1 (en) | 2015-06-23 | 2016-06-17 | Polymer-cyclodextrin-lipid conjugates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016209732A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019009434A1 (en) * | 2017-07-06 | 2019-01-10 | 学校法人京都薬科大学 | Drug delivery polymer micelles |
WO2019116164A1 (en) * | 2017-12-12 | 2019-06-20 | International Business Machines Corporation | Antimicrobial ionene compositions with a variety of functional groups |
CN110234696A (en) * | 2017-01-30 | 2019-09-13 | 生物辐射实验室股份有限公司 | Emulsion compositions and its application method |
US10595527B2 (en) | 2017-12-12 | 2020-03-24 | International Business Machines Corporation | Antimicrobial polymers capable of supramolecular assembly |
US10653142B2 (en) | 2017-12-12 | 2020-05-19 | International Business Machines Corporation | Polymers with antimicrobial functionalities |
US10687528B2 (en) | 2017-12-12 | 2020-06-23 | International Business Machines Corporation | Antimicrobial polymers with enhanced functionalities |
US10687530B2 (en) | 2017-12-12 | 2020-06-23 | International Business Machines Corporation | Hydrophilic polymers with antimicrobial functionalities |
US10743537B2 (en) | 2017-12-12 | 2020-08-18 | International Business Machines Corporation | Monomer compositions with antimicrobial functionality |
US10836864B2 (en) | 2017-12-12 | 2020-11-17 | International Business Machines Corporation | Chemical compositions with antimicrobial functionality |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050186267A1 (en) * | 2002-09-13 | 2005-08-25 | Thompson Diane O. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US20100076209A1 (en) * | 2008-06-11 | 2010-03-25 | Nian Wu | PEG-lipid conjugates for liposomes and drug delivery |
US20100240883A1 (en) * | 2009-03-18 | 2010-09-23 | Nian Wu | Lipid-drug conjugates for drug delivery |
US20120115962A1 (en) * | 2010-10-18 | 2012-05-10 | Rutgers, The State University Of New Jersey | Cyclodextrin-modified polyamines for delivery of therapeutic molecules |
US20120202979A1 (en) | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
US20130004592A1 (en) * | 2011-06-28 | 2013-01-03 | Nian Wu | Pharmaceutical compositions for parenteral administration |
US20150157721A1 (en) | 2013-12-05 | 2015-06-11 | Nian Wu | Polymer-carbohydrate conjugates for drug delivery technology |
-
2016
- 2016-06-17 WO PCT/US2016/038134 patent/WO2016209732A1/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US20050186267A1 (en) * | 2002-09-13 | 2005-08-25 | Thompson Diane O. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
US20100076209A1 (en) * | 2008-06-11 | 2010-03-25 | Nian Wu | PEG-lipid conjugates for liposomes and drug delivery |
US20100240883A1 (en) * | 2009-03-18 | 2010-09-23 | Nian Wu | Lipid-drug conjugates for drug delivery |
US20120115962A1 (en) * | 2010-10-18 | 2012-05-10 | Rutgers, The State University Of New Jersey | Cyclodextrin-modified polyamines for delivery of therapeutic molecules |
US20120202979A1 (en) | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
US20120202890A1 (en) | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
US20130004592A1 (en) * | 2011-06-28 | 2013-01-03 | Nian Wu | Pharmaceutical compositions for parenteral administration |
US20150157721A1 (en) | 2013-12-05 | 2015-06-11 | Nian Wu | Polymer-carbohydrate conjugates for drug delivery technology |
Non-Patent Citations (45)
Title |
---|
"Cremophor-based paclitaxel 'chemo' drug triggers fatal allergic reactions", THE MEDICAL NEWS, 9 June 2009 (2009-06-09) |
A. UENOF. MORIWAKIT. OSAF. HAMADAK. MURAI, TETRAHEDRON, vol. 43, 1987, pages 1571 |
A.O. NORNOOAD.W. OSBORNEBD.S.L. CHOW: "Cremophor-free intravenous microemulsions for paclitaxel: I: Formulation, cytotoxicity and hemolysis", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 349, 2008, pages 108 - 116 |
ADAMS ET AL., PHARM. SCI, vol. 92, 2003, pages 1343 - 1355 |
ALBERTS BJOHNSON ALEWIS JRAFF MROBERTS KWALTER P: "Molecular biology of the cell", 2002, GARLAND SCIENCE, pages: 1874 |
B. CASUG. G. GALLOM.REGGIANIA. VIGEVANI, J. CHEM. SOC. SPEC. PUBL., vol. 23, 1968, pages 217 |
B. GILLETD. J. NICOLEJ. J. DELPUECH, TETRAHEDRON LETT., vol. 23, 1982, pages 65 |
B. P. SCHONBERGERA. C. A. JANSENL. H. M. JANSSEN: "Proceedings of the 4th International Symposium on Cyclodextrins, Munich, 1988", 1988, KLUWER, pages: 61 |
B. SIEGEL, J. INORG. NUCL. CHEM., vol. 41, 1979, pages 609 |
BRIGANDI, RA. ET AL., CLINICAL PHARM IN DRUG DEV., vol. 4, no. 2, 2014, pages 130 - 136 |
CHANKESHWARA, SVCHAKRABORTI, AK., ORG. LETT., vol. 8, 2006, pages 3259 |
CHERIAN ET AL., DRUG. DEV. IND. PHARM, vol. 26, 2000, pages 459 - 463 |
D. A. REES, J. CHEM. SOC. (B, 1970, pages 877 |
D. W. GRIFFITHSM. L. BENDER, ADV. CATAL., vol. 54, 1973, pages 625 |
F. M. MENGERM. A. DULANY, TETRAHEDRON LETT., vol. 26, 1985, pages 267 |
FAHY ESUBRAMANIAM SBROWN HA ET AL.: "A comprehensive classification system for lipids", J. LIPID RES., vol. 46, no. 5, 2005, pages 839 - 61, XP009097309, DOI: 10.1194/jlr.E400004-JLR200 |
FRANK DW ET AL.: "Cyclodextrin nephrosis in the rat", AM J PATHOL, vol. 83, 1976, pages 367 - 82 |
G.D. NOUDEHP. KHAZAELIP. RAHMANI: "Study of the Effects of Polyethylene Glycol Sorbitan Esters Surfactants Group on Biological Membranes", INTERNATIONAL JOURNAL OF PHARMACOLOGY, vol. 4, 2008, pages 27 - 33, XP055252587, DOI: 10.3923/ijp.2008.27.33 |
GOULD S ET AL., FOOD CHEM TOXICOL., vol. 43, 2005, pages 1451 - 9 |
GRIFFIN WC.: "Calculation of HLB Values of NonIonic Surfactants", JOURNAL OF THE SOCIETY OF COSMETIC CHEMISTS., vol. 5, 1954, pages 259 |
ILANI, A.: "The pH dependence of the hemolytic potency of bile salts", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1027, 1990, pages 199, XP023353008, DOI: 10.1016/0005-2736(90)90085-3 |
IRIE T ET AL., J PHARM SCI., vol. 86, 1997, pages 147 - 62 |
JINDRICH J ET AL., CARBOHYDR RES., vol. 266, no. 1, pages 75 - 80 |
K. A. MARTINA. W. CZARNIK, TETRAHEDRON LETT., vol. 35, 1994, pages 6781 |
K. TSUJIHARAH. KURITAM. KAWAZU, BULL. CHEM. SOC. JPN., vol. 50, 1977, pages 1567 |
KAUR ET AL., 1. CONTROL. REI, vol. 127, 2008, pages 97 - 109 |
L. E. FIKESD. T. WINNR. W. SWEGERM. P. JOHNSONA. W. CRARNIK, J. AM. CHEM. SOC., vol. 114, 1992, pages 1493 |
LI YINGJIE ET AL., SCIENTIA SINICA CHIMICA, vol. 40, no. 11, 2010, pages 1682 - 1687 |
LI, B.BERLINER, M., J. ORG. CHEM., vol. 71, 2006, pages 9045 |
LIANHO., J. PHARM. SCI, vol. 90, 2001, pages 667 - 680 |
M. E. BREWSTERT. LOFTSSON, ADVANCED DRUG DELIVERY REVIEW, vol. 59, no. 7, 2007, pages 645 - 666 |
M. JUGM. B. LACAN, RAD. MEDICAL SCIENCES, vol. 32, no. 499, 2008, pages 9 - 26 |
M. POPR, BEILSTEIN J. ORG. CHEM., vol. 10, 2014, pages 1390 - 1396 |
MASON TGWILKING JNMELESON KCHANG CBGRAVES SM: "Nanoemulsions: formation, structure, and physical properties", JOURNAL OF PHYSICS: CONDENSED MATTER, vol. 18, 2006, pages R635 - R666, XP020102622, DOI: 10.1088/0953-8984/18/41/R01 |
MIMURA, T.: "Fatty acids and sterols of the tunicate, Salpa thompsoni, from the Antarctic Ocean: chemical composition and hemolytic activity", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 34, 1986, pages 4562 |
NA ET AL., EUR. J. MED. CHEM., vol. 41, 2006, pages 670 - 674 |
R. ARUN ET AL., SCIENTIA PHARMACEUTICA, vol. 76, no. 4, 2008, pages 567 - 598 |
R. C. PETTERJ. S. SALEKC. T. SIKORSKYG. KUMARAVELF. T. LIN, J. AM. CHEM. SOC., vol. 112, 1990, pages 3860 |
R. CASIDAYR. FREY: "Maintaining the Body's Chemistry: Dialysis in the Kidneys", 3 December 2013, DEPARTMENT OF CHEMISTRY |
T. TAN ET AL., PROTOCOL EXCHANGE., 2011 |
T.P. SILVERSTEIN: "The Real Reason Why Oil and Water Don't Mix", JOURNAL OF CHEMICAL EDUCATION, vol. 75, 1998, pages 116 - 346 |
THOMPSON DO, CRIT REV THER DRUG CARRIER SYST., vol. 14, 1997, pages 1 - 104 |
W. ZHANG ET AL., APPLIED SURFACE SCIENCE, vol. 256, 2010, pages 3000 - 3005 |
X. M. GAOL. H. TONGY. INOUEA. TAI, SYNTH. COMMUN., vol. 25, 1995, pages 703 |
Y. PING ET AL., BIOMATERIALS, vol. 32, no. 32, 2011, pages 8328 - 8341 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110234696A (en) * | 2017-01-30 | 2019-09-13 | 生物辐射实验室股份有限公司 | Emulsion compositions and its application method |
WO2019009434A1 (en) * | 2017-07-06 | 2019-01-10 | 学校法人京都薬科大学 | Drug delivery polymer micelles |
US10687528B2 (en) | 2017-12-12 | 2020-06-23 | International Business Machines Corporation | Antimicrobial polymers with enhanced functionalities |
US10595527B2 (en) | 2017-12-12 | 2020-03-24 | International Business Machines Corporation | Antimicrobial polymers capable of supramolecular assembly |
US10653142B2 (en) | 2017-12-12 | 2020-05-19 | International Business Machines Corporation | Polymers with antimicrobial functionalities |
US10667514B2 (en) | 2017-12-12 | 2020-06-02 | International Business Machines Corporation | Antimicrobial ionene compositions with a variety of functional groups |
WO2019116164A1 (en) * | 2017-12-12 | 2019-06-20 | International Business Machines Corporation | Antimicrobial ionene compositions with a variety of functional groups |
US10687530B2 (en) | 2017-12-12 | 2020-06-23 | International Business Machines Corporation | Hydrophilic polymers with antimicrobial functionalities |
US10743537B2 (en) | 2017-12-12 | 2020-08-18 | International Business Machines Corporation | Monomer compositions with antimicrobial functionality |
US10836864B2 (en) | 2017-12-12 | 2020-11-17 | International Business Machines Corporation | Chemical compositions with antimicrobial functionality |
US11006628B2 (en) | 2017-12-12 | 2021-05-18 | International Business Machines Corporation | Antimicrobial polymers capable of supramolecular assembly |
US11058110B2 (en) | 2017-12-12 | 2021-07-13 | International Business Machines Corporation | Polymers with antimicrobial functionalities |
US11525036B2 (en) | 2017-12-12 | 2022-12-13 | International Business Machines Corporation | Chemical compositions with antimicrobial functionality |
US11617367B2 (en) | 2017-12-12 | 2023-04-04 | International Business Machines Corporation | Antimicrobial polymers capable of supramolecular assembly |
US11723363B2 (en) | 2017-12-12 | 2023-08-15 | International Business Machines Corporation | Polymers with antimicrobial functionalities |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3313857B1 (en) | Polymer-cyclodextrin-lipid conjugates | |
WO2016209732A1 (en) | Polymer-cyclodextrin-lipid conjugates | |
JP6466283B2 (en) | Block copolymer for stable micelles | |
EP3077006B1 (en) | Polymer-carbohydrate conjugates for drug delivery technology | |
JP5934255B2 (en) | Polymer-carbohydrate-lipid complex | |
Anbharasi et al. | Doxorubicin conjugated to D‐α‐tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy | |
US20190038556A1 (en) | Formulations and carrier systems including compound interactive domains | |
JP2018506515A (en) | Amphiphilic polymer system | |
US8629186B2 (en) | Polymer micelles containing anthracyclines for the treatment of cancer | |
WO2019241853A1 (en) | Platinum-based amphiphile prodrugs | |
Al-kaf et al. | Pharmacosomes: an Updated review | |
WO2011139343A2 (en) | Amino acid linked peg-lipid conjugates | |
US20100278928A1 (en) | Polymer micelles containing anthracylines for the treatment of cancer | |
Islam et al. | Self-emulsifying micelles as a drug nanocarrier system for itraconazole oral bioavailability enhancement; in vitro and in vivo assessment | |
Zhang | PEG-derivatized FTS-based micelles for combination cancer therapy | |
Le | The oral delivery of hydrophobic drugs-a role for amphiphilic polymers | |
VANANGAMUDI | Targeted delivery of Doxorubicin conjugated to Folic acid and Vitamin E Da-Tocopheryl Polyethylene glycol succinate (TPGS) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16815095 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017557414 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2988587 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |